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ZUSAMMENFASSUNG 
Der Einfluss von Transkriptionsfaktoren auf die Navigationsentscheidungen axonaler Wachstums-
kegel ist eine wichtige Fragestellung in der modernen Entwicklungsneurobiologie. In der vorliegenden 
Arbeit wurde die Gehirnentwicklung in einem transgenen Mausstamm mit einer Nullmutation des 
Transkriptionsfaktors Foxb1 untersucht. In diesen Mäusen liegt ein Navigationsdefekt eines 
spezifischen Axonbündels, des mammillothalamischen Traktes, vor, welcher eine markante 
anatomische Struktur des Diencephalons ist. In den Mutanten versagt das Wachstum der 
mammillothalamischen Axone zu ihrer eigentliche Zielregion, dem dorsalen Thalamus. Die Neuronen, 
in welchen der mammillothalamische Trakt entspringt, exprimieren Foxb1. Die Fragestellung der 
vorliegenden Arbeit war daher, wie Foxb1 die Navigationsentscheidungen mammillothalamischer 
Wachstumskegel beeinflußt. 
Durch DNA-Microarrays wurden zunächst die Transkriptome im Wildtyp- und Mutantengehirn 
verglichen. Dieser Ansatz lieferte eine Reihe von Kandidatengenen, die potentiell durch Foxb1 
reguliert werden. Diese Kandidatengene wurden anschließend durch in situ-Hybridisierung und 
quantitative PCR validiert. Durch Vergleich dieser Daten mit in der Literatur vorliegenden Angaben 
wurde für weitere Untersuchungen der vielversprechendste Kandidat ausgewählt, die 
Rezeptortyrosinkinase EphA7, für die bereits eine Beteiligung an der Lenkung von Axonen in anderen 
Gehirnbereichen beschrieben wurde. Anschließend wurde untersucht, ob und inwiefern EphA7 das 
Gen (oder eines der Gene) ist, das den biologischen Zusammenhang zwischen dem regulatorischen 
Protein Foxb1 und dem Phänotyp in der axonalen Navigation herstellt. Die vier bekannten Isoformen 
des Gens wurden kloniert und im Hinblick auf ihre Expression in den beteiligten Hirnregionen in 
Wildtyp und Foxb1-Mutante verglichen. Die Expressionsstärke aller vier Isoformen im Diencephalon 
war in der Mutante reduziert. Eine Expressionsanalyse aller bekannten potentiellen Liganden dieses 
Rezeptors ergab, dass einer von ihnen, Ephrin A5, zum richtigen Entwicklungszeitpunkt und in der 
richtigen Region exprimiert ist, um als Interaktionspartner für EphA7 in Frage zu kommen. Um eine 
direkte Kontrolle der EphA7-Expression durch Foxb1 zu untersuchen, wurden mögliche Fox-
Bindungsstellen in Abschnitten des EphA7-Gens identifiziert, die zwischen Mensch und Maus 
konserviert sind. Zur Validierung dieser Bindungsstellen wurden yeast-one-hybrid- und 
electrophoretic-mobility-shift-Untersuchungen durchgeführt. Schließlich wurde untersucht, welche 
dieser Bindungsstellen in Säugetierzellen die Expression eines Reportergens steuern können. 
Unerwarteterweise bewirkte Foxb1 hierbei eine Repression statt – wie aufgrund der Microarray-, in 
situ-Hybridisierungs- und quantitativen PCR-Daten erwartet – einer Aktivierung des Reportergens. 
Die electrophoretic-mobility-shift-Untersuchungen wurden daher auf ein längeres genomisches 
Fragment ausgeweitet, ausgehend von der Annahme, dass in Nachbarregionen des ursprünglich 
gewählten Fragments bisher unbekannte regulatorische Kofaktoren eine Rolle für die Funktion von 
Foxb1 spielen könnten. Durch diesen veränderten Ansatz konnte gezeigt werden, dass Foxb1 
tatsächlich in Säugetierzellen die Expression des Reportergens durch die im EphA7-Gen 
identifizierten Bindungsstellen aktivieren kann. 
Die vorliegende Arbeit zeigt, dass das Gen des Tyrosinkinaserezeptors EphA7 in den Ursprungszellen 
des mammillothalamischen Traktes exprimiert ist, dass der Transkriptionsfaktor Foxb1 spezifisch an 
konservierte genomische Sequenzabschnitte von EphA7 bindet, sowie dass in Abwesenheit von Foxb1 
die Expression aller EphA7-Isoformen deutlich reduziert ist. Diese Ergebnisse legen nahe, dass EphA7 
die Verbindung zwischen Foxb1-Defizienz und dem resultierenden axonalen Navigationsdefekt 
darstellt und dass Foxb1 die Ausbildung mammillothalamischer Axone im Diencephalon zumindest 
teilweise durch eine Modulation der Interaktionen von Ephrin-Liganden und EphA-Rezeptoren 
beeinflusst. 
 
Schlagwörter:   Axonal navigation, Diencephalon, fkh5, Transkription, mammillarykörper, mf3,   
                              Twh,  Mammillothalamischen Trakt, EphA7, Tyrosinkinaserezeptor, protein-  
                               DNA- interaktion, Ephrin  ligand. 
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ABSTRACT 
 
A current question in developmental neuroscience is: how do transcription factors influence the 
navigational choices of axonal growth cones? Here this question has been addressed by analyzing 
brain development in a mouse transgenic line carrying a null mutation of transcription factor 
Foxb1. These mice suffer from axonal navigational failure in a specific axonal bundle, the 
mammillothalamic tract, which is a distinctive anatomical feature of the diencephalic region of 
the brain. In the mutants, the mammillothalamic axons are not able to enter their intended target 
region, the dorsal thalamus. The neurons of origin of this tract express Foxb1. The specific 
question addressed in this work is: how does Foxb1 control the guidance decisions of the 
mammillothalamic growth cones? 
First, DNA microarrays were used to compare the transcriptome of wild type and mutant brains. 
This approach yielded a number of candidates to be downstream from Foxb1. The candidates 
were next validated by in situ-hybridization and quantitative real-time PCR. Then the most 
appropriate candidate was chosen, based on the function of the encoded protein as found in the 
literature. This candidate was the receptor tyrosine kinase EphA7, reported to be involved in 
axonal guidance in other  parts of the brain. 
The biological plausibility of EphA7 as the gene (or one of the genes) between the regulator 
protein Foxb1 and the phenomenon of axonal guidance was then investigated. In order to do so, 
the four isoforms of this gene were cloned and their expression in the appropriate region of wild 
type and mutant brains was determined. All of the isoforms were decreased in expression level in 
the diencephalon. The expression of all the potential ligands for this receptor in the region of 
interest was analyzed. One of them, ephrin A5, was found to be expressed at the right 
developmental stage in the right place to be the partner for EphA7. 
To know if expression of EphA7 is under the direct control of Foxb1, putative Fox binding 
sequences were identified in human-mouse conserved regions of the EphA7 gene. Then 
sequences actually binding to Foxb1 were determined by means of Yeast One-Hybrid Assay, and 
validated by Electrophoretic Mobility Shift Assay. Finally, the ability of these binding sites to 
direct reporter expression in mammalian cells in culture was tested. Since the results obtained 
were paradoxal (Foxb1 repressed expression through these sites, instead of behaving as an 
activator, as could be expected from the microarray, in situ hybridization and quantitative PCR 
data), the experiments were repeated by using larger genomic sequence fragments containing not 
only the EMSA-confirmed binding sites but also the neighboring regions. The rationale was that 
maybe Foxb1 needs hitherto unknown cofactors in order to exert its normal function. These 
experiments showed that Foxb1 is indeed able to activate gene expression in mammalian cells 
through the binding sites found on EphA7.  
These results show that tyrosine kinase receptor gene EphA7 is expressed in the cells that 
originate the mammillothalamic tract; that transcriptional regulator protein Foxb1 binds specific 
conserved genomic sequences of EphA7; and that, in the absence of Foxb1, expression of EphA7 
and all its isoforms is severely reduced. This work suggests that EphA7 is the link between 
Foxb1-deficiency and the resultant axonal navigation phenotype, and that Foxb1 guides the 
mammillothalamic axons at least in part by modulating the ephrin ligand-EphA receptor 
interaction in the diencephalon. 
 
Key words:       Axonal navigation, Diencephalon, fkh5, Transcription, Mammillary body, mf3,   
                           Twh,  Mammillothalamic Tract, EphA7, Tyrosine Kinase Receptor, Protein- 
                           DNA- interaction, Ephrin ligand.
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1 INTRODUCTION 
1.1 REGULATION OF GENE EXPRESSION DURING 
DEVELOPMENT 
The genetic information needed for development and metabolism is encoded in the DNA 
sequences of the chromosomes which, in eukaryotic cells, are located in the nucleus. The 
information in the DNA determines the structure of proteins and contains thereby the instructions 
on how to develop from a fertilized egg into pluripotent stem cells and further along particular 
cell lineages into tissues and organs.  
Although every somatic cell contains the same genetic information, not all the genes are 
transcribed at the same time or at the same level – every cell type expresses a different set of 
genes which fulfill the specific needs of the cell. Transcriptional regulation of gene expression in 
eukaryotes is a complex process highly regulated at many levels. It requires the concerted action 
of several factors to integrate different transcriptional regulatory signals controlling cellular 
responses such as proliferation, differentiation and apoptosis. Gene expression can be regulated at 
the transcriptional level (which genes are transcribed into RNA), on RNA processing level (which 
of transcribed RNAs are transported into the cytoplasm to become messenger RNAs), at the 
translational level (which of the mRNAs are translated into protein), at the protein modification 
level (which proteins are allowed to stay functional in the cell) (Gilbert, 1997). Transcription is 
regulated by a complex assembly of basal transcription initiation factors, sequence-specific DNA-
binding transcriptional activators and repressors and associated cofactors on promoters, enhancers 
and silencers (Tjian and Maniatis, 1994; St-Arnaud, 1998).  
INTRODUCTION 
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1.1.1 Regulatory transcription factors  
Where the basal transcription initiation apparatus is needed for initiation of transcription but is 
unable to regulate the rate of it, this task belongs to regulatory transcription factors. They 
communicate with the basal factors through coactivator proteins. The number of basal factors is 
limited, whereas the number of specific transcription factors is high. The expression of regulatory 
transcription factors may be specific cell types or to a certain stage of development.  
Transcription factors bind to cis-acting binding sites, located adjacent to the promoter, far 
upstream of it or even downstream of the gene. Sequence-specific regulators can be subdivided 
into activators or repressors, but several factors can mediate either activation or repression of the 
core promoter unitilization in a context-dependent manner. The changes in concentration of a 
transcription factor may affect whether it acts as an activator or as a repressor, or the response 
may be dependent upon the ligands present, or the physiological state of the cell (Courey, 2001). 
The expression of regulatory transcription factors needs itself to be regulated, in general by other 
transcription factors (Gilbert, 1997). Often their enhancers and promoters are very complex, 
allowing them to be expressed only in certain cells (Blackwood and Kadonaga, 1998). 
1.1.2 Transcription factor families 
Transcription factors can be divided into several families based on the structure utilized for DNA 
binding or sometimes on the activation domain or oligomerization domain (Mitchell and Tjian, 
1989; Tjian and Maniatis, 1994). There are several different DNA-binding domains and motifs 
that classify transcription families, for example, homeodomain and Myb domain, classical zinc 
finger motif, MADS domain, basic- region- leucine- zipper domain, forkhead motif and bHLH 
(basic helix-loop-helix) motif (Pabo and Sauer, 1992; Fairall and Schwabe, 2001). 
1.2 FORKHEAD FAMILY OF TRANSCRIPTION FACTORS 
1.2.1 General aspects of forkhead proteins 
Forkhead proteins are not among the largest transcription factor families, but they are functionally 
very diverse and are involved in a wide variety of biological processes. The name derives from 
two-spiked head structures in embryos of the Drosophila fork head mutant, which are defective in 
formation of the anterior and posterior gut (Weigel et al., 1989). With the discovery in 1990 of a 
110-amino-acid DNA binding domain that was almost perfectly conserved between FORK 
HEAD and the mammalian HNF-3 transcription factors, it became clear that this motif defined a 
INTRODUCTION 
14 
novel transcription factor family (Weigel and Jackle, 1990). Since then, over 100 genes encoding 
members of the forkhead family have been identified in a variety of eukaryotes ranging from 
invertebrates to humans (Kaufmann and Knochel, 1996). 
1.2.1.1 Nomenclature 
The official nomenclature (Kaestner et al., 2000), which uses Fox (for “Forkhead box”) as the 
root symbol, ensures that the same name is used for orthologous genes in different species and 
reflects phylogenetic relationships by including a letter that indicates subfamily. Seventeen 
subfamilies have been delineated for known chordate Fox proteins. The constantly updated 
phylogenetic tree can be downloaded from the web at http://www.biology.pomona.edu/fox.html 
(Fig.1.1). Within a subfamily, each gene is identified by a number (e.g., FoxB1), the typography 
follows the conventions used in each species (FOXB1 in Homo, Foxb1 in Mus, and FoxB1 in all 
others), and proteins are distinguished from genes by the use of roman type (e.g., FoxB1). 
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Fig.1.1:  phylogenetic tree of chordate Fox proteins. 
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1.2.1.2 Structure of the forkhead domain (DNA-binding domain) 
Clark and co-workers (Clark et al., 1993) worked out the first three-dimentional structure of a 
forkhead domain of FoxA3 (HNF-3γ) bound to a DNA target by using X-ray crystallography. 
They compared the fold with the shape of a butterfly and coined the term “winged helix” to 
describe the structure, which has a helix–turn–helix core of three α helices, flanked by two loops, 
or “wings” (Fig.1.2). “Winged helix” proteins are often used synonymously with forkhead 
proteins (Lai et al., 1993). However, several phylogenetically unrelated proteins  
 
Fig. 1.2: Three-dimensional structure of the DNA-binding domains of FoxA3 bound to DNA (X-ray 
crystallography; Clark et al., 1993) and FoxC2 (NMR; van Dongen et al., 2000). The FoxA3 structure 
shows the recognition helix (H3) filling out the major groove of DNA (viewing angle parallel with the H3 
helical axis). The first wing (W1) reaches upward, approximately parallel with the DNA helical axis and 
beyond the (3′) end of the oligonucleotide, whereas the second wing (W2) makes minor groove contacts in 
the 5′ end of the binding site. The FoxC2 NMR structure shows the helix–turn–helix motif viewed from the 
side facing away from the DNA with two helices, H1 and H2, stacked on top of the recognition helix (H3). 
The first wing (W1) consists of two antiparallel ß-strands (yellow) separated by a short loop (Carlsson and 
Mahlapuu, 2002). 
 
have similar 3D structure and are referred to as winged helix proteins in the literature as well; 
e.g., MotA from bacteriophage T4, LexA from Echerichia coli, E2F, DP, and RFX transcription 
factors as well as double-stranded RNA adenosine deaminase. Care should be taken to distinguish 
between these topologically similar proteins of diverse evolutionary origin and forkhead proteins, 
which form a clearly defined, monophyletic group. A
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forkhead domain are invariant or highly conserved, which implies that there is only limited 
variation in 3D structure and mode of DNA recognition within the forkhead family. This has been 
confirmed by NMR structural analysis of the DNA binding domains of three additional forkhead 
proteins: FOXC2, Foxd3, and FOXO4 (Carlsson and Mahlapuu, 2002). While Clark et al. (1993) 
identified three α helices in FoxA3, the NMR structures all show a short fourth helix in the loop 
between helix 2 and 3. However, Weigelt et al. (2001), point out that the backbone fold in this 
region is nearly identical in all four structures (including FoxA3) and inclusion or omission of a 
fourth helix mostly reflects differences in interpretation. A 5-amino-acid insertion between helix 
2 and 3 found in the FoxO subfamily adds a small extra loop, but has surprisingly little effect on 
the overall structure (Jin et al., 1999; Weigelt et al., 2001). Binding to a DNA target site appears 
to cause only minor structural changes in the forkhead domain (Jin et al., 1999), whereas circular 
permutation data indicate that a substantial bend is induced in the DNA (Pierrou et al., 1994). 
1.2.1.3 DNA binding specificity 
In contrast to most helix–turn–helix proteins, forkhead proteins bind DNA as monomers (Pierrou 
et al., 1994). Hence, the binding sites, which typically span 15–17 bp, are asymmetrical. The 
sequence specificity has been determined for several representatives of this protein family 
through selection of binding sites from pools of short, random-sequence duplexes. A seven-
nucleotide core corresponds to the major groove base contacts made by the recognition helix 
(helix 3). For the majority of forkhead proteins, the core conforms to the RYMAAYA (R _ A or 
G; Y _ C or T; M _ A or C) consensus (Pierrou et al., 1995; Kaufmann and Knochel, 1996). An 
optimal core sequence is essential, but not sufficient for high affinity binding, which also depends 
on flanking sequences on both sides of the core (Overdier et al., 1994; Pierrou et al., 1994; 
Kaufmann et al., 1995; Roux et al., 1995).  
Pairs or small groups of forkhead proteins have DNA binding domains so similar that the 
specificities have to be assumed to be identical; for example FOXD1 and FOXD2 have forkhead 
domains with 100% amino acid identity (Ernstsson et al., 1997), and FOXC1 and FOXC2 are 
97% identical (Kume et al., 1998). This exceptional degree of sequence conservation is confined 
to the forkhead domain--in FOXD-1 and -2, for example, there are no discernable homologies 
between the rest of the proteins. Since experimental data suggest that a considerable sequence 
variation within the forkhead domain can be tolerated with no or little effect on sequence 
specificity, additional interactions and functions are likely to contribute to the selective forces that 
preserve the forkhead domains. 
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1.2.1.4 Transcription effector domains 
Forkhead proteins have been shown to act mostly as transcriptional activators but not exclusively 
so. For example, trans-repression has been reported for FoxG1 and -p1/2/4 (Bourguignon et al., 
1998; Wang et al., 2004). In C. elegans, the forkhead protein LIN-31 is thought to act as either 
repressor or activator, depending on its phosphorylation in response to MAP kinase signaling 
(Tan et al., 1998). Mammalian FoxG1 represses transcription by forming a complex with 
transcriptional co-repressors of the Groucho family and histone deacetylases (Yao et al., 2001). 
Using deletions and substitutions, the regions that contribute to transcriptional activation have 
been mapped in detail for several forkhead proteins, such as FoxA2, -F1, -F2, -N1, and others 
(Pani et al., 1992; Hellqvist et al., 1996; Schuddekopf et al., 1996; Hellqvist et al., 1998). Like 
many other transcription factors, forkhead proteins often contain several activating regions, and 
these can be found in any location relative to the DNA binding domain. 
Little is known about the mechanisms through which forkhead proteins interact with the 
transcriptional machinery. In vitro, FOXF2 binds the general transcription factors TBP and 
TFIIB, and in cotransfection experiments, FOXF2 acts synergistically with TFIIB (Hellqvist et 
al., 1998). 
1.2.1.5 Forkhead genes in development 
Analysis of gene mutations in mouse is offering insight into the diverse range of biological 
processes that forkhead genes influence (summarized in Table 1.1). Additionally, members of the 
Fox family have been shown to be involved in different genetic and tumoral diseases [recently 
reviewed in (Carlsson and Mahlapuu, 2002)] 
 
TABLE 1.1 The phenotypes of mice resulting from inactivation of Fox gene by gene targeting or 
by spontaneous mutant (Carlsson and Mahlapuu, 2002). 
Gene                                        Mutant phenotype                                               References 
Foxa1 (HNF-3α)       Die postnatally with severe growth retardation and hypoglycemia                  Kaestner et al., 1999; Shih et a. 
                                  Reduced pancreatic glucagon production                                                           1999. 
Foxa2 (HNF-3ß)       Absence of node, notochord, and foregut. Embryos do not develop                  Ang and Rossant, 1994; Sund  
                                  beyond E8.5. Conditional inactivation in pancreas causes                                 et al., 2000; Sund et al., 2001; 
                                  hyperinsulinemichypoglycemia                                                                            Weinstein et al., 1994 
Foxa3 (HNF-3γ)       Reduced expression of the hepatic glucose transporter GLUT2 leads to              Kaestner et al., 1998; 
                                  inefficient glucose efflux and fasting hypoglycemia.                                            Shen et al., 2001 
Foxb1 (Mf3)             Variable phenotype including perinatal mortality, growth retardation,                 Alvarez-Bolado et al., 2000;  
                                  nursing defects, and defects in the central nervous system.                                  Labosky et al., 1997;  
                                                                                                                                                                 Wehr et  al., 1997 
Foxc1 (Mf1)             Die at birth with multiple abnormalities including hydrocephalus,                         Hong et al., 1999; Kidson 
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                                 skeletal, ocular, renal, and cardiovascular defects. Heterozygotes have             et al., 1999;Kume et al., 1998,  
                                ocular defects. Together with Foxc2 required for somitogenesis         Smith et al., 2000; Winnier et al.,1999 
Foxc2 (Mfh1)          Die pre- or perinatally with skeletal and cardiovascular defects.               Iida et al., 1997; Kume et al., 2000b, 
                                Heterozygotes have ocular defects. Together with Foxc1 required for       2001; Smith et al., 2000; Winnier et 
                                   somitogenesis.                                                                                                    al., 1997; Winnier et al., 1999 
Foxd1 (Bf2)            Die within 24 h after birth due to renal failure.                                                                     Hatini et al., 1996 
Foxd2 (Mf2)           Viable and fertile, but ca. 40% have renal abnormalities.                                                      Kume et al., 2000b 
Foxe1 (TTF-2)         Die within 48 h of birth exhibiting cleft palate and either a complete or De                        Felice et al., 1998 
                                 partial failure of thyroid gland development. 
Foxe3                      Viable and fertile. Severe cataract and fusion of                                                                   Blixt et al., 2000;  
(dysgenetic lens mutant)         ornea and iris caused by degeneration of lens epithelium.                               Brownell et al., 2000 
Foxf1 (FREAC1,     Die around E9 due to absence of vasculogenesis in yolk sac and allantois                     Kalinichenko et al., 
HFH-8)                   as a result of defects in mesodermal differentiation. Heterozygotes                       Mahlapuu  et al., 2001a,b 
                                have lung and foregut malformations. 
Foxg1 (Bf1)              Die around birth, with a severe reduction in the size of the cerebral                                      Xuan et al., 1995 
                                  hemispheres. 
Foxh1 (Fast)           Embryonically lethal due to failure to form node, prechordal mesoderm,                       Hoodless et al., 2001; 
                                notochord, and definitive endoderm.                                                                              Yamamoto et al., 2001 
Foxi1 (Fkh-10)        Malformations of the inner ear results in deafness and disturbed balance.                        Hulander et al., 1998 
Foxj1 (HFH-4)         Majority die before weaning and show defective ciliogenesis as well as                            Brody et al., 2000; 
                                 randomized left-right asymmetry.                                                                                           Chen et al., 1998 
Foxk1 (MNF)            Viable, but growth retarded. Incomplete muscle regeneration after injury                            Garry et al., 2000 
                                 due to defect proliferation and differentiation of myogenic stem cells. 
Foxl1 (Fkh-6)            The majority die before weaning with intestinal epithelial hyperplasia                         Kaestner et al., 1997; 
                                 due to overactivation of the Wnt/ß-catenin pathway.                                                        Perreault et al., 2001 
Foxm1 (Trident,        Die perinatally with cardiovascular defects and polyploidy in                                           Korver et al., 1998 
HFH-11)                    cardiomyocytes and hepatocytes. 
Foxn1 (Whn)             Exhibit all features of the original nude mutant, such as hairlessness and                  Nehls et al., 1994, 1996 
                                  athymia. 
Foxp3                      (scurfy mutant) Overproliferation of CD4+ CD8-T lymphocytes,                                         Jeffery et al., 2001 
                                 extensive multiorgan infiltration and elevation of cytokines. 
Foxq1                    (satin mutant) Have a silky fur coat due to defects in differentiation of                                   Hong et al., 2001 
                               the hair shaft. 
 
 
1.2.2 Characteristics of forkhead transcription factor Foxb1 
Foxb1 was previously known as Mf3 (Labosky et al., 1996; Labosky et al., 1997), Fkh5 (Kaestner 
et al., 1996). TWH (Dou et al., 1997), and HFH-E5.1 (Ang et al., 1993). The new WH 
nomenclature is described by Kaestner et al. (Kaestner et al., 2000). Foxb1 has 324 amino acids, 
from 13 to 113 is the forkhead domain, a large proportion of amino acids in the forkhead domain 
are invariant and highly conserved (Fig.1.3). It maps to mouse Chromosome 9 near several well 
characterized mouse mutations including prenatal lethal factor 1 (pnlf1), and small thymus (sty) 
(Kaestner et al., 1996; Labosky et al., 1996). 
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Fig. 1.3: Alignment of 17 mouse forkhead domains illustrates the conserved regions in relation to helices 
(H1–H3) and ß-strands (yellow). 
 
 
The expression pattern of Foxb1 has been well characterized (Ang et al., 1993; Kaestner et al., 
1996; Wehr et al., 1997; Alvarez-Bolado et al., 1999; Alvarez-Bolado et al., 2000). Transcripts 
are first localized in the early embryo from day 7.5 p.c onwards in anterior neurectoderm and 
mesoderm and in the presomitic mesoderm. By E8, the expression was seen in the ventricular 
layer of the diencephalons, midbrain, hindbrain and spinal cord. From E9 to E10, the expression 
of this gene is rapidly restricted in the diencephalon and rostral midbrain, the expression in 
diencephalon is restricted in posterior hypothalamus. while it is constant in the region of the 
hindbrain and caudal midbrain. By E12 there is a sudden change in pattern- the rostral midbrain 
acquired a strong expression and the diencephalic restriction of expression stops at the caudal 
hypothalamus, while the caudal midbrain and hindbrain gradually lose expression intensity. In the 
adult, only nuclei of the rostral midbrain (the superior colliculus) and caudal hypothalamus 
(medial mammillary, dorsal premammillary and tuberomedial) show Foxb1 expression. In the 
mammillary body, the medial and lateral mammillary and dorsal premammillary nuclei express 
Foxb1 during development; in the adult, the tuberomammillary nucleus expresses Foxb1 
transiently during development, and the supramammillary nucleus never expresses Foxb1 (Fig. 
1.4). Foxb1 may play a role in the growth and differentiation of a specific segment of the anterior 
CNS.  
Foxb1 is known to participate also in spinal cord differentiation (Dou et al., 1997) as well as in 
the control of lactation (Labosky et al., 1997). 
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Fig. 1.4:  The schematic description of the expression of Foxb1 at E8 (left), E14 (middle) and adult stage 
(right) (Alvarez-Bolado et al., 1999). DI, diencephalon; MB, midbrain; HB, hindbrain; HY, hypothalamus; 
MBO, mammillary body. 
 
1.3 HYPOTHALAMUS 
1.3.1 General aspects about hypothalamus 
The hypothalamus is a morphologically and functionally complex region of the forebrain 
comprising most of the neural structures governing motivated behavior – the behavior originated 
by causes or motivators like danger, thirst, hunger or sexual drive.  
Many behaviors understood as “emotions” in the human, like anger, fear, love (also maternal 
love), desire, etc. are also originated in the hypothalamus. Activation of hypothalamic neural 
systems by motivators leads to basic and highly stereotyped, behaviors, like aggression, escape, 
foraging (for food, water, salt etc.), sexual display and many others. The same behaviors can be 
observed in humans, but with a much larger degree of complexity, and having intricate relations 
with cognitive processes (memory, logical abilities, prospective abilities, etc.). 
1.3.2 Mammillary body 
The mammillary body is a large neuronal group in the caudal/ventral hypothalamus formed by 
three nuclei – the lateral and medial mammillary nuclei, and the dorsal premammillary nucleus 
(Fig.1.5; reviewed by Canteras and Swanson, 1992; Risold and Swanson, 1995). 
INTRODUCTION 
23 
 
 
Fig. 1.5: Organization of the three nuclei of the mammillary body and their projections in the adult mouse. 
The right side of the brain is represented in a sagittal perspective. Rostral is to the left. The three color traits 
coming out of the nuclei represent each one single axonal stem and its two branches (Alvarez-Bolado et al., 
2000). 
 
The mammillary group receives a major input from the postcommissural fornix, which arises in 
the subicular complex of the hippocampal formation and is a major component of the classical 
“papez circuit” (1937), which is now thought to play a role in learning and memory. 
The mammillary axonal complex (Fig. 1.5) is formed by the axons from these nuclei, which share 
a branching pattern – every neuron gives off one axonal stem that bifurcates into two branches. 
One of the branches is directed dorsally to the thalamus and another caudally to the midbrain. 
This peculiar pattern of connections bridging forebrain and midbrain, also shown by other nuclei 
in this boundary region, is considered a major feature of diencephalic circuitry with important 
behavioral implications (Canteras and Swanson, 1992; Risold et al., 1997). In particular, the 
mammillothalamic tract connects the two major subdivisions of the diencephalons (hypothalamus 
and thalamus) and closes the circuit originally described by Papez. 
Mammillothalamic fibers develop as short, collateral branches of the principal mammillary tract. 
The mammillothalamic tract forms a compact bundle, reaching the anterior thalamic nuclear 
group around E18-E19. 
There is considerable evidence that damage to MBO and mtt can result in the deficits in the 
performance of certain spatial memory tasks (Vann and Aggleton, 2003). 
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1.3.3 Foxb1 function in the hypothalamus 
Mice carrying a targeted null mutation in Foxb1 (Dou et al., 1997; Labosky et al., 1997; Wehr et 
al., 1997; Alvarez-Bolado et al., 2000) survive to adulthood and are (with limitations) able to 
reproduce, but lack a large part of the mammillary region of the hypothalamus, the so-called 
mammillary body, MBO. This defect is accompanied by an axonal navigation defect. In wild type 
animals, the mammillary axonal tree is formed by a large bundle of axons coming from the 
neurons of the MBO (Fig.1.5). These axons bifurcate after a short dorsal trajectory. The main 
bundle (the earliest to appear during development) turns then caudally, towards the midbrain. 
Some of these axons form the mammillotegmental bundle (mtg) and end in the tegmentum of the 
midbrain, while other axons form the mammillotectal bundle (mtc) and end in the tectum of the 
midbrain. However, around embryonic day E18.5 they form a branch, the mtt which is directed 
towards the dorsal diencephalon and ending in the anterior thalamus. 
Examination of axonal development in Foxb1 mutants has revealed that the MBO is indeed 
formed during the development of the mutant brain, and it emits the axons of the principal 
mammillary tract, and in due time these axons branch into the meet and start their growth towards 
the anterior thalame tract. In the mutant, however, mtt axons are not able to enter their target, the 
dorsal thalamus, and are instead deflected towards the ventral side. A short time after this 
navigational failure, which happens around E18.5, the MBO disappears almost completely due to 
massive apoptosis (Fig.1.6) (Alvarez-Bolade, Gonzalo et al. 2000). The failure of the mtt to 
connect with its target in the Foxb1 mutant has major consequences. In wild type, the mtt links 
the mammillary region of the hypothalamus to the anterior region of the thalamus, and in this way 
closes the classically described “Papez circuit” (anterior thalamus-cingulate cortex-hippocampus-
mammillary-anterior thalamus), which is crucial for some forms of memory (Sgroi et al. 1999). In 
agreement with this observation, Foxb1-deficient mice suffer from spatial working memory 
problems (Radyushkin et al., 2005). Therefore, the causal link is established between one 
transcriptional regulator, Foxb1, one neural circuit, and one specific brain function. 
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Fig. 1.6: The mammillothalamic tract cannot enter the target in the Foxb1-homozygous brain (upper panel, 
asterisk); Foxb1-deficient mice lack one brain nucleus (lower panel, arrowhead) (Alvarez-Bolado et al., 
2000). 
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1.4 AXONAL NAVIGATION 
The correct wiring of the nervous system relies on the ability of developing axons and dendrites 
to locate and recognize their appropriate synaptic partners. To help them find their way in the 
developing embryo, axons and dendrites are tipped with a highly motile and sensitive structure, 
the growth cone. Extracellular guidance cues can either attract or repel growth cones, and can 
operate either at close range or over a distance (Tessier-Lavigne and Goodman, 1996). By 
responding to the appropriate set of cues, growth cones are able to select the correct path toward 
their target. 
1.4.1 Cellular interactions that guide axons 
Embryological, tissue culture, and genetic experiments indicate that axons respond to the 
coordinate actions of four types of guidance cues: attractive and repulsive cues, which can be 
either short-range or long-range (Fig.1.7). 
 
Fig. 1.7: Guidance forces. Four types of mechanisms contribute to guiding growth cones: contact 
attraction, chemoattraction, contact repulsion, and chemorepulsion. The term attraction is used here to refer 
to a range of permissive and attractive effects, and the term repulsion to a range of inhibitory and repulsive 
effects. Examples are provided of ligands implicated in mediating each of these mechanisms. There is not a 
one-to-one match between molecules and mechanisms because some guidance molecules are not 
exclusively attractive or repulsive, but rather bifunctional, and some families of guidance cues have both 
diffusible and nondiffusible members. Individual growth cones might be "pushed" from behind by a 
chemorepellent (red), "pulled" from afar by a chemoattractant (green), and "hemmed in" by attractive 
(gray) and repulsive (yellow) local cues. Axons can also be guided by cues provided by other axons 
(selective fasciculation). Push, pull, and hem: these forces act together to ensure accurate guidance 
(Tessier-Lavigne and Goodman, 1996). 
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Many neuronal connections are made by secondary (collateral) branches of axons, which form de 
novo from secondary growth cones sprouted along the axon shaft. Both the initiation and 
subsequent guidance of secondary growth cones appear to be directed by the same forces that 
guide primary growth cones (Roskies and O′Leary, 1994).  
The guidance of axons over individual segments of their trajectories appears to involve the 
simultaneous operation of several, and in some cases possibly all four, of these guidance forces. 
Thus, an individual axon might be "pushed" from behind by a chemorepellent, "pulled" from afar 
by a chemoattractant, and "hemmed in" by attractive and repulsive local cues. Push, pull, and 
hem: these forces appear to act together to ensure accurate guidance. However, this well-
engineered redundancy complicates experimental analysis of guidance mechanisms because 
perturbation of any one mechanism often has a limited effect. 
Guidance cues have been classified according to the response they elicit as either attractive or 
repulsive (Tessier-Lavigne and Goodman, 1996; Mueller, 1999). Prominent among these are the 
ephrins, netrins, slits, robos and semaphorins (Dickson, 2002). These are not the only known 
guidance molecules, but they are by far the best understood. I will introduce here in detail only 
the most relevant to my PhD work, i. e., the ephrins and their receptors, the Eph ("eff") tyrosine 
kinases. 
1.4.2 Ephrins and Eph 
The ephrins are membrane-bound ligands for the Eph family of receptor tyrosine kinases (Bartley 
et al., 1994) (Drescher et al., 1995). They are divided into two subclasses, the A-subclass 
(ephrinA1–ephrinA5), which are tethered to the cell membrane by a glycosylphosphatidylinositol 
(GPI) anchor, and the B-subclass (ephrinB1–ephrinB3), members of which have a 
transmembrane domain that is followed by a short cytoplasmic region. 
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Fig. 1.8: The structural classes of vertebrate Eph receptors and ephrins and their binding specificities are 
ummarized. Although binding is promiscuous within each of the Eph/ephrin specificity classes, there are 
differences in affinity that might be functionally important. (GPI, glycosylphosphatidylinositol) (reviewed 
(Wilkinson, 2001)). 
 
The Eph family, is the largest family of receptor tyrosine kinases (RTKs). It consists of 14 
different members subdivided into EphA and EphB receptors on the basis of sequence similarity 
and ligand affinity. A-subclass, which contains eight members (EphA1–EphA8) and a B-subclass, 
which in mammals contains five members (EphB1–EphB6). A-type receptors typically bind to 
most or all A-type ligands, and B-type receptors bind to most or all B-type ligands, with the 
exception of EphA4, which can bind both A-type and most B-type ligands (Fig. 1.8). 
The Eph-receptor extracellular domain is composed of the ligand-binding globular domain, a 
cysteine-rich region and two fibronectin type III repeats (Fig.1.9). The cytoplasmic part of Eph 
receptors can be divided into four functional units; the juxtamembrane domain that contains two 
conserved tyrosine residues, a classical protein tyrosine kinase domain, a sterile a motif (SAM) 
and a PDZ- binding motif. The solved structure of the SAM domain ( 70 amino acids) indicates 
that it could form dimers and oligomers. The PDZ- binding motif located in the carboxy-terminal 
4–5 amino-acid residues — contains a consensus binding sequence that includes a hydrophobic 
residue (usually valine or isoleucine) at the very carboxyl terminus (Kullander and Klein, 2002). 
Functional evidence suggests that Eph receptor - ligands play important roles in the formation of 
topographic mapping (the mechanism by which axon terminals organize themselves onto a target 
area) (Drescher et al., 1995; Nakamoto et al., 1996; Frisen et al., 1998; Wilkinson, 2000), in the 
patterning of forebrain and hindbrain (Xu et al., 1996), and in the formation of certain 
commissures (Park et al., 1997). At the cellular level, ephrins act as contact-dependent  
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Fig.1.9: General features of Eph receptors and ephrins.   A schematic diagram, which shows an ephrin-
expressing cell (top) interacting with Eph-expressing cell (bottom). Ligand–receptor interactions (green) 
have been mapped in detail and have uncovered dimeric and oligomeric Eph–ephrin complexes (not 
shown). GPI, glycosylphosphatidylinositol; SAM, sterile -motif (Kullander and Klein, 2002). 
 
repulsive factors for retinal axons, motor axons, cortical neurons, and neural crest cells (Drescher, 
1997). A role in axon fasciculation and in formation of axon branches of cortical neurons for one 
member, ephrin-A5 (AL-1/RAGS), has been shown in vitro experiments (Bolz and Castellani, 
1997). 
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Signal transduction by the Eph receptors has features that are common with growth-factor 
receptor kinases, and also some unique features. Ephrin induces Eph receptor dimerization and 
kinase activation. Activation of the Eph receptors results in tyrosine phosphorylation of the 
receptor itself and downstream substrates, creating binding sites for SH2 domain-containing 
proteins. In contrast to mitogenic growth factor receptors, which generally activate Ras and MAP 
kinase signalling, Eph receptors do not activate Ras or extracellular signal-regulated kinase 
(ERK). Instead, activation of Eph receptors has been reported to result in recruitment of Ras 
GAP, which then inactivates Ras and suppresses ERK activation. This is consistent with the 
observation that ephrins do not exhibit mitogenic effects. 
Functional analysis of the Eph–ephrin system is challenging for at least two reasons. First, Eph 
receptors can have overlapping functions in vertebrates, and loss of one receptor can be partially 
compensated for by another Eph receptor that has a similar expression pattern and ligand-binding 
specificities. Second, an Eph receptor can also act as a ligand in the same way that an ephrin 
ligand can act as a receptor (introduced above). The functional consequences of Eph-receptor 
redundancy are well described by studies in which the functions of EphB2 and EphB3 were 
examined by targeted deletion of these molecules in mice. Although mice that are singly deficient 
for EphB2 or EphB3 are viable, most EphB2–EphB3 double mutants die at birth due to a 
developmental defect in the upper mouth called cleft palate, which prevents proper food intake. 
Similarly, during retinal ganglion-cell axon guidance to the optic disc, mouse embryos that lack 
both EphB2 and EphB3 show increased frequency of axon guidance errors, which could not be 
detected in the single mutants. Genetic background also has an important role for the discovery 
and penetrance of phenotypes in mice. By shifting mice with an EphB2-targeted deletion from 
129 to CD1 genetic background, increased survival rates and a circling behaviour was shown in 
61% of the cases. Mice that lack both EphB2 and EphB3 receptors in the CD1 background all 
showed a circling behaviour, which indicates that these receptors might also be redundant in the 
CD1 genetic background. 
Mammals have 13 Eph receptors and 8 ephrins. Worms and flies both have just a single Eph 
receptor, with four and one ephrin ligands, respectively. Somewhat surprisingly, the invertebrate 
ephrin and Eph mutants do not have dramatic axon guidance defects. The C.elegans ephrins and 
the Eph receptor do, however, have critical functions in multiple aspects of epithelial 
morphogenesis, as do their vertebrate counterparts. It seems that ephrins and Eph receptors are an 
ancient but versatile system for cell-cell communication that has diversified and acquired its axon 
guidance functions primarily during vertebrate evolution. 
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1.5 MICROARRAY TECHNOLOGY 
I will briefly introduce here the theory and methods of DNA microarray technology, which has 
had an important role in my PhD work. 
1.5.1 Genomics and DNA arrays 
To take full advantage of the large and rapidly increasing body of DNA sequence information, 
new technologies are required. DNA arrays are powerful and versatile tools for genomics and 
genetics research. They allow us to make quantitative parallel measurements of gene expression 
(messenger RNA abundance) for tens of thousands of genes at a time, making possible genome-
wide measurements of transcription, and bridging the gap between genotype and phenotype 
(Lockhart and Winzeler, 2000; Lockhart and Barlow, 2001). 
1.5.2 Affymetrix GeneChips 
There are different types of microarray in common use (for instance, spotted cDNA arrays and 
spotted oligonucleotide arrays). All of them have advantages and disadvantages. For my PhD 
work I have used one particular kind, the commercially available "Affymetrix GeneChips". They 
are comparatively easy to use, and they have been widely utilized already to address problems in 
developmental neurobiology.  
These microarrays are factory-designed and -synthesized. Design is done using software to 
choose a series of 11 25-mer probes from the 3′ end of each transcript or predicted transcript in 
the genome; each of the 11 probes is then paired with a similar mismatch probe that is designed to 
contain a mutation in the centre. The latter serves as a form of control for hybridization 
specificity. Synthesis of arrays is done using light-activated chemistry and photolithography 
methods, and feature size can be reduced to approximately 8 m2, with about 1 million probes in 
a 1.2 cm2 glass area. Probe-set algorithms interpret the signals from each 22-oligonucleotide 
probe set, and derive a single value (signal) from the patterns of hybridization to the 22 individual 
probes. This signal is then normalized to the entire microarray, or to the probe sets across an 
entire project. 
Affymetrix arrays provide multiple measurements — a series of independent or semi-independent 
oligonucleotides query each RNA in solution (the probe set). Affymetrix probe sets are 
constructed from a series of perfect-match and paired-mismatch oligonucleotides, allowing some  
INTRODUCTION 
32 
 
 
Fig. 1.10: Sample processing and microarray interpretation of Affymetrix GeneChips. Flash-frozen tissue 
( 50 mg) is homogenized to isolate total RNA. Single-stranded (ss) cDNA and then double-stranded (ds) 
cDNA is made from 5 g of total RNA. Double-stranded cDNA contains a T7 RNA-polymerase 
promoter adjacent to the 3′ polyA tail of each transcript. It is transcribed in vitro to generate more than 400 
biotinylated cRNA molecules for each ds cDNA molecule. The biotinylated cRNA is fragmented and 
hybridized to the microarrays. Each transcript is queried by one or more probe sets of 11 perfect-match and 
11 paired-mismatch oligonucleotides (the latter contain a centrally located point mutation as a form of 
hybridization specificity control). Currently available Affymetrix microarrays have 54,000 probe sets on 
each 1.28 cm2 glass microarray ( 1.2 million 25-mer oligonucleotides on the HG-U133Plus 2.0 array). The 
biotinylated cRNA fragments hybridize to the appropriate oligonucleotide features. A laser scanner 
determines the amount of bound biotinylated cRNA indirectly through the streptavidin-conjugated 
phycoerythrin fluorescence at each feature within a probe set. The component probe pairs are interpreted 
and averaged to arrive at a single signal that reflects the relative abundance of the original mRNA. Probe 
sets are interpreted by any one of a number of probe-set algorithms, each providing a signal that reflects the 
relative hybridization intensity across the probe set. RT, reverse transcriptase (Collective, 2004). 
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assessment of non-specific binding and performance of the probes. Overall, the Affymetrix probe 
sets provide a variety of measurements that allow robust measures of gene expression. The use of 
multiple perfect-match and mismatch probes for each gene enables the development of different 
methods of interpreting the hybridization patterns across the probe set and calculating a single 
′expression level′ or ′signal′ that reflect the gene′s relative expression level. A number of probe-
set interpretation algorithms for Affymetrix arrays are available (Mills et al., 2001; Collective, 
2004). 
The standard laboratory protocol for generating RNA profiles using Affymetrix microarrays 
involves a series of steps (Fig.1.10). 
Currently available Affymetrix microarrays have 54,000 probe sets on each 1.28 cm2 glass 
microarray (1.2 million 25-mer oligonucleotides on the HG-U133Plus 2.0 array). The biotinylated 
cRNA fragments hybridize to the appropriate oligonucleotide features. A laser scanner 
determines the amount of bound biotinylated cRNA indirectly through the streptavidin-conjugated 
phycoerythrin fluorescence at each feature within a probe set. The component probe pairs are 
interpreted and averaged to arrive at a single signal that reflects the relative abundance of the 
original mRNA. Probe sets are interpreted by any one of a number of probe-set algorithms, each 
providing a signal that reflects the relative hybridization intensity across the probe set. RT, 
reverse transcriptase. 
1.5.3 Application of Affymetrix GeneChips to brain development 
questions, and attending technical challenges 
One of the best illustrations of the future challenges for microarray analysis is provided by 
several recent applications of this technology to studies of neurobiology. At the cellular level, 
there are questions concerning the genetic programs responsible for specification of neural cell 
fates and the differentiation of the myriad neuronal and glial types (Geschwind et al., 2001); 
(Ramalho-Santos et al., 2002). At the circuit level, the processes of axon guidance, target 
selection, synapse formation and refinement of synaptic connections each rely on a combination 
of intrinsic gene-expression patterns and environmental influences (Diaz et al., 2002). In addition, 
at the systems level, there is a drive to fully map the spatial and temporal expression patterns of 
each gene. The utilization of microarrays to probe gene expression patterns at each of these levels 
has resulted in the identification of a considerable number of candidate genes, of which a few 
have been confirmed with in vivo studies (Sandberg et al., 2000; Zhao et al., 2001; Zirlinger et al., 
2001). 
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However, it is important to recognize the technical challenges of these studies. One challenge is 
that many brain regions of interest are tiny, making it difficult to obtain sufficient RNA for 
conventional microarray studies. Another technical challenge for microarray studies of the brain 
arises from the need to dissect different subregions of the brain with functional properties of 
interest. The exquisite sensitivity of microarray analysis and the distinct transcript profiles of 
different brain subregions make analyses of dissected tissues susceptible to false positive 
detections from inclusion of variable amounts of adjacent tissue in a given sample of a desired 
subregion (Mirnics and Pevsner, 2004); (Shoemaker and Linsley, 2002). In almost all cases, 
experiments should be conducted at least in duplicate, with replicates done as independently as 
possible (for example, different mice or independent dissections of a region, independent sample 
preparations and independent hybridizations to physically different arrays). It is not sufficient to 
merely remake samples from the same extracted RNA from the same mouse or tissue sample, or 
to simply rehybridize samples to other arrays, as has been done in some studies. If genetically 
identical, inbred mice are not used, then it is necessary to do more experiments or to pool mice to 
effectively average out differences due to genetic inhomogeneity (Lockhart and Barlow, 2001). 
1.5.4 Validation of microarray data  
Once the appropriate mathematical tools have been used to identify genes likely to be regulated in 
the manner of interest, the next step is biological characterization of these genes. The first stage 
of this process is validation, which requires measuring the expression of specific genes of interest 
using independent methods and independent RNA samples. There are important reasons why a 
gene identified on an array should be validated by another method. For oligonucleotide arrays, the 
labeled RNA used for hybridization to the chip is not the original RNA population but an 
amplified copy whose production requires multiple enzymatic steps, each of which may bias 
array results. Cross-hybridization due to sequence homology may lead to erroneous results, 
especially when using cDNA arrays to examine genes that have many closely related family 
members. Data normalization errors and sample amplification errors are also the obstacle to 
discover the differential expression (Griffin et al., 2003; Collective, 2004; Mirnics and Pevsner, 
2004). 
Quantitative RT-PCR is extremely valuable for high-throughput validation of microarray findings 
whereas in situ hybridization identifies the cellular localization of expression changes (Mimmack 
et al., 2004),. Quantitative RT-PCR is the most sensitive and accurate of the quantification 
methods (Wang and Brown, 1999; Giulietti et al., 2001). Visualizing changes in mRNA 
expression using in situ hybridization allows the cellular localization of regulated genes to be 
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identified. This is critical for the nervous system, where it is the specific pattern of circuitry that 
is the vital information (Blackshaw et al., 2001). 
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2 MATERIALS AND METHODS 
2.1 Routine for animal work 
All work with animals was accomplished according to the regulations of the federal animal law 
for the protection (BGB1 S.1105, ber. S. 181, Abschnitt 2 (§2+3), 5 (§7-9) und 8 (§119)) 
(Germany). Foxb1 deficient mice in a 129/sv background were made available by Dr. Gonzalo 
Alvarez-Bolado (Alvarez-Bolado et al., 2000). EphA7 receptor deficient mice were made by T. 
Ciossek (unpublished) and kindly available from P. Vanderhaeghen (Belgium). 
2.2 General molecular biological methods 
Bibliographical Note: All the techniques used in the present PhD work are well-known and 
commonly used by molecular biologists and histologists all over the world. I have not considered 
it necessary to cite the original methodological literature (first ever description of the concept, 
first ever usage of the method in a practical context, etc.) In carrying these methods out, however, 
I have relied on some specific reference works which have been very useful. For the general 
laboratory work, the classical manual universally known as “the Maniatis” (after the senior author 
of the first edition) (Sambrook and Russell, 2001) has been invaluable. The books of Docherty 
(Docherty, 1996) and Latchman (Latchman, 1999) were very useful for me to understand the 
principles behind DNA-protein interaction, particularly the chapters about EMSA protocols 
(Read, 1996; Dent et al., 1999). 
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2.2.1 Isolation of nucleic acids 
2.2.1.1 Isolation of genomic DNA from tissue samples 
About 0,5cm of the tail from a mouse or leg tissue from a mouse embryo was incubated in 500ul 
of lysis buffer (100mM Tris-Cl, pH8.0; 5mM EDTA, pH8.0; 0,2% SDS; 200mM NaCl) 
containing 25ul proteinase K (10mg/ml, Merck) in thermometer mixture at 56oC with 500rpm 
overnight. An equal volume of phenol/chloroform/isoamylalcohol (PCI) (25:24:1) was added, 
mixed by inverting, and centrifuged at full speed at room temperature for 10min. 250ul of the 
aqueous phase was transfer to a new tube, the DNA was precipitated with the same volume of 
isopropanol. Air dry the pellet 10min at room temperature. Resuspend and dissolve DNA in about 
500ul of TE buffer (pH7.5) (10mM Tris-Cl, pH7.5; 1mM EDTA, pH8.0) in thermometer mixture 
at 37oC with 500rpm. Use 1ul of DNA (about 100ng) for PCR genotyping. 
2.2.1.2 Small-scale isolation of plasmid DNA 
I used the “MACHEREY-NAGEL NucleoSpin® Plasmid” kit (Germany), according to the 
instructions of the manufacturer. Briefly: 5ml of LB medium with the appropriate amount of 
antibiotic was inoculated with a single E. coli colony and incubated overnight at 37°C with 
shaking. Using 1-5ml of this culture, pellet cells in a microcentrifuge for 30s at full speed. Add 
250ul A1, resuspend the cell pellet by vigorous vortexing. Add 250ul A2, mix gently by inverting 
the tube 6-8 times, incubate at room temperature for a maximum of 5min. Add 300ul A3. Mix 
gently by inverting the tube 6-8 times, centrifuge for 10min at full speed at room temperature or 
at 4°C. Place a NucleoSpin plasmid column in a 2ml collecting tube and load the supernatant on 
the column. Centrifuge for 1min at full speed. Discard the flowthrough. Place the NucleoSpin 
plasmid column back into the 2ml collecting tube and add 600ul A4, centrifuge for 1min at full 
speed. To dry the silica membrane completely, reinsert the NucleoSpin plasmid column into the 
2ml collecting tube. Centrifuge for 2min at full speed. Place the NucleoSpin plasmid column in a 
1,5ml microcentrifuge tube and add 50ul AE. Incubate 1min at room temperature. Centrifuge for 
1min at full speed. 
2.2.1.3 Midi preparation of plasmid DNA 
I used the “Qiagen Plasmid Midi Kit” (QIAGEN, USA) according to the instructions of the 
manufacturer. Briefly: In order to isolate a larger amount of plasmid DNA, the midi preparation 
DNA isolation method was carried out. 50ml of miniprep culture was used. Inoculate 50ml LB 
medium containing the appropriate antibiotics and incubated overnight in the shaker (300rpm) for 
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16-18 hours at 37°C. The bacterial suspension was centrifuged at 1300g for 15min at 4°C, and the 
pellet was then resuspended in 4ml of Buffer P1. For the cell lysis, 4ml of Buffer P2 was added, 
then mixed gently but thoroughly by inverting 4-6 times, the suspension was incubated at room 
temperature for 5min. 4ml of Buffer P3 was added to neutralize the suspension and mixed by 
inverting the tube. The suspension was centrifuged at 13000g for 30min and the supernatant 
applied to a previously equilibrated Qiagen-tip100 column (by applying 10ml of Buffer QBT for 
column equilibration) and left to run through the column resin by gravity flow. The column was 
washed twice with 10mL of Buffer QC. The DNA was eluted with 5ml of Buffer QF, and 
precipitated by adding 3,5ml (0,7 volumes) of isopropanol. Which was then centrifuged 
immediately at 13000rpm for 30min at 4°C. The pellet was washed with 70% ethanol, air dried 
for 10 minutes at room temperature and dissolved in 50ul buffer TE. 
2.2.1.4 EndoFree plasmid Maxi protocol 
I used the "QIAGEN Endofree Plasmid Midi Kit" (QIAGEN, USA) according to the instructions 
of the manufacturer, since it yields endotoxin-free DNA, which improves transfection into 
sensitive eukaryotic cells. The protocol is as follows: 
Pick a single colony from a freshly streaked selective plate and inoculate a starter culture of 2-
5ml LB medium containing the appropriate selective antibiotic. Incubate for about 8h at 37°C 
with rigorous shaking. Dilute the starter culture 1/500 to 1/1000 into selective LB medium. For 
high-copy plasmids inoculate 100ml medium, and for low-copy plasmids, inoculate 250ml 
medium. Grow at 37°C for 12-16h with rigorous shaking. Harvest the bacterial cells by 
centrifugation at 6000 x g for 15min at 4°C. Resuspend the bacterial pellet in 10ml Buffer P1. 
Add 10ml Buffer P2, mix gently but thoroughly by inverting 4-6 times, and incubate at room 
temperature for 5min. During this incubation prepare the QIAfilter Cartridge, screw the cap onto 
the outlet nozzle of the QIAfilter Maxi Cartridge. Place the QIAfilter Cartridge into a convenient 
tube. Add 10ml chilled Buffer P3 to the lysate, and mix immediately but gently by inverting 4-6 
times, immediately pour the lysate into the barely of the QIAfilter Cartridge. Incubate at room 
temperature for 10min. Do no insert the plunger. Remove the cap from the QIAfilter outlet 
nozzle, gently insert the plunger into the QIAfilter Maxi Cartridge and filter the cell lysate into a 
50-ml tube. Add 2,5ml Buffer ER to the filtered lysate, mix by inverting the tube approximately 
10 times, and incubate on ice for 30min. Equilibrate a QIAGEN-tip 50 by applying 10ml Buffer 
QBT, and allow the column to empty by gravity flow. Apply the filtered lysate to the QIAGEN-
tip and allow it to enter the resin by gravity flow. Wash the QIAGEN-tip with 2 x 30ml Buffer 
QC. Elute DNA with 15ml Buffer QN. Precipitate DNA by adding 10,5ml (0.7 volumes) room 
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temperature isopropanol to the eluted DNA. Mix and centrifuge immediately at 9500 x g for 1h at 
4°C. Carefully decant the supernatant. Wash DNA pellet with 5ml of endotoxin-free, room-
temperature 70% ethanol (add 40ml of 96-100% ethanol to the endotoxin-free water supplied 
with the kit) and centrifuge at 9500 x g for 30min, carefully decant the supernatant without 
disturbing the pellet. Air-dry the pellet for 5-10min, and redissolve the DNA in a suitable volume 
of endotoxin-free Buffer TE. 
2.2.1.5 Isolation of DNA fragments from agarose gel 
For the isolation of DNA fragments from agarose gel, I used the excellent MACHEREY-
NAGEL, NucleoSpin® Extract 2-in-1 kit. The protocol is as follows: 
Take a clean scalpel to excise the gel containing the DNA fragment to minimize the gel volume. 
Determine the weight of the gel slice and transfer it to a clean tube. For each 100mg agarose gel 
add 300ul NT1, incubate sample at 50°C until the gel pieces have been dissolved (5-10min). 
Vortex the sample every 2-3min briefly. Place a NucleoSpin Extract column into a 2ml collecting 
tube and load the sample. Centrifuge 1min at 8000 x g (10000rpm). Discard flowthrough and 
place the NucleoSpin Extract column back into the collecting tube. Add 600ul NT3, centrifuge 
for 1min at full speed (13000rpm). Discard flowthrough and place the NucleoSpin Extract 
column back into the collecting tube. Add 200ul buffer NT3, centrifuge for 2min at full speed 
(13000rpm) to remove NT3 quantitatively. Place the NucleoSpin Extract column into a clean 
1,5ml microcentrifuge tube, add 50ul elution buffer NE, leave at room temperature for 1min. 
Centrifuge for 1min at full speed (13,000 rpm). 
2.2.1.6 Direct purification of PCR products 
For this procedure, I used again the MACHEREY-NAGEL, NucleoSpin® Extract 2-in-1 kit, 
according to the instructions of the manufacturer. This is a brief description of the procedure: 
Mix 4 volumes of NT2 with 1 volume of sample, insert the NucleoSpin Extract column into a 2ml 
collecting tube. Load sample onto the column. Centrifuge 1min at full speed (11000 x g, 
~13000rpm) at room temperature. Discard flowthrough and place the NucleoSin Extract column 
back into the 2ml collecting tube. Add 600ul of buffer NT3 to the NucleoSpin Extract column. 
Centrifuge at 11000 x g (~13000rpm) for 1min. Discard flowthrough and place the NucleoSpin 
Extract column back into the 2ml collecting tube. Add 200ul buffer NT3. Centrifuge for 2min at 
full speed (11000 x g, ~13000rpm) to remove NT3 quantitatively. Place the NucleoSpin Extract 
column into a clean 1,5ml microcentrifuge tube and add 50ul elution buffer NE. Leave at room 
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temperature for 1min to increase the yield of eluted DNA. Centrifuge for 1min at 11000 x g 
(~13000rpm). 
2.2.1.7 Isolation of total RNA from cells 
I used a very simple protocol based on RNAzol B: 
Cells grown in monolayer are lysed directly in the culture dish by addition of RNAzol B (WAK 
Chemie). Use at least 1ml of the reagent for a 3,5cm Petri dish. Pass the lysate through a pipette 
several times to ensure lysis. Add 0,2ml chloroform per 1ml of RNAzol B, cap the tube and shake 
vigorously for 15-30 seconds. Store the sample on ice (or at least 4oC) for 5 minutes. Centrifuge 
the homogenate at 12000g for 15 minutes at 4oC. Following centrifugation, the sample forms the 
lower blue phenol-chloroform phase, interphase, and the upper colorless aqueous phase. RNA 
remains exclusively in the aqueous phase whereas DNA and proteins are in the interphase and 
organic phase. The volume of the aqueous phase is about 50% of the initial volume of RNAzol B 
plus sample volume. Transfer the aqueous phase to a clean tube, add 0,5ml of isopropanol, and 
store the sample for 5-10 minutes at room temperature. Centrifuge at 12000g for 5 minutes at 4-
25oC. RNA precipitate forms a white pellet at the bottom of the tube. Remove the supernatant and 
wash the RNA pellet once with 75% ethanol, shaking or votexing to dislodge the pellet from the 
side of the tube. Centrifuge for 5 minutes at 7500g at 4-25oC. Use 1ml of ethanol solution per 1ml 
of RNAzol B used for the initial homogenization. Briefly air-dry the RNA pellet (5-10 minutes). 
It is important not to let the RNA pellet dry completely, as this greatly decreases its solubility. Do 
not dry RNA by centrifugation under vacuum. Dissolve the RNA in water with DEPC treatment. 
The final preparation of RNA has an OD260/280 ratio 1,6-1,9. 
2.2.1.8 Isolation of poly(A)-enriched RNA 
To isolate polyadenylated mRNA, I used the Dynabeads Oligo (dT)25 kit (Dynal #610.02 or 
#610.05, DYNAL BIOTECH), following the invaluable protocol developed in our Department by 
Dr. Axel Visel: 
First, set a water bath or heat block to 65°C and prepare and label three 1,5ml tubes: 
(1) PCI extraction, (2) quantitation tube (containing 90ul DEPC-H2O), (3) mRNA storage tube 
(containing 600ul 100% ethanol). 
On ice, mix 4ml of Lys-bind (0,1M Tris, pH7.5; 500mM LiCl; 10mM EDTA; 1%SDS) with 40ul 
DTT (30mg/ml in DEPC-H2O) and take the 1,5ml tubes containing tissues out of the freezer (e.g., 
5 tubes, each containing tissue from wild type mouse). Immediately distribute the cold Lys-bind 
+ DTT mix evenly into the tubes containing the tissue (e.g., 808ul per tube); keep on ice. Use a 
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clean micropestle that fits into a 1,5ml tube to homogenize the tissue. Use a clean 2ml syringe 
with a 0,9mm (20G) needle to transfer the homogenate into the two 2ml tubes. Shear DNA by 
pipetting up and down through the needle 7-9 times. Spin down at full speed for 2min in a 
microcentrifuge. Distribute the supernatant evenly (~1ml each) into the four 2ml tubes containing 
the resuspended Dynabeads (in 400ul Lys-bind each), vortex. Leave at room temperature for 
5min, (annealing), vortex occasionally. Place tubes in magnet rack, after separation remove 
supernatant into bead recycling bottle. Add 400ul Wash-SDS (20mM Tris pH7.5; 1M LiCl; 2mM 
EDTA, 1%SDS) to each tube, vortex, separate in magnet rack, remove supernatant (recycling 
bottle), repeat this step with 400ul Wash-SDS per tube, repeat again with 400ul Wash-high 
(20mM Tris, pH7.5; 1M LiCl; 2mM EDTA) per tube, repeat once more with 400ul Wash-conc 
(10mM Tris, pH 7.5; 150mM LiCl; 1mM EDTA) per tube. Add 55ul DEPC-H2O per tube (220ul 
total), resuspend and incubate 3min at 65°C, resuspend. Separate in magnet rack, transfer 
supernatant into tube (1), put on ice, transfer a 10ul aliquot from tube (1) to tube (2), use contents 
of tube (2) to determine mRNA concentration on a spectrophotometer: 1OD260 = 40ng (= 0,04ug) 
RNA/ul; 1:10 dilution is used and about 200ul of mRNA is left, so OD260 x 80 = total amount of 
mRNA in ug. Add 200ul PCI to tube (1) and vortex rigorously, spin at full speed for 2min in a 
microcentrifuge. Transfer top phase into tube (3), mix and store at -80°C. 
2.2.1.9 Removal of contaminating genomic DNA from RNA samples  
The reaction was: 
  18ul RNA 
  1ul 10x DNase I reaction buffer  
  1ul DNase I (RNase-Free) (2U/ul) (NEB) 
Incubate at 37°C for 10min. Inactive DNase I by incubating at 75°C for 10min. Add EDTA to a 
final concentration of 5mM to protect RNA from being degraded during enzyme inactivation. 
2.2.1.10 Determination of nucleic acid concentration 
The concentration of DNA or RNA was determined photometrically (8452A photometer, Hewlett 
Packard, Hamburg) by measuring absorption of the diluted sample, at 260nm, 280nm and 320nm 
(control). The concentration was calculated according to the following formula: 
C = E260 x f x c 
C = concentration of the sample (ug/ul) 
E260 = absorption at 260nm 
E320 = absorption at 320nm, normally, E320 is nearly zero. 
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f = dilution factor 
c = concentration (standard)/absorption(standard) 
For double stranded DNA, c = 0,05ug/ul; for RNA, c = 0,04ug/ul and for single stranded DNA, c 
= 0,03ug/ul. 
2.2.2 Enzymatic modifications of DNA 
(Restriction enzymes and DNA markers were from NEB unless indicated otherwise). 
2.2.2.1 Restriction of DNA 
Restriction cutting was performed by incubating double-stranded DNA molecules with an 
appropriate amount of restriction enzyme in its respective buffer as recommended by the supplier 
at optimal reaction temperature. Typical digestions included 1-5U of enzyme/ug DNA. The 
reactions were usually incubated for 1-3h to ensure complete digestion. The following is the 
general reaction I used:  
  1ug DNA 
  2ul 10x reaction buffer 
  0,5ul enzyme (10U/ul) 
  add distilled H2O to a total volume of 20ul 
2.2.2.2 Dephosphorylation of plasmid DNA 
To prevent the recircularization of vector plasmid without insertion of foreign DNA, alkaline 
phosphatase treatment was peformed. Alkaline phosphatase catalyzes the hydrolysis of 3′- 
phosphate residues from DNA. The followings were mixed, 
  1-5ug linearized vector DNA  
  5ul 10 x reaction buffer 
  0,5-2,5ul alkaline phosphatase (0,5-2,5U), Calf Intestinal (CIP) 
  add distilled H2O to a total volume of 50ul 
Incubate at 37°C for 60 min and stop the reaction by heating reaction at 85°C for 15min, purify 
DNA by gel purification, spin-column purification or phenol extraction. 
2.2.2.3 Ligation of DNA fragments 
The ligation of an insert into a vector was carried out in the following reaction mix: 
  30ng vector DNA 
  100ng insert DNA 
  1ul 10 x ligation buffer 
MATERIALS AND METHODS 
43 
  1ul T4 DNA ligase (5U/ul) 
  add distilled H2O to a total volume of 10ul 
Blunt-end and cohesive-end ligations were carried out at 16°C overnight.  
2.2.2.4 Quick ligation of DNA fragment 
The Quick Ligation TM Kit (NEW ENGLAND, BioLabsInc ) enables ligation of cohesive end or 
blunt end DNA fragments in 5 minutes at room temperature(25°C). It is a very efficient and time-
saving method to clone DNA fragment into a vector. 
  Combine 50ng of vector with a 3-fold molar excess of insert. 
  Add 10ul of 2 x Quick Ligation Buffer and mix. 
  Add 1ul of Quick T4 DNA ligase and mix thoroughly. 
  Adjust volume to 20ul with distilled H2O. 
Centrifuge briefly and incubate at room temperature (25°C) for 5min. Chill on ice, then transform 
or store at - 20°C. 
2.2.2.5 Preparation of competent E. coli  
A straightforward procedure common in every molecular laboratory: Pick a single colony of 
DH5a and inoculate 10ml of LB-ampicilium, grow overnight at 37°C; add 1ml overnight culture 
to 100ml prewarmed LB media containing 80ug/ml ampicillin in a 500-ml flask, and shake at 
37°C until an OD600 of 0,5 is reached; cool the culture on ice for 5 minutes, and transfer the 
culture to a sterile, round-bottom centrifuge tube; collect the cells by centrifugation at low speed 
(5min, 4000 x g, 4°C); discard the supernatant carefully, always keep the cells on ice; resuspend 
the cells gently in cold (4°C) 30ml TFB1 buffer (100mM RbCl, 50mM MnCl2, 30mM potassium 
acetate, 10mM CaCl2, 15% glycerol, pH5.8; sterile-filter) and keep the suspend on ice for an 
additional 90min; collect the cells by centrifugation (5min, 4000 x g, 4°C); discard the 
supernatant carefully in 4ml ice-cold TFB2 buffer (10mM MOPS, 10mM RbCl, 75mM CaCl2, 
15% glycerol, adjust to pH6.8 with KOH, sterile-filter); prepare aliquots of 100-200ul in sterile 
microcentrifuge tubes and freeze in liquid nitrogen or a dry-ice-ethanol mix. Store the competent 
cells at -70°C. 
2.2.2.6 Transformation of bacteria 
Thaw competent cells on ice. Chill approximately 5ng (2ul) of ligation mixture in a 1,5ml 
microcentrifuge tube. Add 50ul of competent cells to the DNA and mix gently by pipetting up 
and down. Incubate on ice for 30min. Heat shock for 90s at 42°C, chill on ice for 5min. Add 
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950ul of room temperature media and incubate at 37°C for 60min. Spread 200ul onto the 
appropriate solid medium. Incubate overnight at 37°C. 
2.2.2.7 Blunting ends reaction 
Blunting ends 3′overhang removal and 3′recessed end fill-in: 0,1-4ug of digested DNA was 
mixed with 33uM each dNTP and 1-5U of DNA Polymerase I Large Fragment (Klenow) in 1 x 
EcoPol buffer or any restriction buffer. The reaction was incubated at 25°C for 15min. Stop 
reaction by adding EDTA to a final concentration of 10mM and heating at 75°C for 20min. 
2.2.3 Gel electrophoresis 
Gel electrophoresis is the technique by which mixtures of charged macromolecules, especially 
nucleic acids and proteins, are rapidly resolved in an electrical field. 
2.2.3.1 Agarose gel electrophoresis of DNA 
Agarose gels are used to electrophorese nucleic acid molecules from as small as 50bp to more 
than 50kb, depending on the concentration of the agarose and the precise nature of the applied 
electrical field (constant or pulse). 1g agarose was dissolved in 100ml of 0,5 x TAE buffer (50 x: 
242g Tris base, 57,1ml glacial acetic acid, 100ml 0,5M EDTA) by boiling in the microwave, then 
cooled down to about 50°C before adding 3ul ethidium bromide (10mg/ml). The gel was poured 
into a horizontal gel chamber. Before loading samples, 0,1volume of stop mix (10 x loading 
buffer, 0,4% bromophenol blue, 0,4% xylene cyanol FF, 50% glycerol, store at 4oC) was added 
and mixed. The samples were then loaded into the wells of the gel and electrophoresis was 
carried out at a steady voltage. The 0,5 x TAE buffer was also used as electrophoresis buffer. 
2.2.3.2 Agarose gel electrophoresis of RNA 
Non-denaturing gel electrophoresis was employed here. The difference from DNA 
electrophoresis is the way of preparing agarose gel. Dissolve agarose in 0,5 x TAE, treat with 
DEPC and incubate at 37°C overnight before heating up in microwave. 0,5 x TAE for running the 
gel and loading buffer were treated with DEPC. 
2.2.3.3 DNA length standards 
In order to be able to determine the size of the DNA fragments with gel electrophoresis, parallel 
to the DNA samples, 0,5ug of the “1kb DNA Ladder” or “100bp DNA ladder” length standard 
was loaded on the electrophoresis gel. The DNA ladder was diluted in sample buffer. 
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2.2.4 Non-radioactive dye terminator cycle sequencing 
The non-radioactive sequencing was achieved with a Dye Terminator Cycle Sequencing Kit 
(Applied Biosystems) and the reaction products were analyzed with automatic sequencing 
equipment, namely a 377 ABI Prism DNA Sequencer (Applied Biosystems). For the sequencing 
reaction, four different dye labeled dideoxy nucleotides were used. These, when exposed to an 
argon laser, emit fluorescence which could be detected and interpreted. The reaction progressed 
in a total volume of 10ul containing 500ng plasmid DNA or 50ng purified PCR products, 1ul of 
5uM primer, and 2ul reaction mix (contains dNTPs, dideoxy dye terminators and Taq DNA 
polymerase), add distilled H2O to a final volume of 10ul. Elongation and chain termination took 
place during the following program in a thermocycler: 96oC 1min denaturing followed by 25 
cycles of 96°C 5s, denaturing; 50°C 5s, annealing; 60°C 4min, elongation. After the sequencing 
reaction, add 190ul of dH2O into reaction tube, transfer to a 1,5ml tube, add 500ul of 100% 
ethanol and 20ul of 3M NaAc pH4.8, mix. Centrifuge at 13000rpm for 20 minutes at room 
temperature, carefully decant the supernatant. Wash pellet by adding 400ul of 70% ethanol, mix, 
centrifuge at 13000rpm for 10 minutes at room temperature. Decant the supernatant as before, dry 
for 5 minutes in the concentration at room temperature, dissolve the pellet in 2ul of 5:1 
fromamide:dextranblue-EDTA and denatured at 90°C for 2 minutes. Samples can be stored at -
20oC and finally samples were loaded on the sequencing gel. 
2.2.5 Methods of the “polymerase chain reaction” (PCR) 
2.2.5.1 PCR of plasmid-DNA  
A general PCR reaction was conducted as follows with QIAGEN Taq DNA polymerase. The 
reaction was placed in a 50ul reaction tube in a total volume of 20ul. 
  2ul 10 x PCR buffer 
  4ul Q 
  0,2ul 10mM dNTPs 
  1ul upstream primer (5uM) 
  1ul downstream primer (5uM) 
  50ng DNA 
  0,15ul Taq DNA polymerase (5U/ul) 
  add distilled H2O to a final volume of 20ul. 
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Standard program: 
  segment 1 (1x), 4min 94°C (denaturation) 
  segment 2 (35x), 40sec 94°C (denaturation) 
     40sec 55-60°C (annealing) 
     1min 72°C (extension) (1min per 1kb for most polymerases) 
  segment 3 (1x), 7min 72°C (final extension) 
  segment 4, 4°C for ever 
After finishing the PCR, 5ul of the reaction was mixed with loading buffer and run on an agarose 
gel. 
2.2.5.2 Gradient PCR 
The difference between gradient PCR and general PCR is the annealing temperature designation. 
The gradient PCR is to determine the best annealing temperature. The reactions are the same as 
1.2.5.1. Run an analytical (gradient) PCR with 6-7 tubes in a range of 20°C (PCR efficiencies 
may change according to various thermocyclers). The typical gradient program used in the 
Biometra thermocycler: 
Step  Temp(°C) Time (min) Cycles Gradient 
1 94 2.00 1  
2 94 0.20 
3 50 0.20 
4 70 1.10 
34 20 
5 72 9.00 1  
6 4 pause   
2.2.5.3 Single-colony PCR 
To screen large amounts of bacterial colonies for desired inserts, single colony was picked from a 
transformation plate with a sterile toothpick and dotted on a new LB selecting plate. The rest of 
the colony on the toothpick was subjected to a standard 30ul PCR reaction with appropriate 
primers to test for the presence of the insert. For plasmid preparation, the colony that contained 
desired insert vector was inoculated into LB medium with the colony dotted on the LB selecting 
plate. 
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2.2.5.4 High fidelity long fragment pull from single BAC clone by PCR 
Pick up a single BAC clone from the transformation plate and subject to the following 50ul PCR 
reaction with PfuTurbo® DNA Polymerase (STRATAGENE). 
  distilled water 41,6ul 
  10 x cloned Pfu DNA polymerase reaction buffer 5,0ul 
  dNTPs (20mM) 0,4ul 
  upstream primer (5uM) 1,0ul 
  downstream primer (5uM) 1,0ul 
  Pfu turbo polymerase 1,0ul (2,5U) 
  total reaction volume 50ul 
Perform PCR using cycling conditions listed below: 
95°C 1min; (30 x) 95°C 30Sec, 65°C 30Sec, 72°C 4min; 72°C 10min. 
2.2.5.5 Foxb1 mice and EphA7 mice colony genotyping assay by PCR 
2.2.5.5.1 Foxb1 mice colony 
Primers for wild type (WT) band 
GAB20. 5′ CACTGGGATGGCGGGCAACGTCTG3′ 
GAB22. 5′ CATCGCTAGGGAGTACAAGATGCC3′ 
Primers for knock out (KO) band 
GAB20. 5′ CACTGGGATGGCGGGCAACGTCTG3′ 
GAB24. 5′ CGATGCCTGCTTGCCGAATATCATGG3′ 
Each reaction:  
  1ul DNA 
  1ul 10 x PCR buffer 
  2ul Q 
  1ul primer GAB20 (5uM) 
  1ul primer GAB22 (5uM) 
  1ul primer GAB24 (5uM) 
  0,2ul dNTPs (10mM) 
  0,15ul Taq polymerase (5U/ul) (Qiagen) 
  Add dH2O to a final volume of 20ul 
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PCR conditions: 
94ºC, 4min+ 30 x (94ºC, 40sec + 65ºC, 40sec + 72ºC, 40sec) + 72ºC, 7min. 
The size of fragments are 500bp (KO) and 300bp (WT). 
2.2.5.5.2 EphA7 mice colony 
Primers for WT band 
1. 5′TTCTAAGGTCCTATTTTGCCTGAG3′ 
2. 5′GAGTCCAGGATTCCCTCCCAGATC3′ 
Primers for KO band 
3. 5′CGAAGTTATTAGGTCCCTCGAAG3′ 
4. Idem 1 
Each reaction:  
  1ul DNA 
  1ul 10 x PCR buffer 
  2ul Q 
  1ul primer 1 (5uM) 
  1ul primer 2 (5uM) 
  1ul primer 3 (5uM) 
  0,2ul dNTPs (10mM) 
  0,15ul Taq polymerase (5U/ul) (Qiagen) 
  Add H2O to a final volume of 20ul 
 
PCR conditions: 
95ºC, 4min+ 35 x (95ºC, 30sec + 52ºC, 40sec + 72ºC, 40sec) + 72ºC, 7min 
The size of fragments are 270bp (KO) and 620bp (WT). 
2.2.5.6 Reverse transcriptase PCR (RT-PCR) 
ThermoScriptTM RT, an avian RNase H-minus reverse transcriptase (ThermoScriptTM RT-PCR 
System, Invitrogen) was used to synthesize cDNA from RNA template as follows. 
1-5ug total RNA was mixed with 1ul of Random Hexamers (50ng/ul) or oligo (dT)20 primer 
(50uM), and adjust volume to a 10ul with DEPC-treated water in a 0,2 or 0,5ml tube. Denature 
RNA and primer by incubating the reaction tube at 65°C for 5min, then place on ice. Vortex the 5 
x cDNA Synthesis Buffer for 5s just prior to use. Prepare a master reaction mix on ice and vortex 
gently. 
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  5 x cDNA Synthesis Buffer 4ul 
  0,1M DTT 1ul 
  RNaseOutTM (40U/ul) 1ul 
  DEPC-treated water 1ul 
  10mM dNTP-Mix 2ul 
  ThermoScriptTMRT (15U/ul)  
Pipet 10ul of master reaction mix into the reaction tube on ice and incubate at 50°C for 60min in 
a water bath. Stop the reaction by incubating at 85°C for 5min. Add 1ul RNase H (2U/ul) and 
incubate at 37°C for 20min. cDNA synthesis reactions can be stored at - 20°C or used for PCR 
immediately. 10% of the cDNA synthesis reaction (2ul) was used for subsequent PCR. 
2.2.5.7 Quantitative real-time PCR (Q-PCR) and relative gene expression comparisons 
between wild type and knock-out  
An iCycler real-time PCR system (BIO-RAD) was used, which provides a simple 96-well plate 
format for the detection of DNA samples. iQ SYBR Green Supermix (BIO-RAD) (SYBR Green I 
is a double-strained DNA intercalating dye that fluoresces upon laser light excitation) was used in 
the PCR reaction. 
An inherent property of PCR that is exploited in real-time PCR is that the more copies of nuclei 
acid one starts with, the fewer cycles of template amplification it takes to make a specific number 
of products. Therefore, the number of cycles needed for the amplification-associated fluorescence 
to reach a specific threshold level of detection (the CT value) is inversely correlated to the amount 
of nucleic acid that was in the original sample. Because the progress of amplification is monitored 
throughout the PCR process in real-time PCR, a CT value can be determined during the 
exponential phase of a PCR reaction, when amplification is most efficient and least affected by 
reaction-limiting conditions. The quantity of DNA in the sample can then be obtained by 
interpolation of its CT value versus a linear standard curve of CT values obtained from a serially 
diluted standard solution.  
The housekeeping gene elongation factor 1 alpha (EF1α) is used to normalize different cDNA 
samples amounts. 
Primers:  
EF1α-forward: 5′GTCCCCAGGACACAGAGACTTCA3′ 
EF1α-reverse: 5′AATTCACCAACACCAGCAGCAA3′ 
EphA7 full length (FL) - forward: 5′TTCCAAAGAAAATTGGGCTG3′ 
EphA7 full length (FL) - reverse: 5′CCACATGACCAAACAACACC3′ 
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EphA7 truncated 1 (Tr1) –forward: 5′ATGTGTTACCTGCATGCTTCTG3′ 
EphA7 truncated 1 (Tr1) -reverse: 5′TAGGAGGAGGTAGCCAGTATGC3′ 
EphA7 truncated 2 (Tr2) –forward: 5′TAAGAAGTGGATGATTGCATCG3′ 
EphA7 truncated 2 (Tr2) - reverse: 5′TTTCCGGAAGAGAGGATTACAG3′ 
EphA7 truncated 3 (Tr3) – forward: 5′AAGTCAGTTGGAGAAGCCAGAC3′ 
EphA7 truncated 3 (Tr3) - reverse: 5′AGTGTCAGTTGAGAAAAGCTCC3′ 
Mammillary body tissue was dissected and mRNA was prepared from wild type and Foxb1 
mutant as described in Microarray methods 1.3. cDNA was prepared as described in section 
1.2.5.6. Experimental samples were diluted 1:50 with double distilled H2O. A control cDNA 
sample was serially diluted to produce a set of cDNA samples 1:10, 1:100, 1:1000, 1:10000. In 
theory, a perfect primer set should generate a straight line using the CT values of the diluted 
cDNA samples plotted against the logarithm of the cDNA concentration. Gene-specific forward 
and reverse primers were mixed and used at a concentration of 1,4uM each. PCR reactions were 
set up in optical tubes at 15ul reaction volume per tube. To minimize pipetting deviations the 
reaction set-up was combined by preparing a master-mix containing the primer-mix and the 
SYBR-Mix for all of the samples which was added to the cDNA. Each sample was tested as 
triplicate or hexaplicate. 
Each reaction contained: 
  3,75ul cDNA (1: 50 dilution of the cDNA stock solution) 
  3,75ul Primer-mix (1,4uM each) 
  7,5ul 2 x SYBR Green Mix 
 
PCR program: 
Cycle  1: ( 50x, amplification phase) 
  Step  1:   94,0ºC for 00:15 
  Step  2:   59,0ºC for 00:25 
  Step  3:   72,0ºC for 00:20 
  Data collection and real-time analysis enabled. 
Cycle  2: ( 90x, melt curve determination) 
  Step  1:   50,0ºC for 00:10 
  Increase setpoint temperature after cycle 2 by 0,5ºC 
  Melt curve data collection and analysis enabled.  
Cycle  3: ( 1x)  
  Step  1:   4,0ºC HOLD 
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After PCR, amplicon size and reaction specificity were confirmed by melting curve analysis and 
agarose gel electrophoresis using 5ul from each reaction.  
The quantity of each transcript (SQ = starting quantity) in relation to the sample cDNA could be 
determined from the standard curve generated by the serial dilution control cDNA samples. The 
relative expression level of each gene in each sample (e.g. EphA7-FL in knock out) was 
computed as follows:  
 
2.3 DNA arrays  
2.3.1 Mammillary body dissection and tissue collection 
Before start, prepare dry ice, “normal” ice, large Petri dish, small Petri dishes, RNA-grade 1 x 
PBS, dissection tools, RNA-grade eppis (Labeled 1, 2, 3…..and “tissue”) 70% ethanol, paper 
tissue, and logbook to put down the data about the tissue collection. 
Microdissect the anterior and posterior portion of the hypothalamus of E18.5 mouse embryos 
from Foxb1 mutant and wild type littermates. To this effect, the brains were removed whole, 
inverted to make the ventral side of the hypothalamus visible in order to dissect it from the 
telencephalic hemispheres. The resulting medial piece of brain will then be sectioned sagittally, 
and the hypothalami will be separated from the mass of the dorsal thalamus through a horizontal 
cut. A vertical cut at the level of the pituitary will give an anterior (containing among others the 
suprachiasmatic nucleus) and a posterior (containing the mammillary body) portion of the 
hypothalamus. These pieces of tissue will be immediately frozen in dry ice, separately, in 
previously labeled containers. Two types of tissue are of interest for our purpose: Foxb1-/- 
posterior hypothalamus(HO-P), wild type posterior hypothalamus (WT-P). Leg tissue of each 
embryo will be collected at the same time, washed to remove contaminating blood and prepared 
to obtain genomic DNA for the genotyping assay. 
2.3.2 mRNA isolation 
After genotyping by PCR, the tissue was pooled according to genotype, then mRNA was isolated 
by means of Dynabeads® technology (Dynal Biotech, Oslo, Norway). See 1.2.1.8. mRNA quality 
was checked by complementary methods: UV 260/280 ratio, agarose gel electrophoresis and an 
Agilent Bioanalyzer to visualize clear 18S and 28S ribosomal RNA bands. 
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2.3.3 Hybridization 
Hybridization to the Affymetrix Chips, as well as the informatic analysis of the resulting data, 
was done by the Deutsches Ressourcenzentrum für Genomforschung(RZPD, Berlin). We used the 
GeneChip® DNA microarrys made by Affymetrix, specifically, the Murine Genome U74 Set, 
consisting of three Chips Av2, Bv2, Cv2), containing sequences representing approximately 
36000 genes (6000 functionally characterized plus 30000 Expressed Sequence Tags). The 
transcriptome of the tissues was compared (also at RZPD) by means of Affmetrix proprietary 
analytical software. The comparisons were as follows: HO-P vs. WT-P. 
2.4 In situ hybridization on sections 
Note about High-Throughput In Situ Hybridization: The mRNA “in situ” detection necessary 
to carry out this PhD work was performed with the help of a team of technicians of our 
Department, using automated protocols implemented by a Tecan Genesis 2000 Fluid Handling 
Platform (the “In Situ Robot”). This High-Throughput In Situ Hybridization method has been set 
up by Prof. Gregor Eichele in our Department, and has been documented elsewhere (Herzig et al., 
2001; Visel et al., 2004). 
2.4.1 RNA probe preparation 
2.4.1.1 Primer design  
Design a gene specific primers either by using a primer selection program or own 
experience/strategy (GC content in the range of 40 to 60%, the end at which the polymerase will 
extend should have a GC or CG, avoid repeats, no homology to other genes in the genome, no 
long hairpin structures, no dimer formation). Normally 20-24bp long primers are picked up that 
border the desired sequence. The sequence of the T7 or SP6 universal recognition primer, with 3 
extra bases (GCG) to the 5′ end of the forward primer and the 3′ end of the reverse primer are 
attached to allow the polymerase to bind better. The sequence of the T7 promoter is 
GCGTAATACGACTCACTATAGGG and for the SP6 the sequence is 
GCGATTTAGGTGACACTATAG. The annealing temperature depends on the sequence of the 
gene specific part of the primer because the T7 (GCG-TAATACGACTCACTATAGGG) or Sp6 
(GCG-ATTTAGGTGACACTATAG) promoter sequences play no role in binding to cDNA. 
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2.4.1.2 Template preparation 
Here the template is got from PCR product. RT-PCR methods see above 1.2.5.6. Using gradient 
PCR (see 1.2.5.2) to decide the best annealing temperature, those PCRs that show only the 
desired band are pooled and purified. If multiple bands present, all left samples are pooled, re-run 
on an agarose gel, cut out and extract the desired band. Basically 50ng are used for sequencing to 
verify the PCR product (see 1.2.4) and the T7 and SP6 primers could be used for the sequencing 
reaction. In order to prepare template for the RNA probe, a new 100ul PCR is carried out using 
the purified 1st PCR product as template (described above). Analyzed 5ul PCR product on an 
agarose gel and purify the rest with a Qiagens PCR purification kit and finally eluted with 25ul of 
buffer (10mM Tris-Cl, pH8.5). 3ul are used to measure the concentration and determine DNA 
purity. Typically yields are in the range of 200-400ng/ul. 
2.4.1.3 In vitro RNA transcription 
Stratagene RNA transcription kit is used. The RNA polymerase T7 and SP6 are from NEB. The 
following are added to a reaction tube on the ice. 
 conc vol. 
H2O (DEPC)  add to 20ul 
5 x transcription buffer  4ul 
rATP 10mM 2ul 
rCTP 10mM 2ul 
rGTP 10mM 2ul 
rUTP 10mM 1,3ul 
DIG-UTP 250nmol 0,7ul 
DTT 0,75M 2ul 
RNasin 40U/ul 1ul 
RNA Polymerase (T7 or SP6)  50U/ul 0,5ul 
Template  1ug 
 
Incubated the reaction tube is at 37°C for 150min and then 1ul of the following mix is added to 
stop the reaction and remove the template DNA. 
H2O (DEPC) 16,4ul 
MgCl2 (0,3M) 1,6ul 
DNaseI (10U/ul) 2,0ul 
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Incubate the reaction at 37°C for 30 minutes, precipitate the mix with 72ul NH4Ac (4M, 
autoclaved) and 470ul EtOH (100%). RNase free solutions are used. Store at –80°C for 30min 
after adding the solutions, and centrifuge with 13000 rpm for 20min at 4°C. Wash the pellet with 
ice-cold 70% EtOH. Use 25ul DEPC H2O to dissolve the precipitated RNA, 2ul of the RNA are 
analyzed on a 1% agorse gel to check the quality of the RNA probe, eventually adjust the 
concentration with DEPC water to 50ng/ul for the RNA probe and make 50ul aliquots that are 
stored at –80°C. Before using it, dilute the probe with hybridization mix to a concentration of 100 
to 200ng/ml and keep it at –20°C for a maximum of 2 months.  
2.4.2 Preparation and fixation of sections 
Take the embryos of the appropriate stage out of the mother and put into ice-cold phosphate 
buffered saline (PBS) (0.137M NaCl, 0.0027M KCl, 0.01M Na2HPO4, 0.002M KH2PO4, pH 
7.4). Isolate each embryo from placenta, cut the head and put it into ice cold OCT and kept there 
for 5 minutes. The head was transferred to an OCT embedding chamber, where it was frozen 
slowly. The head was sectioned (20um thick) with a Leica CM3050S cryostat (Germany). 
Sections were placed in appropriate positions on a Super Frost Plus microscopy slide (Germany). 
The sections on the slides were fixed for 20 minutes with 4% paraformaldehyde (PFA) (EMS, 
USA) in 1 x PBS solution. Then the slides were washed in PBS twice to remove the fixative, and 
acetylated for 5 minutes (2x) with acetylation solution (0,25% acetic anhydride, 0,1M 
triethanolamine, pH8.0, Sigma, Fluka respectively). The sections on the slides were refixed with 
4% Para formaldehyde (EMS, USA) PBS solution for 20 minutes, then washed for 5 minutes in 
PBS to remove the fixative, and transferred to 0,9% NaCl for 5 minutes and dehydrated the cells 
in a graded series of ethanol (30%, 50%, 70%, 80%, 95% and 2 x 100%) for 2 minutes each step 
at room temperature (Automatic done). The slides were air dried. Slides are storable for up to 3 
months at –80°C in air tight dessicated chambers. 
2.4.3 RNA detection by automated in situ hybridization 
2.4.3.1 Prehybridization 
1. Treat the slides mounted into slide chamber, 6 times for 5 minutes with 300ul of MeOH 
solution (ROTH) containing 0.6% hydrogen peroxide (Fluka, Germany). The slides are then 
washed 6 times with 300µl of PBS with 0.05% Tween-20. 
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2. Then the slides are treated 2 times for 4 minutes with 300ul of 0,2N HCl with 0,05% Tween-
20. Wash the slides with 300µl of PBS with 0,05% Tween-20 8 times. 
3. Next they are treated 2 times for 7 minutes with 300ul of Proteinase K in buffer (with 
appropriate concentration corresponding to the stage of tissue to be treated) (50mM Tris, 5mM 
EDTA, pH 8.0) with 0,05% Tween-20. The slides are then washed 8 times with 300ul of PBS 
with 0,05% Tween-20. 
4. The slides are treated 2 times for 10 minutes with 300ul of 4% PFA in PBS solution with 
0,05% Tween-20, followed by 8 washing steps with 300ul of 0,05% Tween-20 in PBS. 
5. Finally the probes are pre-hybridized with In Situ Hybridization Buffer (Ambion, Cat. # 
B8807G, USA) for 30 minutes at 60°C. 
2.4.3.2 Hybridization 
Incubate the slides with In Situ Hybridization Buffer containing the riboprobe (300µl per slide, 
final concentration of 100ng/ml) overnight at 60°C. 
2.4.3.3 Post hybridization and detection of the hapten-labeled probe (Automated) 
1. Wash 5 times for 6 minutes with 300µl wash solution 1 (5 x SSC) at 65°C. 
2. Wash 5 times for 6 minutes with 300ul of wash solution 2 (1 x SSC, 50% Formamide) at 65°C. 
3. Wash 5 times for 6 minutes with 300ul of wash solution 3 (0,5 x SSC, 50% Formamide) at 
65°C. 
4. Wash 5 times for 6 minutes with 300ul of wash solution 4 (0,1 x SSC) at 65°C. 
5. Wash 3 times with 250ul of NTE (0.05% Tween 20, 5mM EDTA, 10mM Tris, 500mM NaCl, 
pH 7.6). 
6. Incubate 2 times at room temperature, for 5 minutes each, by applying 250µl of 20mM 
Iodoacetamide diluted in NTE.  
7. Wash 3 times with 250ul of NTE. 
8. Incubate 2 times at room temperature, for 45 minutes each, by applying 250µl of heat-
inactivated 4% Sheep-serum (Chemicon International) in TNT solution (0,05% Tween 20 in 
100mM Tris/150mM NaCl, pH 7.6) (filter before use, 0,45um). 
9. Wash 8 times with 250ul of TNT solution. 
10. Incubate 2 times at room temperature, for 30 minutes each, by applying 250ul of TNB 
blocking buffer (0,05% Tween 20 in 100mM Tris/150mM NaCl, 0,5% blocking reagent 
(PerkinElmer Lifesciences) pH 7,6) (filter before use, 0,45um). 
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11. Incubate 2 times at room temperature, for 45 minutes each, by applying 250ul of Roche′s 
Anti-Dig-POD diluted in TNB blocking buffer (1:500 diluted in TNB). 
12. Incubate 8 times at room temperature, for 5 minutes each, by applying 250ul of TNT. 
13. Incubate 2 times at room temperature, for 15 minutes each, by applying 250ul of Tyramide-
Biotin (T/B) diluted with NEN amplification diluent buffer for use with tyramide signal 
amplification (TSA) (PerkinElmer Lifesciences). 
14. Wash 8 times with 250ul of maleate wash buffer (MWB) (100mM Maleate, 150mM NaCl, 
0,05% Tween 20, pH7.5). 
15. Incubate 2 times at room temperature, for 30 minutes each, by applying 250ul of Neutravidin-
alkaline phosphatase conjugate (Pierce) diluted in 1% blocking reagent (Roche) containing MWB 
(1:600 dilution in 1% blocking reagent containing MWB, filter 0,45um before adding antibody). 
16. Wash 8 times with 250ul of maleate wash buffer (MWB) (100mM Maleate, 150mM NaCl, 
0,05% Tween 20, pH7.5). 
17. Wash 2 times with 250ul of TNT solution. 
18. Incubate 3 times at room temperature, for 20 minutes each, by applying 250ul of TMN 
solution (0,1M Tris, 0,05M MgCl2, 0,1M NaCl, 0.05% Tween, pH9.5) containing BCIP (1:250) 
NBT (1:200) (Roche, Germany) containing Levamisol (0,5mg/ml) (Sigma, Germany). This step 
maybe extended depending on signal strength. 
19. Wash 4 times with 250ul water (0,05% Tween). 
20. Wash with 250ul TNT twice. 
21. Fix for 20 minutes with 4% PFA, 0,5% Glutaradehyde (Sigma) containing PBS (with 0,05% 
Tween) by applying 250ul twice. 
22. Wash 4 times with 250ul PBS (with 0,05% Tween). 
23. Wash 4 times with 250ul water (with 0,05% Tween). 
24. Let the slides air dry overnight and coverslip them the next day with aqueous coverslipping 
medium (Hydromatrix). 
2.5 Yeast one hybrid assay 
2.5.1 Introduction 
A one-hybrid system is an in vivo genetic assay used for isolating novel genes encoding proteins 
that bind to a target, cis-acting regulatory element (or any other short, DNA-binding site; Fig.2.1). 
The system can also be used to map the DNA-binding domain of previously known, or newly 
identified, DNA-binding proteins (DNA-BP). 
MATERIALS AND METHODS 
57 
 
Fig.2.1. Detection of DNA-binding proteins using the MATCHMAKER One-Hybrid System. A sequence 
consisting of at least three tandem copies of a known target element (E) is inserted upstream of a reporter gene and 
integrated into the yeast genome to make a new reporter strain. This yeast strain is transformed with an activation 
domain cDNA library that includes a fusion of a target-specific, DNA-binding protein (DNA-BP) of interest and the 
target-independent GAL4 activation domain (AD). Binding of an AD/DNA-BP hybrid protein to one of these target 
elements allows activation of reporter gene transcription. 
 
2.5.2 Prepare target-reporter constructs 
2.5.2.1 Synthesizing tandem copies of target elements 
Each element sense strain has 5′AATT overhang, it is easy to clone the annealed elements into 
the vector of pHISi, pHISi-1 and pLacZi with the digestion of EcoRI and SmaI. 
E1 sense strain: 
AATT.AATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATA
AATAAATA 
E1 anti-sense stain: 
TATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATT 
E2 sense strain:  
AATT ATAAATACAAACATGC AATAAATACAAACATGCAATAAATACAAACATGC 
E2 anti-sense strain:  
GCATGTTTGTATTTATTGCATGTTTGTATT TATTGCATGTTTGTATTTATT 
E3 sense strain:  
AATT.CACAAACAAAACAAACACACCACAAACAAAACAAACACACCACAAACAAAA
CAAACACAC 
E3 anti-sense strain:  
GTGTGTTTGTTTTGTTTGTGGTGTGTTTGTTTTGTTTGTGGTGTGTTTGTTTTGTTTGTG 
E4 sense strain:  
AATT.CAATAAATACAAATAATCCACAATAAATACAAATAATCCACAATAAATACAA
ATAATCCA  
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E4 anti-sense strain: 
TGGATTATTTGTATTTATTGTGGATTATTTGTATTTATTGTGGATTATTTGTATTTATT
G 
E5 sense strain:  
AATT.ACCAATAAATAAACAAATAACCAATAAATAAACAAATAACCAATAAATAAAC
AAATA 
E5 anti-sense strain: 
TATTTGTTTATTTATTGGTTATTTGTTTAT TTATTGGTTATTTGTTTATTTATTGGT 
E6 sense strain:  
AATTCAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAA
ACAAACAAA  
E6 anti-sense strain:  
TTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTG 
2.5.2.2 Insert tandem copies of target upstream of reporter genes  
For each construct planned, mix 0,1mg of sense-strand and 0,1mg of antisense-strand 
oligonucleotide in 10ml of 50mM NaCl. Anneal the oligonucleotides by heating at 70°C for 5min 
and then slowly cooling to room temperature (~30min). Use a standard method to do ligation and 
transformation reaction. 
2.5.3 Small-scale LiAC yeast transformation procedure 
Inoculate 1ml of YEPD (Yeast extract 2g/liter, Pepton 4g/liter, Glucose 4g/liter) or SD (Yeast 
Nitrogen Base (W/O AA) 6.7g/liter, Glucose 20g/liter, 10% the appropriate sterile 10 x Dropout 
Solution) with several colonies of Yeast YM4271, 2-3mm in diameter. Vortex vigorously for 
5min to disperse any clumps. Incubate at 30oC for 16-18h with shaking at 250rpm to stationary 
phase (OD600 > 1,5). Transfer 30ml of overnight culture to a flask containing 300ml of YEPD. 
Check the OD600 up to 0,2-0,3. Incubate at 30oC for 3h with shaking (230rpm). At this point, the 
OD600 should be 0,4-0,6. Place cells in 50-ml tubes and centrifuge at 1000 x g for 5min at room 
temperature (20-21oC). Discard the supernatants and thoroughly resuspend the cell pellets in 
sterile TE (1 x TE: 10mM Tris, 1mM EDTA, pH7.5). Centrifuge at 1000 x g for 5min at room 
temperature. Decant the supernatant. Resuspend the cell pellet in 1,5ml of freshly prepared, 
sterile 1 x TE/1 x LiAc (0,1M LiOAC, 1 x TE). Add 0,1ug of plasmid DNA (linearized or 
supercoil) and 0,1mg of herring testes carrier DNA to a fresh 1,5ml tube and mix. Add 0,1ml of 
yeast competent cells to each tube and mix well by vortexing. Add 0,6ml of sterile PEG/LiAC 
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solution (0,1M LiOAC, 40% PEG3350, TE, pH7.5) to each tube and vortex at full speed for 
10sec to mix. Incubate at 30oC for 30min with shaking at 200rpm. Add 70ul of DMSO. Mix well 
by gentle inversion. Do not vortex. Heat shock for 15min in a 42oC water bath. Chill cells on ice 
for 1-2min. Centrifuge cells for5 sec at 14000 rpm at room temperature. Remove the supernatant. 
Resuspend cells in 0,5ml of sterile 1 x TE buffer. Plate 100ul on each SD agar plate (Yeast 
Nitrogen Base (W/O AA) 6.7g/liter, Glucose 20g/liter, 20g/liter agar, 10% the appropriate sterile 
10 x Dropout Solution) that will select for the desired transformants. Incubate the plates, up-side-
down, at 30oC until colonies appear (generally, 2-4 days). 
2.5.4 Test yeast colonies for background expression 
2.5.4.1 Yeast colonies with integrated target pHISi or target pHISi-1 
Pick a single colony and suspend it in 1ml of TE buffer. Plate 5ul of the suspension on SD/- His+ 
15mM, 30mM, 45mM, 60mM 3-AT (Yeast Nitrogen Base (W/O AA) 6.7g/liter, Glucose 
20g/liter, Agar 20g/liter, Lys 30mg/liter, Ade 20mg/liter, Trp 20mg/liter, Tyr 30mg/liter, Leu 
30mg/liter, Ura 20mg/liter).  
If yeast grows on SD/- His, +>45 mM 3-AT, then background HIS3 expression is high (very 
leaky). 
 
If yeast only grows on SD/-His and < 45mM 3-AT, then background HIS3 expression is low. 
  
Compare results for yeast colonies with integrated target-pHISi or target-pHISi-1. Identify the 
HIS3 reporter strain with lower background level of HIS3 expression for use in the one-hybrid 
screening. 
2.5.4.2 Yeast colonies with integrated target pLacZi construct in a ß-gal filter assay 
Reagents and Materials: Whatmann #5 paper filter, sterile; Forceps for handling the filters; Z 
buffer (Na2HPO4 .7H2O 16,1g/L, NaH2Po4 7H2O 5,5 g/L, KCl 0,75 g/L, MgSO4.7H2O 0,246 g/L, 
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adjust to pH 7.4 and autoclave); X-gal stock solution (Dissolve 5-bromo-4-chloro-3-indolyl-ß-D-
galactopyranoside (X-GAL; #8060-1) in N,N-dimethylformamide (DMF) at a concentration of 
20mg/ml, store in the dark at -20oC); Z buffer/X-gal solution (100ml Z buffer, 0,27ml ß-
mercaptoethanol (ß-ME; sigma #M-6250), 1,67 ml X-gal stock solution); Liquid nitrogen 
Use fresh colonies, 1-3mm in diameter. For each plate of transformants to be assayed, presoak a 
sterile Whatmann #5 paper by placing it in 2,5-5ml of Z buffer/X-gal solution in a clean 100 or 
150mm plate. Using forceps, place a clean, dry filter over the surface of the plate of colonies to 
be assayed. Gently rub the filter with the side of the forceps to help colonies cling to the filter. 
Poke holes through the filter into the agar in three or more asymmetric locations to orient the 
filter to the agar. When the filter has been evenly wetted, carefully lift it off the agar plate with 
forceps and transfer it (colonies facing up) to a pool of liquid nitrogen. Using the forceps, 
completely submerge the filters for 10sec. After the filter has frozen completely (~10sec), remove 
it from the liquid nitrogen and allow it to thaw at room temperature. Carefully place the filter, 
colony side up, on the presoaked filter. Avoiding trapping air bubbles under or between the 
filters. Incubate the filters at 30oC and check periodically for the appearance of blue colonies. 
If the colony life turns blue in < 15 min, then background LacZ expression is high. Do not use 
pLacZi reporter strain. 
If colony lift turns blue in > 15 min, then background LacZ expression is low. Use pLacZi 
reporter strain to construct a dual reporter. 
2.5.5 Screening Foxb1 protein binding elements 
Foxb1 coding region including 21 nucleotides upstream of the start ATG was PCR-amplified 
from plasmid GAB2 (from Gonzalo), EcoRI restriction site and BamHI restriction site with two 
protection bases were added to the forward primer and the reverse primer respectively. The PCR 
product was cloned into pGAD424 plasmid. After the sequence verification, transform 
pGAD424-Foxb1 (supercoil) into pHISi-pLacZi and pHISi-1pLacZi dual reporter strain 
respectively, and plate the transformation mixture on each agar plate containing SD/-His, -Ura3, -
Leu (Yeast Nitrogen Base (W/O AA) 6.7g/liter, Glucose 20g/liter, Agar 20g/liter, Lys 30mg/liter, 
Ade 20mg/liter, Trp 20mg/liter, Tyr 30mg/liter); +15mM 3-AT. Incubate at 30oC for 4-6 days. 
Pick the largest colonies and resuspend in 1ml of TE buffer. Plate 5ul of the suspension in SD/-
His, -Ura3, -Leu, + optimal 3-AT. Colonies resulting from HIS3 activation should grow and 
colonies resulting from leaky HIS3 expression should not grow. Streak the colonies onto 
duplicate SD/-His, -Ura3, -Leu, + optimal 3-AT plates, and use one set of plates for a ß-
galactosidase filter Assay. 
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2.6 Transient cotransfections and reporter assays 
2.6.1 Cell culture 
P19 cells (ECACC) were cultured in Alpha MEM (SIGMA)+ 2mM Glutamine (GIBCO BRL) + 
1% Non Essential Amino Acids (NEAA) (SIGMA) +2,5% Fetal Calf Serum (FCS) (GIBCO 
BRL) +7,5% Calf Serum(CS) (GIBCO BRL). Transfer cells with the transport medium into a 
25cm2 flask and add 15ml of fresh medium. Re-gas with 5%CO2 where appropriate and incubate 
overnight at 37oC. At confluence trypsinise by decanting culture medium and washing the cell 
sheet twice with PBS and adding 2ml of trypsin/EDTA solution to a 25cm2 flask ensuring that all 
cells are covered. Incubate at 370C until cell sheet detached, usually 5 minutes. Resuspend cells in 
fresh media at the recommended seeding density. Prepare freeze medium by allowing 1ml for 
each ampoule. 90% FCS +10%DMSO was used for P19 cells. 
2.6.2 Plasmids 
Foxb1 coding region was under the CMV promoter in GAB2 plasmid (+Foxb1). GAB3 has a 
reverse orientated promoter, as a control plasmid of GAB2 (-Foxb1). Regulation element was 
cloned at the MCS upstream of the promoter of reporter plasmid pGL3-C (Promega). TKß is a ß-
galactosidase expression plasmid. ß-galactosidase expression level is the internal control of the 
transfection efficiency. All plasmids were prepared with “QIAGEN Endofree Plasmid Midi Kit”, 
see 1.2.1.4. 
2.6.3 Transfection 
The day before transfection, seed 1,5~5 x 104 cells per well of a 24-well plate in 0,7 ml of the 
complete growth medium. Incubate the cells at 37oC in a CO2 incubator until the cells are 50-80% 
confluent (usually about 18 hours). For each well in a transfection, dilute 600ng DNA into 25ul 
medium without serum, add 4ul PlusTM Reagent (Cat. No. 11514-015, Invitrogen), mix again, and 
incubate at room temperature for 15min. Dilute 1,5ul LipofactamineTM Reagent (Invitrogen) into 
25ul dilution medium without serum in a second tube and mix. Combine pre-complexed DNA 
and diluted LipofectamineTM reagent, mix and incubate for 15min at room temperature. While 
complexes are forming, replace the medium on the cells with 0,2ml of cell growth medium 
without serum. Add the DNA-PlusTM-LipofactamineTM Reagent complexes to each well of cells 
contaning fresh medium. Mix complexes into the medium gently; incubate at 37oC at 5% CO2 for 
4 hours. After incubation, add medium and serum to bring the final composition and volume to 
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that of normal growth medium. Assay cell extracts for transient gene expression 48 hours after 
the start of transfection. To minimize pipetting deviations the complex set-up was combined by 
preparing a pre master-mix containing GAB2 or GAB3 and TKß. Each combination sample was 
tested as triplicate or hexaplicate, which was prepared as a master mix for 3 or 6 wells.  
2.6.4 Harvesting of transfected cells and luciferase activity assay 
Take out the cells from the incubator and place them at room temperature about 15 minutes 
before lysis. Also put the MEM-a medium (Gibco) at room temperature. Aspirate the medium 
from the wells. Wash cells in each well once with 500ul MEM-a medium. To each well add 100ul 
of 1 x reporter lysis buffer (Promega). Shake for 15 minutes at room temperature with 150-
200rpm, meanwhile put the tube containing the Steady-Glo (Promega) in water bath at room 
temperature. From each well save 50ul cell lysate for ß-Galactosidase assay. Mix well the Steady-
Glo reagent in the tube and add 50ul into each well, shake for 15 minutes at room temperature 
with 150-200rpm. Transfer 70ul from each well in a costar-3610 96 wells plate. Measure the 
luciferase activity in LUMIstar (BMG-Lab Technologies, in IPF lab) or Fluoroskan AscentFL 
(Thermo, in MHH lab). 
2.6.5 ß-Galactosidase activity measurement 
ß-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (Cat.# E2000, Promega) was 
used. Add 30ul of Assay 2 x Buffer to 30ul of cell lysate, incubate at 37°C for about 30min. 
When the reaction color turns yellow, the reaction was stopped by addition of 100ul of 1M 
Na2CO3, and the relative galactosidase activity was measured with a spectrophotometer at 420nm, 
Assay 2 x Buffer took the place of cell lysate and was used in blank.  
2.7 FoxB1 protein expression and purification in E.coli 
2.7.1 FoxB1 coding region enframing construct 
Digest pGAD424-Foxb1 (from yeast one hybrid assay, see 1.5.5) with EcoRI, treat with Klenow, 
then was digested with PstI, the fragment of Foxb1 coding region including 21 nucleotides 
upstream of the start ATG (EcoRIk - PstI fragment) was cloned into the MCS sites of SmaI-PstI 
site of pQE-31 plasmid. After the sequence verification, transform pQE-31-Foxb1 into XL1-blue 
competent cells according to the standard procedure. 
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2.7.2 FoxB1 expression in E.coli 
2.7.2.1 IPTG-induction of E. coli, small scale induction 
Prepare an over-night culture (each culture from a picked colony) of at least 2ml in LB selective 
medium (amp, 80mg/l). Inoculate 4ml of selective LB medium (amp, 80mg/l) with 0,4ml of your 
fresh over-night culture (it should be dense/stationary); Store over-night culture at -4°C for 
further use and/or make glycerol stocks. Let the cultures grow for 1,5h to 3h (~ 2 generations, to 
give the cells time for “physiologically adjusting” to the fresh medium). Measure the OD600 (a 
1:10 dilution is recommendable). Prepare 4,4ml culture (amp, 80mg/l) with OD600 = 0,7 for each 
sample using above cultures and fresh amp (calculation: 0,7 x 4,4 ml/ OD600 measured = ml of 
culture you have to take, 4,4ml – ml of culture to take = ml of fresh medium to add. Cells should 
be in log-phase before inducing them). Measure OD600 again (a 1:5 dilution is recommendable; 
vortex the freshly prepared cultures before taking samples for the measuring). Induce the cultures 
with 44ul 100 mM IPTG (to a final concentration of 1mM) for 4 hours. 
2.7.2.2 SDS-PAGE electrophoresis and western Blotting 
2.7.2.2.1 Sample preparation 
Harvest cells from above culture in an eppendorf tube by centrifugation (1min, 14000rpm), 
remove supernatant thoroughly, resuspend the cells in 100ul sterile water, add 1 volume 2 x SDS-
PAGE sample buffer (20% glycerol; 0.1M DTT; 2% SDS; 0.09M Tris-Cl, pH6.8; 0,02 % bromo-
phenol blue), mix by vortexing, and boil at 100°C (90°C is also ok) for 5 minutes. Go forward or 
store extract at -20°C. 
2.7.2.2.2 Detection by Tris –Glycine SDS-PAGE electrophoresis 
Assemble the glass plates according to the manufacture′s instructions and prepare two gel mold 
(Bio-RAD system, 10cm x 8cm x 0.1cm). Prepare 10ml 12% acrylamide solution for the 
resolving gel (H2O, 3,3ml; 30% acrylamide mix, 4,0ml; 1.5M Tris, pH8.8, 2,5ml; 10% SDS, 
0,1ml; 10% ammonium persulfate, 0,1ml; TEMED, 0,004ml), without delay, swirl the mixture 
rapidly and pour the acrylamide solution into the two gaps between the glass plates respectively, 
and leave enough space for the stacking gel, overlay the acrylamide solution with 70% 
isopropanol. After polymerization is complete (30min), pour off the overlay and wash the top of 
the gel several times with deionized water to remove any unpolymerized acrylamide. Prepare the 
stacking gel 3ml (H2O, 2,1ml; 30% acrylamide mix, 0,5ml; 1,0M Tris, pH6.8, 0,38ml; 10% SDS, 
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0,03ml; 10% ammonium persulfate, 0,03ml; TEMED, 0,003ml), without delay, swirl the mixture 
rapidly and pour directly onto the surface of polymerized resolving gel. Immediately insert a 
clean comb (from Bio-RAD system) into the stacking gel solution. After polymerization is 
complete (30min), remove the comb carefully and wash the wells immediately with deionized 
water to remove any unpolymerized acrylamide. Mount the gel in the electrophoresis apparatus 
(Bio-RAD system). Add Tris-glycine electropheresis buffer (25mM Tris; 250mM glycine, pH8.3; 
0.1% SDS) to the top and bottom reservoirs. 
Load 20ul of each of the samples in a predetermined order into the bottom of the wells. By using 
protein markers of known molecular weight (NEB, #P7708S), estimate the molecular weight of 
target protein. 
Attach the electrophoresis apparatus to an electric power supply and apply a voltage of 120V and 
run the gel until the bromophenol blue reaches the bottom of the resolving gel. And turn off the 
power supply. Remove the glass plates from the electrophoresis apparatus and separate the gels 
out, one can be fixed and stained with Coomassie Brilliant Blue. Another one gel was used for 
western blotting.  
2.7.2.2.3 Detection with Ni-NTA AP Conjugate, western blotting procedure 
To verify Foxb1 expression, find out which strain has high expression level, and find out the 
differences between not induced and induced cultures, apply 10ul of above samples on the gel for 
western blotting. See above. 
Incubate the gel for 40 minutes in transfer solution (190mM glycin, 25mM Tris, 20% methanol, 
0,05% SDS), softly shaking at room temperature; prepare 4 filter papers (3MM whatman) the size 
of the gel (measure size of the gel), prepare an Immobilon TM -P Transfer Membrane (Millipore) 
the size of the gel, dip it in methanol, and equilibrate in transfer buffer for 30 minutes, softly 
shaking at room temperature, then submerse in transfer solution to avoid air bubbles (remove any 
air bubbles with an test tube), build on BLACK part of the blotting apparatus (to the top): 
BLACK => wet sponge => 2 filter paper => gel => membrane => 2 filter paper => wet sponge 
=> WHITE, transfer at 1 hour at 50V and 4°C, mark marker bands by pinching little holes with a 
needle. Wash membrane twice for 10min each time with TBS buffer (10mM Tris-Cl, pH7.5; 
150mM NaCl). Incubate for 1h in 3% BSA in TBS at room temperature. Wash 3 times for 10 min 
with TBS-Tween buffer (20mM Tris-Cl, pH7.5; 500mM NaCl; 0,05% Tween 20). Incubate the 
membrane for 1h at room temperature in TBS-Tween buffer containing a 1/1000 dilution of Ni-
NTA AP (alkaline phosphatase) Conjugate stock solution (QIAGEN). Wash 3 times for 10min in 
TBS-Tween buffer at room temperature. Stain with AP staining solution (66 µl NBT stock 
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solution and 33 µl BCIP stock solution to 10ml buffer of 100mM Tris-Cl, pH 9.5, 100mM NaCl, 
5mM MgCl2) until the signal is clearly visible (approximately 5–15 min for AP). Do not shake 
blots during color development. Stop the reaction by rinsing the membrane twice in water. Dry 
the membrane and photograph as soon as possible. 
2.7.2.3 Large scale induction and purification on Ni-NTA beads 
Inoculate 200 ml LB (amp, 80mg/l) with 4 ml (= 1/50 volume) of fresh over-night culture and 
measure OD600 every hour. As soon as the cells reach an OD600 = 0.7 – 0.9, add 2.004ml 100mM 
IPTG to a final concentration of 1mM. After 4 hours induction, divide the culture into 4 tubes and 
50ml culture per tube, harvest the cells by centrifugation at 4000 x g for 20 minutes at 4oC. 
Remove the supernatant and use one tube of cells to go forward, and store the rest cell pellets at -
20oC for further use. Resuspend the cell pellet in 5ml of lysis buffer (50mM NaH2PO4, 300mM 
NaCl, 10mM imidazole, adjust pH to 8.0 using 1N NaOH) with 200ul of 100mM PEFABLOC 
(Roche) and 200ul 100mM Complete Mini, EDTA-Free (Roche) proteinase inhibitor. Add 
Lysozyme to 1mg/ml and incubate on ice for 30 min. Centrifuge lysate at 10000 x g for 20-30min 
at 4oC to pellet the cellular debris. Save supernatant. Add 200ul of the 50% Ni-NTA matrix 
(QIAGEN), tumbling for 1h at 4oC. Centrifuge for min at 13000rpm, take out the supernatant 
away carefully. Wash the protein-Ni-NTA mixture twice with 4ml wash buffer(50mM NaH2PO4, 
300mM NaCl, 20mM imidazole, adjust pH to 8.0 using 1N NaOH) by tumbling at 4oC for 10min. 
Centrifuge and take the supernatant away. Elute the protein 3 times with 100ul elution buffer 
(50mM NaH2PO4, 300mM NaCl, 250mM imidazole, adjust pH to 8.0 using 1N NaOH) with 4ul 
of proteinase inhibitor 100mM PEFABLOC and 100mM Complete Mini, EDTA-Free. Collect the 
eluate in three tubes and analyze by SDS-PAGE. 
2.8 DIG Gel Shift Assay 
DIG Gel Shift Kit, 2nd Generation (Cat. No.3353591, Roche) was used. 
2.8.1 Annealing and labeling of oligonucleotides 
Oligonucleotides were synthesized and HPSF purification in MWG. Mix ss oligonucleotide into a 
molar ratio of 1:1 in TEN-buffer (10mMTris, 1mMEDTA, 0,1MNaCl, pH8.0, incubate 10min at 
95oC and cool slowly to 15-25oC. Dilute with sterile TEN-buffer to 4pmol/ul. Add 4pmol ds 
oligonucleotide and sterile double distilled water to a final volume of 10ul to a reaction vial. Add 
the following on ice. 
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Reagent  Volume Final conc. 
5 x labeling buffer 4ul 1x 
CoCl2-solution 4ul 5mM 
DIG-ddUTP solution 1ul 0,05mM 
Terminal transferase 1ul 20U/ul 
 
Stop the reaction by adding 2ul 0,2M EDTA (pH8.0). Add 3ul double distilled water to a final 
volume of 25ul, to obtain a final concentration of 4 ng/ul of the labeled oligonucleotide. 
2.8.2 Determination of labeling efficiency 
Prepare a dilution series of labeled control oligonucleotide from the kit and experimental labeled 
oligonucleotides as described in the table. 
Tube Oligo(ul) From tube 
# 
TEN-
buffer 
Dilution Final concentration 
fmol/ul           ng/ul 
1  Original 0 - 155 4 
2 2 1 18 1:10 15,5 0,4 
3 2 2 18 1:100 1,55 0,04 
4 2 3 18 1:1000 0,15 0,004 
5 - - 20 - 0 0 
 
Apply a 1ul spot of tubes 1-5 from the labeled oligonleotides and the labeled control to the nylon 
membrane (positively charged, Roche). Fix the nucleic acid to the membrane by cross linking 
with UV-light. Transfer the membrane into a plastic container with 20 ml washing buffer (0.1M 
Maleic acid, 0.15M NaCl; pH7.5; 0.3% Tween 20) and incubate under shaking for 2min at 25oC. 
Incubate for 30min in 10ml blocking solution (Dissolve blocking reagent 1% (w/v) in maleic acid 
buffer under constantly stirring on a heating block (65oC), the solution remains opaque). Incubate 
for 30min in 10ml antibody solution (centrifuge Anti-Digoxigenin-Ap for 5min at 10000rpm in 
the original vial prior to each use and pipet the necessary amount carefully from the surface. 
Dilute anti-digxigenin-AP 1:100000 in blocking solution). Wash with 10ml washing buffer, 2 x 
15min. Equilibrate 2-5min in 10ml detection buffer (0,1M Tris-Cl, 0,1M NaCl, pH9.5). Place 
membrane with DNA side facing up on a fresh plastic membrane and apply 0,1ml CSPD working 
solution (dilute 0,1mg/ml stock solution 1:100 in detection buffer). Immediately cover the 
membrane with the rest part and spread the substrate evenly and without airbubbles over the 
membrane, incubate for 5min at 25oC. Squeeze out excess liquid. Drying of the membrane during 
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exposure will result in dark background. Incubate the damp membrane for 10min at 37°C to 
enhance the CSPD chemiluminescent reaction. Expose to X-ray film. Multiple exposures can be 
taken to achieve the desired signal strength. X-ray film was developed in KODAK X-OMAT 
M43 Processor. 
2.8.3 DIG Gel shift reaction 
2.8.3.1 Prepare reaction 
Each reaction prepared three samples: Sample 1, labeled oligonucleotide without Foxb1 protein; 
sample 2, labeled oligonucleotide with Foxb1 protein; sample 3, labeled oligonucleotide with 
Foxb1 protein and with an 125-fold excess of unlabeled oligonucleotide for specific competition. 
5 x binding buffer is: 100mM Hepes, adjust to pH7.9 with 1N NaOH; 5mM DTT; 1% Tween 20 
(w/v); 150mM KCl; 5mM MgCl2. 
 sample 1 sample 2 sample 3 
5 x Binding buffer 4ul 4ul 4ul 
poly [d(I-C)] [1ug/ul] 1ul 1ul 1ul 
poly L-lysine, [0.1ug/ul] 1ul 1ul 1ul 
DIG-labeled oligo-nucleotide[0.4 ng/ul] 2ul 2ul 2ul 
double dist. water 12ul 10ul 8ul 
unlabeled oligo-nucleotide[10uM] - - 2ul 
FoxB1 protein [100ng/ul] - 2ul 2ul 
 
Mix carefully and incubate for 30min at 4°C, place tube on ice. Add to each sample 5µl of 
loading buffer with bromophenol blue, apply sample immediately to a pre-electrophoresed 
polyacrylamide gel. 
2.8.3.2 Polyacrylamide gel electrophoresis 
One day before, prepare a native polyacrylamide gel 8% acrylamide in 0,5 x TBE buffer (15cm x 
15cm x 0,1cm PAGE). The gel must be pre-run (45min). Before loading samples, clean sample 
wells to remove APS, residual polyacrylamide to ensure sample application without diffusion. 
Load the samples to the gel. Run PAGE in 0,5 x TBE buffer at 120 V and run dye 2/3 of the way 
to the bottom of the plates (2,5h). 
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2.8.3.3 Blotting and crosslinking 
After electrophoresis, remove one glass plate carefully from the gel. Equilibrate a sheet of nylon 
membrane trimmed to the size of the gel for 5min in transfer buffer (0,5 x TBE buffer). Place 
equilibrated nylon membrane carefully onto the gel. Place 4 layers of gel-sized Whatman 3MM 
papers, presoaked in transfer buffer on the filter. Roll with a glass rod or a pipette over the 4 
layers Whatman 3MM paper to remove air bubbles. Remove pad of Whatman 3MM paper/nylon 
membrane/gel from the other glass plate. Add 4 layers of pre-soaked Whatman 3MM papers on 
the other side of the gel. Place resulting sandwich between the electrodes of the electroblotting 
device. Transfer is performed for 30min at 100V (Bio-RAD System). Place the membrane on a 
Whatman 3MM paper presoaked with 2 x SSC (NaCl 87,65g/liter, sodium citrate 44,1g/liter, 
adjust to pH7.0 with NaOH ), cross-link at 120 mJ in a Stratalinker twice. 
2.8.3.4 Chemiluminescent detection 
Rinse membrane briefly (1-5) min in Washing buffer. Incubate for 30min in 100ml Blocking 
solution. Incubate for 30min in 20ml Antibody solution. Wash 2 x 15min in 100ml Washing 
buffer. Equilibrate 2-5min in 20ml Detection buffer. Place membrane with DNA side facing up 
on a fresh plastic membrane and apply 1ml CSPD® working solution. Immediately cover the 
membrane with the rest part of the fresh plastic membrane, spread the substrate evenly and 
without airbubbles over the membrane. Incubate for 5min at 15 to 25°C. Squeeze out excess 
liquid. Drying of the membrane during exposure will result in dark background. Incubate the 
damp membrane for 10min at 37° C to enhance the luminescent reaction. Expose to X-ray film 
for 15-25min at 25°C. Multiple exposures can be taken to achieve the desired signal strength. 
2.9 Histological staining 
2.9.1 Immunohistochemical staining 
In these techniques an antibody is used to link a cellular antigen specifically to a stain that can be 
more readily seen with a microscope. Detection of antigens in tissues is known as 
immunohistochemistry. 
Detection of ß-galactosidase in Foxb1 mutant tissue with Polyclonal Rabbit Antibody was done 
as follow. Paraffin section was used because it provides for excellent morphological detail and 
resolution. 
Fresh embryo head or adult brain taken out of the mouse after perfusion was fixed in 4% 
formaldehyde in 1x PBS for 4 days. Then transfer to 50% ethanol (one day), 75% ethanol for one 
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day, 2 x 100% ethanol (one day each), 2 x Tuluol (one day each), 3 x fresh liquid paraffin (one 
day each). Then process for embedding in paraffin wax. And paraffin blocks were sectioned at 
20um. For the section deparaffinization and hydration, incubate sections in 2 x Xylene, 10 
minutes each; 100% absolute ethanol, 10 minutes; 100% absolute ethanol, 5 minutes; 90% 5 
minutes; 75% ethanol, 5 minutes; 50% ethanol, 5 minutes. Dip slides shortly in water, then 
amount slides containing sections into the immuno-rack in 1 x PBS. Gently wash slides with 1 x 
PBS 3 times. Incubate sections in 1 x PBS with 3% H2O2 for 15 minutes. Wash slides with 1 x 
PBS 3 times, Preincubate sections in PBSTF (1 x PBS, 0.1% Tx-100, 10% FCS) for one hour. 
Apply 200ul anti-ß- galactosidase (1:500 dilution in PBSTF, Eugene, Oregon, USA) per slide, 
incubate overnight at 4oC in the dark. The next day morning, rinse slides gently with 1 x PBS 3 
times. Apply 200ul anti-rabbit biotin-conjugated antibody directed against rabbit 
immunoglobulins (1:300 dilution in PBSTF), incubate one hour. Rinse slides gently with 1 x PBS 
3 times. ), apply 200ul Extravidine peroxidase conjugate (1:100 dilution in PBSTF, SIGMA) and 
incubate one hour. Rinse slides with 1 x PBS 3 times and add substrate diaminobenzidine (DAB) 
(1ml 10 x DAB; 9ml 1 x PBS, 30ul H2O2) until desired color intensity has developed (3-5min). 
Wash slides with 1 x PBS and dissemble slides in 1 x PBS, for the dehydration, transfer slides to 
distilled water for a few seconds, incubate slides in 50% ethanol 5 minutes, 75% ethanol 5 
minutes, 90% ethanol 5 minutes, 100% ethanol 5 minutes, 100% ethanol 10 minutes, xylene 
twice 10 minutes each, coverslip slides with Pertex medium. 
2.9.2 Nissl staining 
Principle: Neurons contain Nissl substance, which is primarily composed of rough endoplasmic 
reticulum, with the amount, form, and distribution varying in different types of neurons. Because 
of the RNA content, Nissl substance is very basophilic and will be very sharply stained with basic 
aniline dyes. By varying the pH and the degree of differentiation, both Nissl substance and nuclei 
or only Nissl substance may be demonstrated. 
Procedure: the whole work was done in a series of manual staining racks. First for the 
deparaffinization and hydration, the sections were incubated in 2x for 10min in xylene, then 
transfer to the following ethanol grade (100%, 95%, 70%, in each case 2 x 5min). After 5min in 
water, incubate slides for 10-30min (10min embryo, 30min P56 brain) into 1% Cresyl violet 
(Chroma 1A396) staining solution (2,721% sodium acetatic, 100ml, 1,2% glacial acetic acid 
400ml, pH3.8-4 adjusted by using 1,2% glacial acetic acid; 0,1% Cresyl violet). Put slides in 70% 
isopropanol/0.1% CH3COOH for approximately 15 seconds, then into water for a few seconds. 
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Incubate slides in 70% ethanol for 5 minutes, 95% ethanol for 5 minutes, 100% ethanol for 5 
minutes, in xylene twice, 5 minutes each. coverslip slides with Pertex medium. 
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3 RESULTS 
3.1 FINDING A DOWNSTREAM CANDIDATE FOR Foxb1 
IN THE CAUDAL HYPOTHALAMUS 
For our genomic analysis of the regulatory chain starting with Foxb1, we needed relatively large 
amounts of tissue. Since the mouse strain 129Sv, of choice in the preparation of targeted mutant 
lines (Nagy et al., 2002), gives small litters, we decided to backcross this mutant line into an 
outbred one, NMRI, of current use in our institute, which normally yields litters of around 12 to 
14 pups. The 129Sv line is highly inbred, that is, has a very high degree of homozygosis. This 
means the mice are as homogeneous genetically as possible. It also means this line is “weaker”, in 
the sense that mutant phenotypes can be more obvious than in outbred lines, which have a high 
degree of heterozygosis. The outcome is that a primary concern at this point was the maintenance 
of the mammillary axonal phenotype in this outbred line. A “robust” phenotype is largely 
independent on the alleles whose products interact with the protein produced by the mutated 
gene, while a “weak” phenotype will be more or less obvious (more or less abnormal) depending 
on the genotype of the genes whose products interact physiologically with the product of the 
mutated gene. 
3.1.1 The mammillary axonal phenotype of the Foxb1 mutant is 
conserved in the NMRI genetic background. 
The original 129Sv mutant mice were crossed into wild type NMRI strain for 7 generations, then 
the analysis of the phenotype was started. First paraffin blocks were prepared which contained 
formaldehyde-fixed heterozygous or homozygous brains of different embryonic ages, and cut 
along the sagittal plane of section and treated them with anti-ß-galactosidase antibody. The 
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rationale was that the reporter gene for this targeted mutation is tau-LacZ, which generates a 
fusion protein containing a tau moiety (tau is an intermediary filament protein typical but not 
exclusive of neuronal axons) and a ß-galactosidase moiety (this is a bacterial enzyme which can 
be easily detected by specific, commercially available antibodies and whose expression in 
heterozygous or homozygous tissues “reports” on the transcriptional activity of Foxb1). In this 
way, I was able to detect the axons coming from the mammillary body (MBO) in the 
heterozygous (which shows a completely normal phenotype (Alvarez-Bolado et al., 2000) and 
homozygous brain. To identify structures in the embryonic brain, my main reference was the 
“Developing Brain Maps” Atlas (Alvarez-Bolado and Swanson, 1996). At embryonic day 14.5 
(E14.5), the profile of the MBO was easily distinguishable in both heterozygotes and 
homozygotes (Fig.3.1A, B). The principal mammillary (pm) tract emerged from the dorsal 
surface, and first spread out more dorsally, then extended parallel to the ventral part, caudally 
reaching ventral and dorsal midbrain tegmental nuclei. It showed a well developed 
mammillotegmental bundle (mtg). At this age, no difference was observed between heterozygotes 
and homozygotes. By E17.5 differences between heterozygotes and homozygotes started to be 
evident: the axons of the heterozygous principal mammillary tract extended a new outgrowth. 
This was the mammillothalamic tract (mtt) (Fig.3.1C, D). In the mutants, however, only a few 
growing axonal tips were present at the collateral bifurcation (Fig.3.1D). Within 24 hours, 
another axonal tract, the mammillotectal tract (mtc), started to be visible (Fig.3.1E). This tract 
coursed first dorsally, then turned caudally in the direction of the midbrain tectum, and was well 
established by E18.5 (Fig.3.1E,F).The mtc is probably formed by principal axons from the dorsal 
premammillary nucleus, and not by collateral branches of the principal mammillary tract 
(Canteras and Swanson, 1992; Alvarez-Bolado et al., 2000). In heterozygotes, the mtt tract was 
clearly visible at E18.5 (Fig.1E), formed by pioneer fibers provided with growing tips advancing 
dorsalward into the dorsal thalamus. However, in homozygotes, only a few short outgrowths 
could be seen to hang towards their target, dorsal thalamus.  
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Fig.3.1: The Foxb1 mutant (NMRI, F7) 
mammillothalamic tract fails to enter the target 
region and most of the mammillary body cells die 
immediately afterwards. (A, B) Sagittal paraffin 
sections through heterozygous (A) and homozygous 
(B) E14.5 mouse brains reacted for the detection of 
ß-galactosidase. In A and B, principal mammillary 
tract (pm) can be seen and mammillotegmental tract 
developed very well at this stage, but there is no 
difference between A and B. (C, D) Sagittal paraffin 
sections through heterozygous (C) and homozygous 
(D) E17.5 mouse brains reacted for the detection of 
ß-galactosidase. In D, a few outgrowth of principal 
mammillary axons can be seen forming a second 
bifurcation towards the thalamus (arrow). (E, F) 
Sagittal paraffin sections through heterozygous (E) 
and homozygous (F) E18.5 mouse brains reacted for 
the detection of ß-galactosidase. In E and F, the 
third bifurcation mammillotectal tract can be seen 
and is well developed at this stage. In F, a small 
outgrowth of mammillothalamic tract starts towards 
the thalamus (arrow). (G, H) Sagittal paraffin 
sections through heterozygous (G) and homozygous 
(H) new born mouse brains reacted for the detection 
of ß-galactosidase. In H, mammillothalamic tract is 
almost absent at this stage. (I, J) Sagittal paraffin 
sections through heterozygous (I) and homozygous 
(J) P15 mouse brains reacted for the detection of ß-
galactosidase. In J, one or two axons from 
mammillothalamic tract extended, but did not enter 
the target of dosal thalamus, and the mammillary 
body (MBO) is much smaller compared to the 
mammillary body in I. MBO, mammillary body; 
mtt, mammillothalamic tract; mtc, mammillotectal 
tract; mtg, mammillotegmental tract, pm, principal 
mammillary tract. 
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At P0 (day of birth), the heterozygous mtt tract was a compact fiber bundle spanning the distance 
between MBO and anterior thalamic complex and expanding terminal fiber arbors into it 
(Fig.3.1G). In the mutant, the mtg, mtc bundles followed an apparent normal trajectory, but the 
mtt tract was almost completely absent, except for a few short axons, at E18.5, or later (Fig.3.1F, 
H). We concluded that, as in the 129Sv background, the NMRI Foxb1 mutant develops a medial 
mammillary nucleus (MM), but fails to develop or maintain a mtt. The size of the MBO was 
normal in homozygotes at P0 (Fig.3.1H). By P15, the size of MBO was abnormally decreased.  
 
 
 
 
Fig.3.2: The Foxb1 mutant 
(129Sv, NMRI) lacks one brain 
nucleus, the medial mammillary 
nucleus, and the size of the lateral 
mammillary nucleus is much 
smaller by the detection of several 
hypothalamic maker antibodies. 
(A, B, G, H) Transverse paraffin 
sections through wild type 129Sv 
(A), NMRI (G) and homozygous 
129Sv (B), NMRI (H) adult mouse 
brains reacted for the detection of 
lateral mammillary nucleus 
marker: parvalbumin. In B and H, 
much less cells were in the lateral 
mammillary nucleus. (C, D, I, J) 
Transverse paraffin sections 
through wild type 129Sv (C), 
NMRI (I) and homozygous 129Sv 
(D), NMRI (J) adult mouse brains 
reacted for the detection of 
calretinin. In D and J, medial 
mammillary nuclei that were 
surrounded by the calretinin-
expressing cells could not be 
detected. (E, F, K, L) Transverse 
paraffin sections through wild type 
129Sv (E) and homozygous (F) 
129Sv adult mouse brains reacted 
for the detection of medial 
mammillary nuclei marker: mGluR 
2/3. In F and L, medial 
mammillary nuclei cells 
completely disappeared. LM, 
lateral mammillary nucleus; MM, 
medial mammillary nuclei; f, 
fasciculus retroflexus.  
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Most MBO cells died (Fig.3.1J), probably due to apoptosis, as has been established for the 129Sv 
strain mutant (Alvarez-Bolado et al., 2000). 
Transverse paraffin sections were prepared from Foxb1 mutant adult brains and treated with 
different hypothalamic marker antibodies respectively to detect the size of MBO in Foxb1 
mutants (Fig. 3.2) (A, B, C, D, E, F were from Alvarez-Bolado, Gonzalo). A group of cells in the 
lateral nucleus of wild type were detected by anti-parvalbumin (Fig. 3.2 A, G), but, there were 
only a few cells in the lateral mammillary nucleus in the homozygotes were detected and the size 
of lateral mammillary nucleus in homozygotes was obviously smaller than that in wild type 
(Fig.3.2B, H). In wild type, the lateral nucleus and the medial mammillary nuclei were dorsally 
surrounded by calretinin-expressing cells (Fig.3.2C, I). The morphology was completely different 
in the homozygotes by the detection of anti-calretinin and the medial mammillary nuclei 
disappeared (Fig.3.2 D, J). mGluR2/3 is a medial mammillary nuclei marker (Fig.3.2E, K), anti-
mGluR2/3 did not detect even one single cell in the MBO region in homozygotes (Fig.3.2F, L). 
The third ventricle that was very low and near the border (Fig.3.2 H, J, L) also showed that 
medial mammillary nuclei disappeared. 
 
 
 
 
 
 
 
Fig.3.3: Confirmation that Foxb1 mutant 
(NMRI) lacked a medial mammillary nuclei 
and had smaller size of lateral mammillary 
nucleus by Nissl staining. Sagittal paraffin 
sections of the posterior hapothalamus of 
wild type (A, C, E, G) and homozygous (B, 
D, F, H) adult brains stained with Cresyl 
violet. By which  the subdivisions of 
mammillary body were shown (A, C, E, G). 
In B, Lateral mammillary nucleus is smaller; 
in D, there was no lateral subdivision of 
medial mammillary nuclei; in F, there was no 
medial subdivision of medial mammillary 
nuclei; in H, there was no median subdivision 
of medial mammillary nuclei. LM, lateral 
mammillary nucleus; MM lat, lateral 
subdivision; MMm, medial subdivision; 
MMn, median subdivision; SUM, 
supramammillary nucleus; pm, principal 
mammillary tract; fx, fasciculus retroflexus; 
PMd, dorsal premammillary nucleus; PMv, 
ventral premammillary nucleus. 
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Different nuclei of the mammillary body: lateral mammillary nucleus (LM), lateral subdivision 
(MM lat) of medial mammillary nuclei (MM), medial subdivision (MMm) and median 
subdivision (MMn,) were shown by the staining with Cresyl violet on paraffin sagittal sections 
from wild type adult mouse brains (Fig.3.3A, C, E, G). The lateral mammillary nucleus (LM) was 
less compact and very much reduced in the Foxb1 NMRI mutant (Fig. 3.3B). The mutant were 
absent of all MM lat, MMm, and MMn subdivisions of MM. 
It was concluded that the mammillary axonal phenotype in the Foxb1 mutant on the NMRI 
genetic background was very similar or identical to that of the Foxb1 mutant on the 129Sv strain. 
The Foxb1 mutants on both genetic backgrounds lacked MM, and had very reduced lateral 
mammillary nucleus. This robust phenotype could then be analyzed in the more productive NMRI 
strain. 
3.1.2 The transcriptome of the caudal hypothalamic region in the 
Foxb1 mutant is different from that of the wild type 
Once the mutant phenotype in the NMRI background had been established, this mutant line was 
used in order to compare the mutant and wild type transcriptomes of caudal hypothalamus. The 
rationale behind this experiment was that this comparison would show which genes are 
downstream of Foxb1 (i. e., those whose expression was altered in the mutant). Although mRNA 
is not the end product of a gene, the transcription of a gene is both critical and highly regulated, 
thereby providing an ideal point of investigation (Brazma and Vilo, 2000). 
3.1.2.1 Tissue collection and mRNA extraction 
First, the posterior portion of the hypothalamus of E18.5 mouse embryos from heterozygous 
Foxb1-NMRI crossings was microdissected. A piece of embryonic tissue outside the brain (leg 
tissue) for each piece of hypothalamus collected was taken carefully, so that genomic DNA can 
be isolated and used for PCR to find the genotype of each piece of brain tissue collected. Then the 
tissue was pooled according to genotype. The Dyna Beads method was used (see Materials and 
Methods) to isolate mRNA from wild type and homozygous tissue pools. The mRNA used to 
make samples for Affymetrix genechips has to be of the highest quality. The quality integrity of 
the mRNA was assessed by optical density (OD) measurements, and made sure that OD260/280 
was always above 1.9 (indicating no contamination from protein or solvent) (Fig.3.4A). And 
agarose gel electrophoresis was used to abserve the sharp ribosomal RNA (18S, 28S) bands on 
the gel to control for possible degradation of the mRNA samples. Other bands on the gel were 
because of the secondary structure of RNA, which disappeared after the denaturation of sample 
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(Fig.3.4B). Finally, the Agilent 2100 Bioanalyzer system was used to confirm the quality of the 
samples as an independent method, with very satisfactory results: no degradation and no 
ribosomal RNA (18S and 28S) peaks (Fig.3.4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.4: mRNA quality assessment. 
(A) Optical density measument of 
mRNA. At 260nm, there is a nucleic 
acid absorption peak and the ratio 
(260nm/280nm) is equal to 1.96. 1OD 
at 260nm = 40µg/ml pure RNA. (B) 
Agarose gel electrophoresis analysis 
of mRNA. In 1, the sharp 28S and 
18S ribosomal RNA bands were seen. 
In 2, sample was incubated at 70oC 
for 10 minutes and RNA secondary 
structure disappeared. (C) Agilent 
2100 Bioanalyzer plots depicting 
highly pure mRNA. RNA size 
distribution did not shift to the smaller 
fragments and there was no 
degradation.  There was no presence 
of ribosomal RNA peaks, and the 
mRNA was highly pure. 
 
Two series of microdissections were preformed. For the first one, the dissected pieces of 
hypothalamus were large, including not only the caudal hypothalamus, but also other 
hypothalamic parts dorsal to the mammillary region. Fifteen brains of each genotype were 
pooled. This mRNA was used for the first (1st large) and second (2nd large) microarray 
hybridizations. The second series of microdissections used small dissections, containing probably 
only the mammillary subdivision of the hypothalamus; 10 brains of each genotype were pooled. 
This mRNA was used for the third microarray hybridization (1st small) (Fig.3.5B). 
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3.1.2.2 Microarray analysis 
Preparation of the probe and hybridization to 
the Affymetrix Microarrays (Murine Genome 
U74 A, B and C), as well as the informatic 
analysis of the resulting data, was done by the 
Deutsches Ressource Zentrum für 
Genomforschung (RZPD, Berlin) for a fee. We 
used the GeneChip® DNA microarrys made by 
Affymetrix, specifically, the Murine Genome 
U74 Set, consisting of three Chips (Av2, Bv2, 
Cv2), containing sequences representing 
approximately 36,000 genes (6000 functionally 
characterized plus 30000 Expressed Sequence 
Tags.). The transcriptome of the tissues was 
compared (also at RZPD) by means of 
Affymetrix proprietary analytical software. 
The comparison was as follows: HO-P vs. WT-
P (HO: homozygotes; p: posterior 
hypothalamus) (Fig.3.5A). 31 genes altered 
from the first hybridization, 120 genes altered 
from the second hybridization, and 160 genes  
altered from the third hybridization (Fig.3.5B). 
Real signals were distinguished from noise by 
imposing an arbitrary threshold of signal 
difference between experiments and baseline. 
This is done in terms of the so-called Signal 
Log Ratio (SLR). The SLR is related to the 
fold change by the following formulas: 
 
 
Fig.3.5. Sample process, microarray hybridization and data summary. (A) mRNA was isolated from 
wild type and homozygous tissues and sent to RZPD for the synthesis probes and hybridization with 
Affymetrix Murine Genome U74 Set Genechips. (B) The third hybridization (1st small) was done with 
tissue from new, more precise dissections. Thirty-one genes were obtained from the first hybridization, 120 
genes from the second, 160 genes from the third. (C) In total we found 36 genes with SLR>=1 (19 
decreased, 17 increased), and 106 genes with SLR>=0.5 (71 decreased, 35 increased).  
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   Fold change = 2SLR for SLR ≥0 
   Fold change = (-1) x 2- SLR for SLR <0 
So, for instance, an SLR of +2 means a fourfold increase in expression in experimental 
(homozygote) as compared to control (wild type). An SLR of -2 would mean a fourfold decrease. 
We ranked the genes by fold change, from high to low. There were 36 genes with the SLR >=1 
(That is, at least twofold increase or decrease). I selected for further analysis the SLR changes (an 
increase or decrease of SLR >=0.5) plus all the genes detected in the three hybridizations, to a 
total of 106 genes (Fig.3.5C). 
For the following validation, we used an automated, high-throughput in situ procedure developed 
in this department under the direction of Prof. Eichele (Herzig et al., 2001; Visel et al., 2004). 
This procedure routinely provides high-quality, very reproducible data. The second technique, 
quantitative real-time PCR (Q-PCR), was used to detect small differences in the level of 
expression, and as such helps to eluminate “false positive” given by microarray. This 
combination of DNA microarrays and Q-PCR is rapidly becoming a standard approach to 
expression analysis (Sgroi et al., 1999; Mills et al., 2001); (Mutch et al., 2001); (Mayanil et al., 
2001); (Jiang et al., 2002). Of note, Q-PCR will add a numerical value to the magnitude of 
change and thus complement the data obtained by in situ hybridization. 
3.1.2.3 Validation of microarray data by In situ hybridization (GenePaint) and 
quantitative PCR 
Among the list of 106 genes that had been compiled and annotated, on the basis of the 
information found in the literature, we selected the 76 potentially more interesting genes to be 
validated. To carry out this selection, an "educated guess" was made on which kind of genes can 
be affected in the Foxb1 mutant, given the phenotype: genes with specific expression in brain, 
involved in development or in processes like axonal pathfinding, cell differentiation, etc. were 
preferred over ubiquitously expressed genes, house-keeping genes, mesoderm-specific genes, etc. 
These 76 downstream candidates were then submitted to a first round of validation through in situ 
hybridization. Any true downstream genes to Foxb1 involved in the mammillary phenotype have 
to be expressed in the mammillary body. With the help of technicians, in situ probes were 
prepared against 57 of the 76 candidates by means of RT-PCR1. In situ hybridization was made  
                                                     
1
 Probes for the remnant 19 genes proved to be difficult to clone. The time-consuming task of solving the 
specific cloning problems for each of them has been taken up by the team of technicians of GenePaint in 
our Department. 
RESULTS 
80 
 
 
Fig.3.6: Candidate genes differentially expressed in wild type and Foxb1 homozygotes. In situ 
hybridization was performed on cryostat sections of wild type (A, B, C) and homozygous (A′, B′, C′). 
(A, A′) E18.5 mice with riboprobe against EphA7 mRNA. In A, EphA7 is very specifically expressed in the 
mammillary body (arrow), while in A′, expression was much decreased in the mutant mammillary body 
(arrow). (B, B′) E18.5 mice with riboprobe against cadherin 11 (Cdh 11). Cdh 11 is expressed specifically 
in the mammillary body (B, arrow), however, in B′, the expression of cadherin 11 was almost absent in 
mammillary body (Arrow). (C, C′) E18.5 mice with the riboprobe of CLCA1gene. In C, CLCA1 did not 
express in the mammillary body (arrow), however, it was present in C′ (arrow). MBO, mammillary body. 
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on cryostat sections of wild type E14.5 and E18.5 mice. The expression data so obtained revealed 
that 32 of the candidates were not interesting: they were either not expressed on the mammillary 
body, or ubiquitously expressed. Specific expression patterns in the hypothalamus, including the 
mammillary body, were found for 25 of the candidates. 
The next validation step consisted of proving that expression of the 25 MBO-specific candidates 
was actually altered in mutant tissue. Probes for the 25 MBO-specific downstream candidates 
were hybridized to cryostat sections of E18.5 Foxb1 homozygous brains. The patterns of 4 of the 
candidates were actually altered in the mutant. Three of them were reduced (EphA7, Cdh11 and 
Foxb1) and one was increased in the mutant as compared to the wild type: CLCA1 (Fig.3.6). 
Although the purpose of my thesis work was not to evaluate microarray technology, it is maybe 
worth to summarize here some conclusions about the method which can be gathered from my 
data. As evidenced by validation results, the fold change (SLR) can not be used alone to ascertain 
expression changes between wild type and mutant tissues. ISH data showed 14.3% concordance 
with microarray data, and Q-PCR analysis demonstrated 27% ISH and Q-PCR agreed on 73% of 
the cases. 
3.1.2.4 Identity and function of the downstream candidates to Foxb1 
First of all, finding that Foxb1 transcripts are very much reduced in the Foxb1 mutant did not 
come as a surprise, and it is mentioned as a further validation of the method. 
EphA7 encodes a membrane receptor tyrosine kinase (Ciossek et al., 1999; Rogers et al., 1999) 
whose ligands are the ephrins A. The Eph receptor-ephrin interaction has a major involvement in 
axonal guidance (Gale et al., 1996b; Ciossek and Ullrich, 1997; Zhou, 1998; Holmberg et al., 
2000). 
Cdh11 (cadherin 11) encodes a transmembrane protein acting as a homophylic cell-cell adhesion 
molecule, and has been involved also in axonal guidance and in selective aggregation of neurons 
to form brain nuclei (Marthiens et al., 2002). 
CLCA1 (calcium-sensitive chloride conductance protein) encodes a transmembrane protein 
forming a activated during apoptotic processes (Gandhi et al., 1998; Elble and Pauli, 2001). 
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3.2 BIOLOGICAL VALIDATION OF EphA7 AS A 
DOWNSTREAM CANDIDATE TO Foxb1 IN THE 
HYPOTHALAMUS 
3.2.1 EphA7 is a biologically relevant downstream candidate for 
Foxb1 in the diencephalon. 
All further work focuses on EphA7 as the most interesting candidate. Since EphA7 is a receptor 
molecule, the finding that its expression is altered in the Foxb1 mutant would reach biological 
significance only in the case that expression of appropriate ligands in the caudal hypothalamus 
could be demonstrated. From the literature the EphA7 receptor binds the family of cell-attached 
ephrin-A ligands (Gale et al., 1996a; Ciossek and Ullrich, 1997; Drescher et al., 1997; Flanagan 
and Vanderhaeghen, 1998; Wilkinson, 2001). Consequently, and with the assistance of technical 
personnel of the department, GenePaint technology was used to demonstrate the pattern of 
expression of the five known genes of the ephrin A family on E18.5 wild type and Foxb1 mutant 
mouse hypothalamus (Fig.3.7). Foxb1 mutant hypothalamus was also used. The results showed 
that the expression pattern of each ligand in ephrin A family did not alter in Foxb1 mutant, and 
that ephrin-A1, ephrin-A2 and ephrin-A3 have ubiquitous expression in the brain at E18.5. 
Ephrin-A4 is apparently not expressed in the brain at that age (data not shown). Finally, ephrin-
A5 showed a specific expression pattern in diencephalon, specifically in the dorsal 
thalamus(Fig.3.7E,F), which is the target region of the mtt axons whose failure to enter this 
region is the hallmark of the Foxb1 diencephalic phenotype (Alvarez-Bolado et al., 2000). This 
finding shows that EphA7 is a biologically relevant downstream candidate for Foxb1. 
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Fig.3.7: Expression analysis of ephrin A ligand family at E18.5 stage on wildtype (A, C, E, G) and Foxb1 
(B, D, F, H) homozygous hypothalamus. (A, B) ephrin A1 had ubiquitous expression in the brain. The 
same expression pattern for ephrin A2 ligand (C, D) and ephrin A3 ligand (E, F). (G, H) ephrin A5 showed 
no expression difference between wildtype and mutant (After checking the whole series of sections of the 
brain). Ephrin A5 showed however very specific expression pattern in hypothalamus. 
Abbreviations: pm, principal mammillary tract; mtt, mammillothalamic tract; MBO, mammillary body; 
DOR, dosal thalamus; fr, fasciculus retroflexus. 
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3.2.2 Expression of known and novel isoforms of receptor tyrosine 
kinase gene EphA7 is very much reduced in the caudal 
hypothalamus of the Foxb1 mutant. 
The receptor EphA7, originally called EBK or MDK1 or EHK3 (Ciossek et al., 1995a; Ellis et al., 
1995; Valenzuela et al., 1995). The EphA7 locus encodes not only a typical receptor tyrosine 
kinase (TK+), but also isoforms lacking the tyrosine kinase domain (TK-), produced by alterative 
RNA splicing (Ciossek et al., 1995b; Mori et al., 1995; Talukder et al., 1997).  
By searching Genebank, at mRNA level, two different EphA7 full length (EphA7-FL) transcripts 
were found, both of them consisting of 18 exons. The Genebank accession number of EphA7 full 
length is XM_131334. One of them is 5336bp, the other is 12bp shorter. The first truncated 
variant, EphA7-Tr1 (Genebank Accession No.: X79083), has 10 exons and is 2901bp long. The 
second truncated variant, EphA7-Tr2 (Genebank Accession No.: X79084), also has10 exons and 
is 2323bp long. By BLAST sequence comparison against the NCBI nucleotide database (Altschul 
et al., 1990), I found a yet un-described truncated variant (Genebank Accession No.: AK032973) 
which is 3189bp long (Fig. 3.8C). In total, there are five variants, in coincidence with the 
"expected transcripts" for the EphA7 locus in the Celera sequence database (Fig. 3.8A). All of 
them are different at 3′ UTR region. 
At protein level, one of the full length transcripts was 4 amino acids shorter than the other (994 
amino acids vs. 998 amino acids). The missing amino acids correspond to the intracellular 
domain. Since both full length forms have the ephrin binding domain and two fibronectin III 
domains in the extracellular part, as well as the tyrosine kinase domain and SAM domain in the 
intracellular part (Fig.3.8B), they are probably equivalent functionally. 
As for the truncated transcripts, EphA7-Tr1 and EphA7-Tr2 encode the same protein, 662 amino 
acids. They have ephrin binding domain and two fibronectin III domains in the extracellular part, 
and can dock on the cell membrane. They are missing the tyrosine kinase domain (Fig.3.8B), and 
consequently can bind the ligand and probably serve an adhesive function (Holmberg et al., 2000) 
but do not signal to the interior of the cell. 
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Fig.3.8: Schematic map of EphA7 receptor variant transcripts and their predicted proteins. (A) The Celera 
sequence database expected five transcripts from EphA7 locus. (B) Protein structure of EphA7 five variants 
and their length. Numbers above show the position in the protein sequence. (C) Sequence alignment among 
all variants mRNA, the corresponding accession number in Genebank, and the specific primers position 
which were against each variant 3′ UTR region (arrows and the number behind show primer position, 
numbers above show the position in the sequence). 
Abbreviations: FL, EphA7-Full length; Tr1, Tr2, Tr3, EphA7 truncated 1, 2, 3; EPH_lbp, ephrin ligand 
binding domain; FN3, fibronectin III domain; TyrKc, tyrosine kinase domain, SAM, Sterile a-motif.  
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The novel truncated form (EphA7-Tr3, 451 amino acids) showed ephrin binding domain but only 
one fibronectin III domain, and very likely is not able to dock on the membrane (secreted?). It 
contains 2 amino acids at the end which are different from other variant forms (Fig.3.8B). 
primers specific for each of the variants (but only for one of the full length transcripts) were 
designed: EphA7-FL, EphA7-Tr1, EphA7-Tr2, EphA7-Tr3, which are against each variant 3′ 
UTR region (Fig.3.8C). Specific probes for them were cloned by RT-PCR. In situ hybridization 
performed on tissue sections of developing mouse brain at ages E16.5, E17.5, E18.5 showed 
expression of all forms in the developing diencephalon. All of them were expressed in the whole 
of the dorsal thalamus, as well as very specifically in MBO, and in a group of cells alongside the 
mammillothalamic tract to the thalamus. EphA7-FL was the predominant expressed form during 
development in the diencephalons. The expression of all isoforms was very much decreased in 
the developing homozygotes, EphA7-FL (Fig.3.9); EphA7-Tr1 (Fig.3.10); EphA7-Tr2 (Fig.3.11); 
EphA7-Tr3 (Fig.3.12). 
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Fig.3.9: EphA7 full length (EphA7-FL) is strongly expressed in the wildtype developing diencephalon (A, 
C, E); its expression was very much reduced in the developing homozygous mammillary body (B, D, F). 
(A, B) EphA7-FL expression in E16.5 hypothalamus. In B, the expression was much decreased in 
mammillary body. (C, D) EphA7-FL expression in E17.5 hypothalamus. In D, the expression was much 
decreased in mammillary body. (E, F) EphA7-FL expression in E18.5 hypothalamus. In F, the expression 
was much decreased in mammillary body. In A, C, E, EphA7-FL strongly expressed in the dorsal thalamus, 
the patch of cells alongside mammillothalamic tract and mammillary body. 
Abbreviations: DOR, dosal thalamus; mtt, mammillothalamic tract; pm, principal mammillary tract; MBO, 
mammillary body; fr, fasciculus retroflexus. 
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Fig.3.10: EphA7 truncated 1 
(EphA7-Tr1), expressed in the 
developing diencephalon and the 
expression was very much 
reduced in the developing 
homozygous mammillary body. 
(A, B) EphA7-Tr1 expression on 
wild type (A) and homozygous 
(B) E16.5 hypothalamus. (C, D) 
On wild type (C) and 
homozygous (D) E17.5 
hypothalamus. (E, F) On wild 
type (E) and homozygous (F) 
E18.5 hypothalamus. In A, C, E 
EphA7-Tr2 expressed in the 
dorsal thalamius, the patch of 
cells located alongside the 
mammillothalamic tract and 
mammillary body. In B, D, F, the 
expression was much decreased 
in mammillary body. DOR, dosal 
thalamus; mtt, mammillothalamic 
tract; pm, principal mammillary 
tract; MBO, mammillary body; fr, 
fasciculus retroflexus.  
 
 
Fig.3.11: EphA7 truncated 2 
(EphA7-Tr2) expressed in the 
developing diencephalon and the 
expression was very much 
reduced in the developing 
homozygous mammillary body. 
(A, B) EphA7-Tr2 expression on 
wild type (A) and homozygous 
(B) E16.5 hypothalamus. (C, D) 
On wild type (C) and 
homozygous (D) E17.5 
hypothalamus. (E, F) On wild 
type (E) and homozygous (F) 
E18.5 hypothalamus. In A, C, E 
EphA7-Tr2 expressed in the 
dorsal thalamius, the patch of 
cells alongside 
mammillothalamic tract and 
mammillary body. In B, D, F, 
the expression was much 
decreased in mammillary body. 
DOR, dosal thalamus; mtt, 
mammillothalamic tract; pm, 
principal mammillary tract; 
MBO, mammillary body; fr, 
fasciculus retroflexus. 
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Fig.3.12: EphA7 truncated 3 (EphA7-Tr3) was expressed in the developing wildtype diencephalon (A, C, 
E) and the expression was very much reduced in the homozygous (B, D, F) mammillary body. (A, B) 
EphA7-Tr3 expression in E16.5 hypothalamus. (C, D) Expression in the 17.5 hypothalamus. (E, F) 
Expression in the E18.5 hypothalamus. In A, C, E, EphA7-Tr3 expressed in the dorsal thalamus, the patch 
of cells alongside mammillothalamic tract and mammillary body. In B, D, F, the expression was much 
decreased in mammillary body. 
DOR, dosal thalamus; mtt, mammillothalamic tract; pm, principal mammillary tract; MBO, mammillary 
body; fr, fasciculus retroflexus. 
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3.2.3 All of the EphA7 isoforms were equally decreased in the Foxb1 
mutant hypothalamus. 
Next it was investigated if some of the isoforms were more affected than others by the Foxb1 
deficiency. Quantitative RT-PCR was used to determine the proportion of decrease in mRNA 
amount for each of the variants. 
Caudal hypothalamus of E18.5 wild type and homozygous mouse fetuses was microdissected, 
and mRNA and cDNA were prepared from them. Then I used specific primers to amplify 75-
150bp fragments of each of the variants in the two genotypes. Amplification was evident from all 
samples while the negative control (no template) responded appropriately. SYBR Green I dsDNA 
dye was used to monitor fluorescence. Amplification products were identified by melting curve 
profile analysis and confirmed by gel electrophoresis. Unknown sample concentration was 
optimized by the analysis of amplification plot (threshold cycle: CT). The housekeeping gene 
elongation factor 1 alpha (EF1α) was used to normalize different cDNA samples amounts. The 
results showed a decrease of 20 to 55% for all of the isoforms in the mutant. (Fig.3.13).  
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Fig. 3.13: Quantitative real-time PCR of EphA7 isoforms (SYBR Green I assay). (A) Real-time 
amplification plots for EphA7-FL, EphA7-Tr1, EphA7-Tr2, EphA7-Tr3 genes. The chart showing a plot 
for each PCR reaction based upon its relative florescence unit (RFU). The cycle numbers (Cycle threshold, 
CT) necessary to achieve the given level of florescence (horizontal level), Baseline subtraction is made at 
the lowest point where linear amplification of the PCR reactions is occurring. (B) The standard curve with 
each isoform was obtained by plotting of signals in (A) for four concentrations of standards (blue points, 
each concentration was examined in three or six replicates). Similarly, the unknown was analyzed in 
parallel replicates (Red points). (C) The relative expression of each isoform in wild type and homozygous 
hypothalamus after normalization with the control of Ef1a expression. EphA7-FL was 55% decreased in 
homozygous hypothalamus, other truncated forms were around 25% decreased in homozygous 
hypothalamus.  
 
3.2.4 Foxb1 can bind EphA7 through putative binding sites as 
demonstrated by the One Hybrid Assay in Yeast 
To judge from the axonal phenotype of the Foxb1 mutant mouse, Foxb1 is part of the cis-
regulatory genetic circuitry controlling axonal pathfinding in the diencephalon. In order to place 
EphA7 more precisely in this circuitry, to find out if EphA7 is under the direct control by the 
Foxb1 DNA-binding protein. The alternative hypothesis would be that EphA7 expression is at the 
end of a chain of transcriptional regulation events starting with Foxb1 but including one or more 
intermediate steps (i. e. transcription factors downstream Foxb1, etc.) before reaching EphA7. 
In contrast to most helix–turn–helix proteins, forkhead proteins bind DNA as monomers (Pierrou 
et al., 1994). Their specific binding sites, which typically span 15–17bp, are asymmetrical. The 
sequence specificity has been determined for several representatives of this protein family 
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through selection of binding sites from pools of short, random-sequence duplexes (Pierrou et al., 
1995). A seven-nucleotide core corresponds to the major groove base contacts made by the 
recognition helix (helix 3). For the majority of forkhead proteins, the core conforms to the 
RYMAAYA consensus (Overdier et al., 1994; Pierrou et al., 1994; Kaufmann and Knochel, 
1996), where R stands for A or G; Y for C or T, and M for A or C). I used this seven nucleotide 
consensus as motif to search the 170kb EphA7 genomic sequence (+ 10kb on either side), with 
the help of the Celera Database. I found out that some RYMAAYA sequences are present on the 
genomic sequence of EphA7 with high frequency: 
 
ATAAATA is present   80 times on the genomic sequence of EphA7 
ACAAACA  ,,  46   ,, 
ACAAATA  ,,  38   ,, 
GCAAACA  ,,  28   ,, 
ATAAACA  ,,  24   ,, 
ACCAATA  ,,  15   ,, 
ATCAATA  ,,  13   ,, 
GTAAAATA  ,,  13   ,, 
GCAAATA  ,,  12   ,, 
GTAAAACA  ,,  12   ,, 
GTCAATA  ,,  12   ,, 
ACCAACA  ,,  10   ,, 
GCCAATA  ,,  10   ,, 
ATCAACA  ,,  7   ,, 
GCCAACA  ,,  6   ,, 
GTCAACA  ,,  3   ,, 
 
I selected the 6 RYMAAYA which were repeated with the highest frequency on EphA7 genome 
for further investigation (in bold lettering in the above list). As a first approach to the question of 
the direct interaction of Foxb1 protein with these binding sites, I used a "One Hybrid" strategy on 
a yeast model (Matchmaker kit, Clontech) to detect which DNA element which Foxb1 protein 
can bind. First, I designed oligonucleotides based on the candidate binding sequences, and had 
them commercially synthesized. I gave them the names element 1 (E1), element 2 (E2), element 3 
(E3), element 4 (E4), element 5 (E5) and element 6 (E6), respectively: 
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E1) A ATAAATA A ATAAATA AATA 
E2) AATAAATACAAACA 
E3) C ACAAACA AA ACAAACA CAC 
E4) CA ATAAATACAAATA 
E5) ACCA ATAAATAAAACAAATA 
E6) CAA ACAAACA A ACAAACA AA 
 
Next, three tandem copies were ligated into the EcoRI-SmaI sites (i. e. in front of the basal 
promoter) of plasmid vectors pHISi and pHISi-1 (which contains the yeast HIS3 gene 
downstream of the multiple cloning sites and the minimal promoter of HIS3locus, so allowing 
HIS3-defective YM4271 yeast strain to grow on Histidine-deficient selection medium) and of 
plasmid vector pLacZi (which carries the LacZ reporter gene downstream of the minimal 
promoter of the yeast iso-1-cytochrome C gene (Pcyc1), and which is ready for integration in the 
ura locus). All vectors were from the Matchmaker Kit of Clontech. The constructs so generated 
were called pHISi-E1, E2, E3, E4, E5, E6, pHISi-1-E1, E2, E3, E4, E5, E6 and pLacZi-E1, E2, 
E3, E4, E5, E6 respectively. These constructs have now not only the minimal promoter but the 
tandem repeats upstream which should function as enhancers if it is true that they bind Foxb1. 
The reason why two different HIS vectors are used is that in some circumstances one of them 
gives higher background than the other (the backbones of these plasmid vectors are different). It 
is up to the researcher to determine which one will be more suitable for her experiments. 
The constructs were then sequentially integrated into the genome of the YM4271 yeast strain to 
obtain two strains for each element (E). One of them was carrying pHISi-pLacZi-E (1-6) and the 
other pHISi-1-pLacZi-E (1-6). 
The next step was to perform controls of the suitability of these vectors for the experiment: in the 
absence of Foxb1, the constructs are not supposed to activate expression of the survival reporter 
HIS3 or the blue reporter LacZ (ß-gal). Because of the basal promoter these vectors carry, the 
transformed yeast strain will be able to produce some HIS3 gene product and survive in deficient 
medium (leaky expression; background). 3-AT, a competitive inhibitor of the yeast HIS3 protein, 
eliminates this “leaky expression”. I performed a “leaking test” by culturing all strains on SD/-
His, -Ura3, +15mM, 45mM and 60mM 3-AT selection plates. The purpose of this test is to find  
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Fig.3.14: Test yeast pHISi-pLacZi-E 
(1-6) and pHISi-1-pLacZi-E (1-6) 
colonies for HIS 3 expression. (A) 
pHISi-pLacZi-E (1-6) (left plate), 
pHISi-1-pLacZi-E (1,2,4-6) (right 
plate), 0mM 3-AT. (B) pHISi-
pLacZi-E (1-6) (left plate), pHISi-1-
pLacZi-E (1,2,4-6) (right plate), 
15mM 3-AT. pHISi-pLacZi-E4 
could not grow in left B; pHISi-1-
pLacZi-E2, 4, 5, 6 could not grow no 
the right plate. (C) pHISi-pLacZi-E 
(1-6) (left plate), pHISi-1-pLacZi-E 
(1,2,4-6) (right plate), 45mM 3-AT. 
pHISi-1-pLacZi-E1 could not grow 
on the right plate. (D) pHISi-pLacZi-
E(1-6) (left plate), pHISi-pLacZi-E 
(1,2,4-6) (right plate), 60mM 3-AT. 
(E) pHISi-1-pLacZi-E3 could not 
grow on selection plate with 45mM 
3-AT.  
 
 
 
 
 
 
 
 
 
 
Fig.3.15:  After the transformation of pGAD424-Foxb1 vector, the 
pHISi-1pLacZi-E1, E3, E5, E6 strains could grow on the SD plates 
with 15mM 3-AT. The control without pGAD424-Foxb1 could not 
grow. 
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out which strain has low background expression and which one is suitable for the experiment. 
pHISi- pLacZi-E4, pHISi-1-pLacZi-E1, E2, E3, E4, E5 E6 could not grow on the selection plate 
with 45mM 3-AT. (Fig.3.14). These were selected for the experiment. Then the background ß-gal 
(LacZ) expression of each strain was checked with ß-Gal filter assay: after 2 hours incubation, 
none of them turned blue (data not shown), indicating they were appropriate for the experiment. 
Next Foxb1 cDNA was cloned into the EcoRI-BamHI sites of the pGAD424 vector, this 
construct was called pGAD424-Foxb1. Transform pGAD424-Foxb1 into the pHISi-1pLacZi-E 
(1-6) strains respectively, growing them afterwards on minimal synthetic dropout (SD) plates (-
His -Ura3, , -Leu). The strains carrying tandem repeats of E1, E3, E5, E6 were discovered that 
they could not grow on the SD plates (Fig.3.15). 
To confirm the above results, the positive colonies were picked up and performed 3-AT assay 
according to standard protocol: the pHISi-1-pLacZi-E1 yeast strain transformed with pGAD424-
Foxb1 did grow on SD plates supplemented with 45mM 3-AT; the pHISi-1-pLacZi-E3 yeast 
strain transformed with pGAD424-Foxb1 did grow on SD plates supplemented with 15mM of 3-
AT; the pHISi-1-pLacZi-E5 yeast  strain transformed with pGAD424-Foxb1 did grow on SD 
plates supplemented with 60mM of 3-AT; the pHISi-1-pLacZi-E6 yeast strain transformed with 
pGAD424-Foxb1 did grow on SD plates supplemented with 60mM 3-AT respectively. The 
control yeast strain without pGAD424-Foxb1 transformation did not grow at all on the SD plates 
supplemented with corresponding experimental concentration of 3-AT(Fig.3.16A). By a ß-gal 
filter assay, all positive colonies turned blue in about 30 minutes, however, the control did not 
turn blue in this period (Fig.3.16B). It was concluded that Foxb1 can bind the DNA sequences 
E1, E3, E5, and E6. 
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Fig.3.16: 3-AT assay and ß-Gal filter assay of positive colonies. (A) 3-AT assay. Positive colonies could 
grow on SD selection plates supplemented with relative concentration of 3-AT, the control without Foxb1 
could not grow. (B) ß-Gal filter assay. Positive colonies turn blue in about 30 minutes, but the control 
remained unstained after that period of time. 
 
 
3.2.5 Foxb1 can regulate gene expression through E1, E3, E5 and E6 
in mammalian cells in culture 
To investigate the ability of Foxb1 to regulate gene expression in mammalian cells through these 
binding sites, each of the Foxb1 binding sequences identified by One-Hybrid Assay was inserted 
into MCS sites upstream of SV40 promoter of pGL3-C (Promega) respectively, which carrys the 
luciferase reporter gene. Those four binding sites were called Ea, Eb, Ec, Ed and these constructs 
corresponded to Ea, Eb, Ec, Ed respectively. 
In order to perform the experiments, in a system as biologically significant as possible, a cell line 
expressing Foxb1 endogenously was searched. The rationale was that, if the cells express Foxb1,  
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Fig.3.17: Optimization of transient co-transfection assay. (A) Co-transfection assay with different cells 
number. 25000 cells per well gave highest luciferase activity. (B) Co-transfection assay with different 
amount of PLUS reagent. 4ul of PLUS reagent per well gave highest luciferase activity. (C) Co-transfection 
assay with different total amount of plasmids. 600ng plasmids per well gave highest luciferase activity. 
(D).Co-transfection assay with different ratio of plasmids. The ratio 1:1 of Foxb1 expressing plasmid to 
reporter plasmid (total amount is 600ng) per well gave highest luciferase activity. (E) Co-transfection assay 
with different transfection time. 4 hours transfection gave highest luciferase activity. (F) Co-transfection 
assay with different solution. Growth medium without serum as transfection medium gave highest 
luciferase activity. (G) Co-transfection assay with different amount of Lipofectamine reagent. 1.5ul of 
Lipofectamine reagent per well gave highest luciferase activity. 
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they will probably have any (yet unknown) cofactors that Foxb1 needs to bind, etc. I chose the 
P19 cell line (ATCC No. CRL-1825), which was derived from an embryonal carcinoma induced 
in a C3H/He mouse, and it is pluripotential (McBurney and Rogers, 1982). This was confirmed 
by RT-PCR that these cells express Foxb1 endogenously (not shown). With these reporter 
constructs plus a vector constitutively expressing full-length Foxb1 under the control of the CMV 
promoter, (plus the TKß plasmid, expressing ß-gal, as transfection efficiency control) a series of 
standard transient cotransfection assays were performed in P19 cells to optimize transfection 
conditions. The optimal conditions were: in each well, 25000 cells, 600ng total amount of DNA, 
1:1 of the ratio of Foxb1 expression plasmid to reporter plasmid, 4ul of "Plus" reagent, 1.5ul of 
"Lipofectamine" reagent, growth medium without serum as transfection medium, 4 hours 
transfection time (Fig.3.17). Use Ea, Eb, Ec, Ed and Foxb1 expressing plasmid with TKß to 
perform the transient co-transfection assay (See materials and methods). The luciferase activity 
was summarized in Table 3.1. 
 
Table 3.1: Luciferase and ß-Gal activity after transfection with Ea, Eb, Ec, Ed constructs 
respectively 
samples Luciferase  
     (Luc) 
ß-Gal  Luc/ß-Gal   
(normalization) 
 Luc/ß-Gal  
    (mean) 
328900 0,514 639883 
307710 0,518 594035 
pGL3-C 
354060 0,588 602143 
612020 
183270 0,473 387463 Ea (+ Foxb1) 
209510 0,514 407607 
355803 
95302 0,516 184694 
115609 0,696 166105 
Eb (+ Foxb1) 
128522 0,777 165408 
172069 
51583 0,373 138292 
53734 0,419 128243 
Ec (+ Foxb1) 
81032 0,549 147599 
138045 
71239 0,635 112187 
63031 0,607 103840 
Ed (+ Foxb1) 
58019 0,554 104727 
106918 
362430 0,623 581750 
276580 0,504 548770 
Ea (– Foxb1) 
215940 0,512 421758 
517426 
294150 0,686 428790 
371010 0,649 571664 
Eb (– Foxb1) 
261840 0,488 536557 
512337 
175620 0,513 342339 
150243 0,492 305372 
Ec (– Foxb1) 
106087 0,393 269941 
305884 
136006 0,55 247284 
213980 0,608 351941 
Ed (– Foxb1) 
98885 0,46 214967 
271397 
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Fig.3.18: (A) Foxb1 inhibits transcription of reporter gene luciferase through putative binding sites Ea, Eb, 
Ec, Ed. (B) Schematic structure of each construct and the combination of each co-transfection. 
 
These results seemed to indicate that Foxb1 was exerting an inhibitory influence on reporter 
expression (This was done three times). This was contradictory with the results of DNA 
microarray, the ISH and Q-PCR, which showed clear decrease of EphA7 expression in the 
mutant, indicating that Foxb1 is an activator. One possible explanation for the disagreement was 
that the short stretches of putative binding sequence for Foxb1 were not enough to elicit the full 
natural regulatory function of the protein. Perhaps if placed in their genomic context, the binding 
sequences would give results more according to what the ISH showed. 
Since the stretches of DNA sequence used for binding of regulatory factors are very important for 
correct development and hence for survival, it is usually assumed that biologically relevant 
putative binding sites will be found in those parts of the genome that are conserved between 
different species. The Celera Database was used to find the putative Foxb1 binding sites on 
human-mouse conserved portions of the genomic sequence of EphA7. A large conserved 
fragment with numerous Foxb1 binding sites was found on the 3′ flanking region of EphA7 
genomic sequence from 161,073bp to 163,969bp. This large conserved genomic fragment was  
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Fig.3.19: 3′ flanking conserved EphA7 genomic fragment and the different smaller fragments generatead 
from it.  Nde, KpnI, EcoRI, PstI, are the corresponding restriction enzyme digestion sites. 
 
 
cloned by long-range PCR using as template a BAC clone RP230134E11 (Invitrogen) containing 
EphA7. 
The PCR product was confirmed to contain the desired fragment by restriction enzyme digestion 
and agarose gel electrophoresis, as is usual. Several reporter gene constructs were generated from 
this big fragment, in which different lengths of 3′ flanking sequence were contained upstream of 
the SV40 promoter in pGL3-C (Promega), which has reporter gene luciferase following the 
promoter. Reporter constructs designated PC28, PC28NP5, PC28E4, PC28NP3, PC28EN2, 
PC28K1 plasmids contained 2896bp, 935bp, 1700bp, 1943bp, 896bp, 336bp 3′ flanking 
sequences of EphA7, respectively (Fig.3.19). 
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Then a transient cotransfection assay was used again to investigate the ability of Foxb1 to 
regulate reporter expression through the EphA7 genomic domains. The luciferase activity was 
summarized in Table 3.2, Table, 3.3, Table 3.4 respectively. Interestingly, Foxb1 can  
 
 
Table 3.2 Luciferase and ß-Gal activity after transfection with pC28, pC28NP5 constructs 
respectively. 
samples Luciferase  
     (Luc) 
ß-Gal     Luc/ß-Gal   
(normalization) 
 Luc/ß-Gal  
    (mean) 
5,20E+04 0,285 1,82E+05 
7,09E+04 0,335 2,12E+05 
5,00E+04 0,321 1,56E+05 
4,05E+04 0,267 1,52E+05 
5,65E+04 0,305 1,85E+05 
pGL3-C 
3,45E+04 0,152 2,27E+05 
1,86E+05 
1,07E+05 0,437 2,45E+05 
1,49E+05 0,37 4,03E+05 
1,29E+05 0,356 3,62E+05 
9,98E+04 0,37 2,70E+05 
8,29E+04 0,36 2,30E+05 
pC28 (+ Foxb1) 
8,62E+04 0,33 2,61E+05 
2,95E+05 
6,83E+04 0,293 2,33E+05 
6,79E+04 0,306 2,22E+05 
7,28E+04 0,341 2,13E+05 
5,95E+04 0,34 1,75E+05 
6,71E+04 0,343 1,96E+05 
pC28 (-Foxb1) 
4,98E+04 0,305 1,63E+05 
2,00E+05 
5,20E+05 0,503 1,03E+06 
5,02E+05 0,482 1,04E+06 
4,72E+05 0,509 9,27E+05 
4,45E+05 0,478 9,31E+05 
3,42E+05 0,431 7,94E+05 
pC28NP5 (+Foxb1) 
1,50E+05 0,367 4,09E+05 
8,56E+05 
9,44E+04 0,285 3,31E+05 
8,71E+04 0,333 2,62E+05 
9,62E+04 0,335 2,87E+05 
9,13E+04 0,345 2,65E+05 
1,45E+05 0,334 4,34E+05 
pC28NP5 (-Foxb1) 
1,45E+05 0,378 3,84E+05 
3,27E+05 
 
 
 
Table 3.3 Luciferase and ß-Gal activity after transfection with pC28E4 construct. 
samples Luciferase  
    (Luc) 
ß-Gal     Luc/ß-Gal   
(normalization) 
 Luc/ß-Gal  
    (mean) 
23627 0,158 149538 
31670 0,280 113107 
pGL3-C 
52819 0,321 164545 
142397 
73088 0,291 251162 
189910 0,464 409289 
pC28E4 (+Foxb1) 
171960 0,466 369013 
343155 
187280 0,476 393445 
195470 0,454 430551 
pC28E4 (-Foxb1) 
183210 0,413 443608 
422535 
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Table 3.5 Luciferase and ß-Gal activity after transfection with pC28K1, pC28EN2, 
pC28NP3 constructs respectively. 
samples Luciferase  
     (Luc) 
ß-Gal     Luc/ß-Gal   
(normalization) 
 Luc/ß-Gal  
    (mean) 
1,53E+05 0,569 2,69E+05 
1,48E+05 0,533 2,78E+05 
1,78E+05 0,66 2,70E+05 
1,68E+05 0,596 2,82E+05 
8,70E+04 0,43 2,02E+05 
pGL3-C 
1,06E+05 0,36 2,94E+05 
2,66E+05 
7,80E+04 0,44 1,77E+05 
7,80E+04 0,361 2,16E+05 
7,20E+04 0,395 1,82E+05 
6,10E+04 0,378 1,61E+05 
7,40E+04 0,422 1,75E+05 
pC28K1 (+Foxb1) 
3,30E+04 0,204 1,62E+05 
1,79E+05 
5,69E+04 0,268 2,12E+05 
6,62E+04 0,343 1,93E+05 
6,00E+04 0,289 2,08E+05 
6,10E+04 0,397 1,54E+05 
7,80E+04 0,339 2,30E+05 
pC28K1 (-Foxb1) 
7,10E+04 0,351 2,02E+05 
2,00E+05 
9,01E+03 0,296 3,04E+04 
9,13E+03 0,331 2,76E+04 
9,77E+03 0,347 2,81E+04 
8,79E+03 0,326 2,70E+04 
1,03E+04 0,351 2,93E+04 
pC28EN2 (+Foxb1) 
1,09E+04 0,355 3,07E+04 
2,89E+04 
1,16E+04 0,31 3,74E+04 
1,19E+04 0,298 3,99E+04 
1,27E+04 0,345 3,68E+04 
1,07E+04 0,398 2,69E+04 
1,41E+04 0,334 4,22E+04 
pC28EN2 (-Foxb1) 
1,29E+04 0,515 2,50E+04 
3,74E+04 
1,61E+05 0,321 5,02E+05 pC28NP3 (+Foxb1) 
1,25E+05 0,261 4,79E+05 
4,90E+05 
1,18E+05 0,235 5,02E+05 
1,58E+05 0,303 5,21E+05 
1,47E+05 0,284 5,18E+05 
1,88E+05 0,303 6,20E+05 
pC28NP3 (-Foxb1) 
2,11E+05 0,322 6,55E+05 
5,63E+05 
 
 
differentially regulate these genomic domains in p19 cells (Fig.3.20). Foxb1 activates reporter 
gene expression through PC28, PC28NP3, PC28E4, PC28NP5. The most significant activation 
was observed from PC28NP5. PC28NP5 has a potential Foxb1 binding site ATCAATA, which 
was not shown in yeast one hybrid results. However, Foxb1 indeed was able to repress reporter 
gene expression through PC28K1 and PC28EN2. These experiments demonstrate that Foxb1 can 
activate gene expression on mouse cells through binding sites in certain genomic regions of 
EphA7. 
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Fig.3.20: Foxb1 can differentially regulate 3′ flanking conserved EphA7 genomic fragments in p19 cells. 
(A) Foxb1 activates reporter gene luciferase expression through PC28, PC28NP3, PC28E4, PC28NP5. 
Foxb1 represses reporter gene luciferase expression through PC28K1 and PC28EN2. (B) The schematic 
structure of each construct and the combination of each cotransfection.. 
 
 
3.2.6 Electrophoretic Mobility Shift Assays ("Band Shift") show that 
Foxb1 can bind Ea, Ec, Ed, Ee 
As a final experiment in order to support the hypothesis of direct interaction between Foxb1 and 
EphA7, I wanted to show that the protein Foxb1 can bind to the candidate genomic fragment in 
vitro. To this end, I first produced His-tagged Foxb1 recombinant protein (see Materials and 
Methods). I confirmed specific Foxb1 protein expression by western blotting with Ni-NTA AP 
conjugate and by the size on SDS-PADE gel after purification. One band of the right size (42kD) 
was specifically detected on the blot (Fig.3.21). 
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Fig.3.21: Expression and purification of Foxb1 protein in E.Coli. (A) Foxb1 protein (42KD) was expressed 
from pQE31 in XL1 blue cells and detected by Alkaline Phosphatase staining solution used for the western 
blots with Ni-NTA AP (upper arrowhead). There was another band which might be a truncated form 
(17KD) (lower arrowhead). CL, cell lysate from different single clone; control, without Foxb1 protein. (B) 
Foxb1 protein was purified using Ni-NTA Agarose with the indicated imidazole concentrations in the wash 
and elution steps. Protein (42KD) was visualized by Coomassie staining (arrowhead). CL, the protein was 
purified from different single clone; the control, without Foxb1 protein in the cells. 
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A binding assay was performed by incubating the recombinant protein together with end-labeled 
oligonucleotides carrying each the sequence of one of the putative binding sites Ea, Ec, Ed 
identified by One-Hybrid Assay and Ee (not identified by One-hybrid Assay, but shown in the 
fragment of PC28NP5 which was observed the most significant activation in transient co-
transfection assay) (with the help of DIG Gel Shift Kit, 2nd Generation, Cat. No. 3353591, 
Roche). Finally, the incubated samples were seperated by polyacrylamide gel electrophoresis 
(PAGE). As shown in Fig.3.22, Ea, Ec, Ed and Ee form complexes with Foxb1 protein. The 
specificities of these complexes were confirmed by being competed off when unlabeled 
corresponding elements were included in the reaction. And the negative control element did not 
form the complex with Foxb1 under the same condition. 
 
The oligonucleotides are:  
Ea:  GTGACAGTTGT ATAAATAAATAAATA AACG  
Ec:  GTGACAGTTGT ATAAATAAACAAATA AACG 
Ed:  GTGACAGTTGT ACAAACAAACAAACA AACG 
Ee:  GTGACAGTTGT CCTAATCAACACTAT AACG  
Econ: GTGACAGTTGT  CAGTTGTACAGTTGT AACG 
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Fig.3.22: DIG Gel Shift Assay with Foxb1 protein and oligonucleotides, the Foxb1 protein specifically 
bound the sites on Ea, Ec, Ed, Ee oligonucleotides. Gel mobility shift assays were performed with the 
Foxb1 protein and Foxb1 putative binding oligonucleotides. The reaction components were separated on an 
8% native polyacrylamide gel, then transferred to a nylon membrane by electroblot. DIG-labeled moieties 
were detected in a chemiluminescent assay (CSPD substrate, about 20 min exposure, X-ray film). Lane 1: 
DIG-labeled Ea oligonuleotide (1ng) after incubation with 200ng Foxb1protein. Lane 2: Same as lane 1, 
except the incubations also contained increasing amounts of unlabeled nucleotide Ea (125-fold) Lane 3, 4: 
Same as lane 1 and 2, except the oligo is Ec. Lane 5, 6: Same as lane 1 and 2, except the oligo is Ed, lane 7, 
8: Same as lane 1 and 2, except the oligo is Ee. Lane 9, 10: Same as lane 1 and 2, except the oligo is Econ, 
Upper band, protein oligonucleotide complex (arrowhead); lower band, unbound oligonucleotide 
(arrowhead). 
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4 DISCUSSION 
 
Genetics as a science tries to find out how genes influence the development and physiology of the 
organism. The main approach of the geneticist is the study of mutant phenotypes. In order to learn 
more about the way in which genes influence axonal navigation, the brain phenotype of a mouse 
line carrying a mutation in transcription factor gene Foxb1 was studied. Since the gene and its 
mutant phenotype were already well characterized, this work went one step further, trying to find 
out through which other genes (effector genes) Foxb1 influences axonal navigation in the 
developing diencephalon. Starting with a high-throughput, genomic approach (DNA microarray 
analysis), and going through a series of “filtering” steps, one candidate gene (tyrosine kinase 
receptor EphA7) was isolated, known to be involved in axonal navigation in other systems. 
Several quantitative and non-quantitative techniques were used to demonstrate that its expression 
is reduced in the Foxb1 mutant, to prove the biological plausibility of this gene as a Foxb1 
downstream candidate and to demonstrate that its expression is directly regulated by Foxb1. 
Although EphA7 might of course be not the only Foxb1 downstream gene involved in the axonal 
phenotype under study, its identification as a bona fide effector in the Foxb1 signaling cascade is 
a major contribution to the analysis of axonal pathfinding in the central nervous system.  
 
DISCUSSION 
109 
4.1 The Microarray Approach and Validation of 
Microarray Data 
4.1.1 Microarray data: issues of consistency/reliability, need for 
validation 
Justification of DNA Microarray Approach. Previous attempts of this group to find genes whose 
expression is altered in the Foxb1 mutant by manual in situ hybridization with probes for 
candidate genes gleaned from the literature proved a very slow process which did not give any 
results. The “guessing approach” (guessing probable candidates from the literature on brain 
development) has thus been inefficient and disappointing. At this point, we felt that large-scale 
analysis of gene expression in brain using microarray technology had the potential to elucidate 
molecular changes in gene transcription regulation event. 
Reliability. Although it can be said that DNA microarray analysis of expression is in its 
beginnings, the literature dealing with potential problems of consistency and reliability of the data 
generated by this technique is already sizable [see the review in (Chuaqui et al., 2002)]. The main 
reasons for these concerns are probably the lack of experience with this novel approach, and the 
large data sets that the technique generates. In general terms, the questions that arise are two: are 
these data accurate? and: are they biologically relevant? We will deal with the second question 
below. As for the accuracy of the data, factors like not perfectly reproducible dissections, DNA 
amplification protocols and other can influence the repeatability of each individual result. A 
measure of the variability of the data sets generated by this approach can be given by the 
following summary of our DNA microarray results: the first hybridization of DNA microarrays 
gave 31 genes whose expression was changed in the mutant vs. the wild type. When we 
hybridized DNA microarrays a second time with a probe obtained from the same pool of mRNA, 
we obtained 120 genes changed, while only 9 of them were common to the two hybridizations. 
The third hybridization, with a probe from new, more precise dissections of the mammillary 
body, found 160 genes changed, and 5 genes coincided between the three hybridizations (were 
found to be changed in the three data sets). 
Validation Methods. As was already clear from the literature, validation of the DNA microarray 
data by independent methods was essential. A consensus seems to be building among DNA 
microarray practitioners about validation methods (Rajeevan et al., 2001; Barlow and Lockhart, 
2002; Chuaqui et al., 2002), with Quantitative Polymerase Chain Reaction (Q-PCR) and in situ 
hybridization (ISH) being the most widely used and recommended. 
DISCUSSION 
110 
ISH is able to show spatial localization of expression and even relatively large quantitative 
changes in expression (although admitedly not being a quantitative technique). The main 
advantage of ISH is of course the spatial localization, because the complex anatomical 
organization of the brain necessitates a method with high spatial resolution. 57 genes were 
analyzed by in situ hybridization. Of these, 50 (88%) yielded detectable in situ hybridization 
signals in the brain. Of which, 30 (61%) showed signal in MBO, but, among these, only 10 
showed MBO specific expression and the rest were genes with ubiquitous expression (including 
of course MBO expression). From the point of view of the comparison between wild type and 
mutant tissue, among all 57 genes we tested, 7 cases (13%) were fully consistent with DNA 
microarray data, 4 of them decreased in the mutant, and 3 of them increased. Maybe because 
probe design and hybridization parameters for each gene in the microarray, it is possible that the 
actual false negative and false positive rate is lower than we observed.  
Q-PCR is an independent technique that provides greater accuracy in terms of individual gene 
targets and should ideally be used to confirm results from microarray (Sgroi et al., 1999; 
Rajeevan et al., 2001; Elkahloun et al., 2002; Mimmack et al., 2004). 30 genes were validated by 
Q-PCR. Of them 8 (27%) were consistent with microarray data, but, intriguingly, 73% of the Q-
PCR results show coincidence with the ISH data. Nonreproducibility of microarray results does 
not necessarily mean that these results are invalid, however, because outbreed mouse genetic 
background, differences in tissue harvesting, RNA secondary structures, splice variants, complex 
poly A tails, low transcript expression, and many other factors can influence both microarray and 
Q-PCR results.  
Summary. In this project, DNA microarrays pointed at a relatively small number of possible 
candidate genes (57), although with “low confidence”. Considering that the mouse genome (as 
well as the human) is believed to have some 30.000 protein-coding genes (Lander et al., 2001; 
Waterston et al., 2002), this is not a bad approximation. On the basis of this relatively small group 
of genes, and by applying other more laborious techniques (less high-throughput than the DNA 
microarrays), I narrowed down the list to only a small, experimentally approachable, number of 
genes. 
4.1.2 Microarray data: Issues of biological validation 
The next issues of importance were those of “biological validation” and “narrowing down to 
hypothesis-driven research”. 
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Biological validation. In other words, what matters in this type of analysis is not so much the 
confirmed quantitative variation in the expression of a gene, as the significance of the role of that 
gene in the particular process under study. This means that the mere fact that expression of a gene 
changes in the mutant in comparison with the wild type does not mean that the gene is directly 
responsible for the mutant phenotype. In the particular case of the mutant phenotype of a 
transcription factor, it is obvious that quantitative expression changes do not imply that the gene 
is directly under the control of the particular transcriptional regulator of interest. One first 
indication that a certain candidate is actually important is given by the function of the protein 
codified. Functional data gathered from the literature, databases, etc., are an essential. In the 
present study, it was immediately obvious that EphA7 was an important candidate, since it 
belongs to a much-researched family of tyrosine kinase receptors which, together with their 
specific ligands (the ephrins), have a major involvement in axonal guidance [the original 
literature is too complex and extensive, see (Wilkinson, 2001; Dickson, 2002; Knoll and 
Drescher, 2002; Kullander and Klein, 2002) for reviews]. Together with the very strong and 
specific expression of EphA7 in the wild type MBO, and the validated decrease in expression in 
the mutant, the functional data made of this particular gene an outstanding candidate. But perhaps 
the most important biological validation for a receptor is the availability of specific ligand(s) in 
the precise region and at the precise time when the mutant phenotype appears. The expression 
data on ephrin A5, whose mRNA was detected by us in the dorsal and ventral thalamus around 
E18.5, were definitive from this point of view: EphA7 was from that moment on a candidate with 
high probability of being involved in the axonal guidance model under study. 
Narrowing  down. Genomic or “high-throughput” projects present a peculiar problem, which is 
intimately related to the question of biological validation. These projects make available to the 
biologist huge quantitative data sets of the kind previously available only to astrophysicists and 
the like (e. g. automatic readings from radiotelescopes, etc.) These are novel problems for the 
biologist, and are causing much excitement, commentary and discussion [see for instance 
(Smalheiser, 2002; Weinstein, 2002; Kell and Oliver, 2004; Steinhauser et al., 2004)]. Although 
extreme positions have been announced, between partisans of the “omic” (genomic, proteomic, 
cellomic, etc.) research and seriously skeptical, “hypothesis-driven” practitioners (Allen, 2001), a 
consensus seems to be building around a “synergism” of both kinds of approach [see for instance 
(Weinstein, 2002)]. It is maybe not too much of a simplification to describe this synergistic 
process as a series of cycles, whereby “classical” scientific thinking about very complex systems 
and processes generates questions which prompt researchers to produce large amounts of “omic” 
data, and then again hypothesis are needed to make the data into information. The paradigm that 
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underlies most biological research seems to be a molecular version of the “Domino Effect”: one 
molecule pushes (interacts with) another, which pushes the next, etc. According to this, we could 
summarize: high-throughput methods let us know the number of dominoes, and hypotheses place 
each domino in its place in the chain. Since the experimental confirmation that is the aim of much 
hypothesis-driven research cannot usually be carried out for very large numbers of molecules and 
/ or processes, the “classical” part of the cycle we just described includes a first step of 
“narrowing down” to those data (genes, etc.) perceived as important or perhaps simply more 
accessible to experimental manipulation. The biological validation (see above) is an essential part 
of this process: faced with a large group of genes potentially involved in our favorite biological 
problem, we focus on those genes (on that gene) we can make sense of on the basis of the 
functional information at hand. Again, in the case of the present study, focusing on EphA7 was 
the most logical next step. 
4.1.3 Biological plausibility of EphA7 as a candidate to be involved in 
the Foxb1 axonal phenotype 
The reported function of EphA7 matches the phenotype under study. Examination of axonal 
development in the diencephalon of Foxb1 mutants has revealed an axonal navigation failure 
starting around E18.5: mtt axons are not able to enter their target, the dorsal thalamus (Alvarez-
Bolado et al., 2000). A large number of molecules have been showed to be involved in the 
process of axonal guidance from their site of origin to their target area, such as the netrins and 
their receptors (Dcc and Unc5), the semaphorins and the neurophilin and plexin receptors, the 
Slits and Robos, as well as the ephrins, which interact with receptor tyrosine kinases of the Eph 
family [a subject abundantly reviewed, see especially (Tessier-Lavigne and Goodman, 1996; 
Mueller, 1999; Dickson, 2002)]. After the discovery of the first biochemically characterized 
ephrin (Cheng and Flanagan, 1994) 10 years ago, numerous contributions have appeared 
underlining the importance of their receptor-ligand interactions in the development of 
topographically organized axonal projections such as retinotectal projection (Cheng and 
Flanagan, 1994; Drescher et al., 1995). 
EphA7 is expressed in the MBO at the onset of the phenotype. The full length form of EphA7, as 
well as all its shorter isoforms, are appropriately and very specifically expressed in the cells of 
origin of the mtt (the MBO neurons) as well as in the group of cells alongside the mtt tract at least 
from E16.5 to E18.5 (the age of onset of the mutant phenotype), as we have shown by ISH. 
Expression of all of them is reduced in the mutant.  
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Appropriate ligands are expressed in the region at the onset of the phenotype. The tyrosine kinase 
receptor EphA7 binds the five known cell-attached ephrin-A ligands (Wilkinson, 2001). We have 
shown by ISH that, on E18.5, ephrin A1-A3 are widely expressed in the brain (including the 
diencephalon), and ephrin A5 has very specific diencephalic expression pattern, complementary 
with that of EphA7 (ephrin A4 was not expressed in the brain at this age). On the basis of these 
results, an involvement of EphA7 / ephrin A in mammillary axonal navigation is probable. 
4.1.4 EphA7 in the developing mammillothalamic tract: a mechanistic 
hypothesis 
The players. In order to hypothesize a plausible mechanistic explanation for the formation of the 
mtt and the appearance of the mutant phenotype, I will first enumerate the key molecular and 
cellular players: 
1) Full length and truncated EphA7. Most experimental evidence indicates that the Eph family 
exerts its function by a repellent mechanism, although there are some reports of an adhesive or 
permissive function of Eph receptors and ligands (Dickson, 2002; Kullander and Klein, 2002). 
The truncated (non-signalling) and full length (signalling) isoforms of EphA7 have been shown to 
serve different functional roles (Holmberg et al., 2000). Since truncated forms bind the ligand 
without signalling to the interior of the cell (they are missing the tyrosine kinase domain), they 
act as adhesive factors; the full length protein, however, upon binding to the ligand, starts a 
signalling pathway leading to repulsion (Holmberg et al., 2000). By means of specific antibodies, 
it has been shown that, in the MBO, the truncated forms of EphA7 are positioned in the cell body 
membrane, while the full length protein is found in the membrane of the tip of the axons (Ciossek 
et al., 1999; Rogers et al., 1999). 
2) The ephrin ligands. Ephrin-As can be secreted and act as soluble factors although in principle 
associated with the cell membrane through GPI (Guan and Rao, 2003). The surrounding cells of 
the diencephalon, as we have shown here, express ephrin A5, which presumably repel the 
growing mtt axons preventing them to stray from the right pathway. 
3) The EphA7 “bridge”. Here we have shown that there is a small group of cells expressing 
EphA7 in the region between MBO and dorsal thalamus. By E16.5, these cells form a “bridge” 
spanning the distance later to be covered by the mtt axons. We have shown that, at E18.5, the mtt 
actually follows the pathway formed by those cells in order to reach the target region (dorsal 
thalamus). 
A plausible scenario. Therefore, we would have EphA7-displaying axonal growth cones (the 
developing mtt) advancing on a “bridge” or “carpet” of equally EphA7-displaying cells. But why 
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are the mtt growth cones not repelled by secreted ephrin A5, and what has the EphA7 “bridge” to 
do with this? In principle, that EphA7-displaying axons navigate on top of EphA7-displaying 
cells seems counterintuitive: a receptor interacts with a receptor? The concept of “masking” by 
Eph receptors offers a possible explanation to these questions. It has been shown that areas of the 
brain expressing high amounts of Eph receptors can bind soluble ephrin ligands (secreted by other 
cell groups) with such efficiency that they act as “sinks” for those ligands, effectively “masking” 
their repulsive activity (Sobieszczuk and Wilkinson, 1999; Helmbacher et al., 2000). The same 
“masking” concept has been seen to work for Sema3F (ligand) and its receptor neuropilin2 in the 
developing brainstem (Watanabe et al., 2004). A plausible scenario could be as follows: The 
nascent mtt, expressing EphA7 and therefore sensitive to the repulsive power of ephrins, 
presumably obeying to a powerful soluble attractant secreted by the anterior dorsal thalamus, has 
to navigate through an area of intense expression of ephrins. It does so by growing on top of an 
elongated group of cells (a “bridge”) leading from the branching point to the dorsal thalamus 
(target region). These cells express EphA7 which acts as a sink for ephrins, effectively masking 
their repulsive effect for as long as the axons do not stray from the straight path to the target 
region. In Foxb1-deficient mutants, EphA7 expression is severely reduced in the MBO (but not in 
the bridge, which is intact in the mutant since it does not express Foxb1), making the mtt axons 
less sensitive to the repulsive ephrins, and allowing them to stray, perhaps following 
inappropriate rostral attractants meant for axons of different origin. In this way, by combining our 
original observations and current concepts in the field, we have, first, contributed to explain our 
results, and second, generated a complex hypothesis that can be further explored by future 
studies. 
Matching phenotypes? An obvious question here would be: do we expect the EphA7 mutant 
phenotype then to match the Foxb1 phenotype in the diencephalon? Two reasons seem to indicate 
that the reasonable answer is “no”. 1) Foxb1 is a transcription factor, i. e., it regulates the 
expression of other genes, probably several of them; alteration of only one of its effectors (EphA7 
in this case), is not likely to reproduce all details of the Foxb1 mutant phenotype; 2) The Eph 
receptor and the ephrin families of genes are very numerous (14 different receptors and eight 
ligands so far, all of which are widely expressed in the central and peripheral nervous systems 
during development and in the adult) and they bind each other promiscuously [reviewed for 
instance by (Drescher, 1997; Flanagan and Vanderhaeghen, 1998; Kullander and Klein, 2002) 
and many others], which gives this system a high degree of functional redundancy, particularly in 
regions where, like the developing diencephalon, several members of these gene families are 
coexpressed. 
DISCUSSION 
115 
4.2 EphA7 as a Direct Target of Foxb1 protein 
4.2.1 Direct interaction 
Once the search had narrowed down to this particular candidate, the problem became quite 
different. Now the hypothesis “EphA7 expression in MBO is controlled by Foxb1” demanded 
experimental confirmation or falsification. The first straightforward step to be taken was to find if 
putative binding sites for Foxb1 were present on conserved regions of the genomic sequence of 
EphA7. Since the binding sites of Foxb1 are not yet known, experiments destined to find out this 
information would seem to be the next step. However, Fox proteins seem to have very conserved 
binding requirements through the whole gene family (Carlsson and Mahlapuu, 2002), and so a 
consensus binding site for Fox proteins has been defined. The binding DNA sequence specificity 
has been determined for several representatives of forkhead family through selection of binding 
sites from pools of short, random-sequence duplexes (Pierrou et al., 1995). A seven-nucleotide 
core corresponds to the major groove base contacts made by the recognition helix (helix 3). For 
the majority of forkhead proteins, the core conforms to the RYMAAYA (R _ A or G; Y _ C or T; 
M _ A or C) consensus (Kaufmann and Knochel, 1996). Since every Fox gene whose binding 
requirements have been analyzed binds to the consensus sequence RYMAAYA, it was logical to 
use this consensus in order to investigate the possibility of direct interaction between Foxb1 
protein and EphA7 genomic sequence. It was encouraging to find out that, on the EphA7 receptor 
genomic sequence170kb (+ 10kb on either side), RYMAAYA sequences can be found with high 
frequency (here it is also interesting to mention that I could not find on EphA7 any DNA binding 
sites for transcription factor Pax6: not every combination of nucleotides is present on conserved 
regions of every gene). Here again, although at a different scale, bioinformatics made available 
for me a relatively large amount of data: the large number of RYMAAYA sequences on  EphA7. 
Consequently, the next step was again to narrow down this data set by focusing on consensus 
sequences showing high frequency on the genome and clustering together. The new hypothesis 
was “Foxb1 is able to bind to these sequences”. In order to test it, I used the three standard 
methods accepted in the field as proof of direct interaction. I used Yeast One-Hybrid Assay and 
Electrophoretic Mobility Shift Assay (EMSA) in order to prove that the RYMAAYA sites that I 
selected on the EphA7 genomic sequence do bind Foxb1, and I used cotransfection on cultured 
cells in order to prove that Foxb1 not only binds to those sequences but is able to influence 
EphA7 transcription through them. Both the yeast one-hybrid system (Liao and Fang, 2000; 
Sieweke, 2000) and the EMSA (or band shift assay) (Lane et al., 1992; Rippe et al., 2001) are 
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highly stringent, widely utilized methods to identify the recognition site of a transcription protein. 
Perhaps not surprisingly, these two methods gave the most clear-cut (and indeed positive) results: 
Foxb1 protein is able to bind to the RYMAAYA sequences found on EphA7.  
4.2.2 Is Foxb1 an activator or a repressor of EphA7 transcription? 
The next question, if through this binding Foxb1 is able to influence EphA7 transcription, is 
perhaps the last occurrence in this study of the “Biological Significance Question” discussed 
above, now narrowed down to the final test. To answer it I relied on the cotransfection approach, 
routinely used for this type of questions and well accepted in the field of molecular and cell 
biology (Claudio, 1992; Hauser et al., 1995; Zhang and Danielsen, 2001). However, as a 
reflection of the huge complexity of intact living cells as opposed to the oversimplification of in 
vitro assays, the results of these experiments were at first contradictory or paradoxal (instead of 
the expected activation we found evidence of repression of EphA7 by Foxb1). Forkhead proteins 
have been shown to act mostly as transcriptional activators but not exclusively so: trans-
repression has been reported for FoxC2, -D2, -D3, and -G1 and, in C. elegans, the forkhead 
protein LIN-31 is thought to act as either repressor or activator, depending on its phosphorylation 
in response to MAP kinase signaling (Carlsson and Mahlapuu, 2002). Even so, the repressor role 
of Foxb1 in the context of this study contradicted our DNA microarray, ISH and Q-PCR results. 
The problem could be that we were oversimplifying again. Foxb1 does not bind to isolated 
RYMAAYA sequences, but to RYMAAYA sequences embedded in a genomic context, that is, 
surrounded by other sequences which can be the target of DNA binding proteins acting as 
cofactors or modifiers of Foxb1 function. Like many other transcription factors, forkhead proteins 
often contain several activating regions, and these can be found in any location relative to the 
DNA binding domain. Little is known about the mechanisms through which forkhead proteins 
interact with the transcriptional machinery. In vitro, FOXF2 binds the general transcription 
factors TBP and TFIIB, and in cotransfection experiments, FOXF2 acts synergistically with 
TFIIB (Carlsson and Mahlapuu, 2002). Accordingly, my cotransfection experiments using long 
stretches of genomic sequence rather than “pure” RYMAAYA sequences were able to show 
Foxb1 as activator, in agreement with our data previously obtained by other methods. 
4.2.3 Foxb1 as modulator of EphA7 transcription 
However, EphA7 receptor expression did not disappear completely in Foxb1 null mutant.  
Higher eukaryotes exploits signal integration and combinational control to a great degree. One 
case to illustrate this strategy is human interferon-ß gene, three signals are integrated to switch on 
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that gene (Ptashne and Gann, 2002).Studies of the EphA7 genomic sequence has identified a huge 
number of transcription factor binding sites both proximal and further downstream. This 
suggested that factor may modulate other transcription factors by direct interaction and by 
blocking their binding at the promoter. EphA7 receptor genome is 170kb and quite long, how 
might enhancer-binding proteins and their associated coactivators establish a productive 
interaction with the cognate promoter? Looping between the enhancer and promoter has been an 
attractive and popular hypothesis (Wang and Giaever, 1988; Blackwood and Kadonaga, 1998).
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5 ABBREVIATIONS 
 
 
3-AT  3-amino-1,2,4-triazole 
amp  Ampicillin 
BAC  Bacterial artificial chromosome 
bp  Base pairs 
CMV  Cytomegalovirus 
CNS  Central nervous system 
cDNA  Complementary DNA 
CT  Threshold cycle 
DAB  Diaminobenzidine 
DEPC   Diethylpyrocarbonate 
DI  Diencephalon 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
DNase   Deoxyribonuclease 
dsDNA  Double-strain DNA 
dNTP   Deoxynucleotide 
DIG   Digoxygenin 
DTT   Dithiotheitol 
E   Embryonic day  
EDTA   Ethylene diamine tetraacetic acid 
EF1a  Elonggation factor 1a 
EMSA  Electrophoretic mobility shift assay 
Fig.  Figure 
Fox  Forkhead box 
GluR2/3 Glutamine receptor 2 or 3 
GPI  Glycosylphosphatidylinostitol 
HB  Hindbrain 
HEPES  N-2-hydroxyethylpiperazine-N’-2-ethane-sulfonic acid  
ISH  In situ hybridization 
IPTG   Isopropyl-ß-thiogalactopyranoside 
kb  Kilo base 
LB   Lauria-Bertani medium 
LiAC  Lithium Acetate 
LiCl  Lithium Chloride 
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M  mol/liter 
MB  Midbrain 
MBO  Mammillary body 
mL   Milliliter 
mM  Millimol 
min   Minutes 
mRNA  Messager RNA 
NaAc  Sodium Acetate 
NBT   Nitro-blue tetrazolium 
NMR  Nuclear magnetic resonance 
NTE   Sodium tris EDTA 
P  Postnatal day 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PFA  Paraformaldehyde 
PCR   Polymerase chain reaction 
Q-PCR  Quantitative real-time PCR 
RNA   Ribonucleic acid 
RNase   Ribonuclease 
rpm  Revolutions per minute 
RTK  Receptor tyrosine kinase 
RT  Reverse transcriptase 
SD  Minimal synthetic dropout medium 
SDS  Sodiumdodecylsulfate 
SLR  Signal log ratio 
SQ  Start quantity 
SSC  Saline-sodium citrate buffer 
TAE  Tris-acetate-EDTA 
Taq  Thermus aquaticus 
TBS  Tris borate EDTA 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TNT   Tris sodium tween 
Tris   Tris[hydroxymethyl]-aminomethane 
U  Unit (Enzyme) 
UTR  Untranslated region 
Vs.  Versus 
X-Gal   5-bromo-4-chloro-3-indolyl-ß-galactosidas 
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